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ABSTRACT
The aim of this Thesis was to investigate haemostatic
function in diabetes mellitus and to relate abnormalities to the
presence of micro- and macrovascular disease. Since poor metabolic
control appears to favour the development of diabetic vascular
complications, the influence of hyperglycaemia on haemostatic
function was also studied.
In Part I, evidence that thrombosis is involved in the
pathogenesis of micro- and macroangiopathy was discussed and the
physiology of platelets and of the coagulation and fibrinolytic
systems, with particular reference to their respective roles in
thrombus formation, was reviewed.
In Part II, platelet aggregation and a battery of tests
of coagulation and fibrinolysis were performed on 3^ patients attending
a diabetic out-patient clinic. Compared with non-diabetic controls,
significantly higher levels of fibrinogen, factors II, V, VII, VIII:C,
OC^-macroglobulin and c^-esterase inhibitor and lower levels of factor
XI and antithrombin III were found, though the threshold concentrations
of ADP, adrenaline and collagen required to produce second phase
platelet aggregation were similar in diabetics and controls.
The refinement of a new, non-radioisotopic method for the
measurement of platelet survival was described in Part III. Using this
method, platelet survival of 12 diabetics was found to be significantly
shorter than that of 12 controls. Diminished platelet survival may
result from alterations in the platelet membrane; further evidence for
membrane abnormalities in platlets from diabetic subjects was provided
by the observation that platelets from 8 patients with severe retinopathy
had significantly increased "^I-fibrinogen binding compared with 9
non-diabetic controls, fibrinogen binding of platelets from 8 diabetics
with slight retinopathy being intermediate between the two groups.
Similarly, ADP-induced first phase platelet aggregation was found to be
significantly increased in the group with severe retinopathy compared
with the controls. Sensitivity of the platelets to ADP was found to be
significantly correlated with the HbA^ concentration, but not with the
degree of fibrinogen binding, suggesting that platelet aggregation and
fibrinogen binding were related to the extent of microvascular disease,
but that aggregation may also be increased by poor metabolic control.
In Part IV, the effect of diabetic serum on the production
of PGI^ by thrombin stimulated cultured human vascular endothelial cells
was assessed. Both PGI -like activity and 6-keto-PGFT concentrations
were significantly lower in cells cultured in 20% serum from diabetics
with proliferative retinopathy compared with non-diabetic controls, with
a significant correlation between the depression in 6-keto-PGF^ production
and the concentration of HbA-. Production of 6-keto-PGFT was not affectedI la
by changes in glucose concentration in the culture medium, and there
were no significant differences when cells cultured in serum from well
controlled diabetics were compared with serum from poorly controlled
diabetics in the absence of vascular disease.
In Part V, effects of metabolic control on haemostatic
function were studied. Compared with the results after stabilization
of the diabetes, II patients with ketoacidosis had significantly raised
levels of factors VIII:C and VIIIRrAg and fibrin degradation products,
a shorter partial thromboplastin time and reduced concentrations of
antithrombin III. These changes may indicate vascular damage and intra¬
vascular fibrin deposition. Out of three deaths, two diabetics with the
hyperosmolar syndrome had evidence of disseminated intravascular
coagulation. In a second study, the effect of control of hyperglycaemia
on haemostatic function was observed in IA- non-insulin dependent diabetics.
After 2 months treatment with diet alone, II were given the sulphonylurea
gliclazide, the others remaining on diet only. Compared with pretreatment
values, significant reductions inplatelet retention, factors VIIIjC and
VIIIR:Ag and plasma heparin neutralizing activity accompanied a fall in
the plasma glucose concentration due to diet alone or diet plus gliclazide.
This Thesis has shown that diabetes mellitus is associated
with a number of alterations of the haemostatic system. These changes
appear to indicate tissue, and particularly vessel wall, injury and may
in part be reversed by improved metabolic control. It remains uncertain
whether such alterations predispose to diabetic vascular disease, though
clinical trials of antithrombotic drugs during diabetic coma and in the
long term prevention of micro- and macroangiopathy in diabetic patients
may be indicated.
PART I INTRODUCTION
SECTION I DIABETES MELLITUS AND VASCULAR DISEASE
I
DIABETES MELLITUS AND VASCULAR DISEASE
Diabetes mellitus is not a modern disease. The earliest
description may be contained in the Ebers papyrus (Egypt 1500 BC), though
the description of polyuria is not specific for diabetes mellitus„ The
first to detail the other acute symptoms and signs of the condition
was the Arab physician, Aretreus of Cappodokia (2nd Century AD) and
eight centuries later another Arab physician, Avicenna (967 - 1037 AD),
described the association of diabetes and gangrenec Diabetes was also
recognized by the 3^d Century AD in both China and Japan and in the
Indian Vedic literature of Sushrutha (3th Century AD). These historical
aspects have been reviewed by Papaspyros (1964).
No mention of diabetes appeared in European literature
until Thomas Willis (died 1673) wrote of the "diabetes or pissing
evil" (Malins, 1968) and it was not until 1852 that Marchal rediscovered
diabetic gangrene.
Prior to the introduction of insulin treatment, diabetes
was an incurable and largely untreatable disease with a high mortality,
the majority dying rapidly from ketoacidosis or septicaemia (Marks, I97l)°
Records of patients attending the Joslin Clinic confirm this pessimist¬
ic outlook. Between 1914 and 1922 the mortality rate of 30 year-old
diabetics was 236.8/1000 per year but the start of insulin therapy in
1922 resulted in a dramatic fall in annual mortality to 74-8/1000
between 1922 and 1926 (Marks, I97l)°
However, despite the undoubted improvements in the manage¬
ment of diabetic patients since the 1920's, it has been apparent for
many years that the life expectancy of diabetics is reduced compared
to the non-diabetic population, and may not have significantly improved
over the last thirty or forty years (Kessler, I97l)« A number of careful
studies have confirmed that the age and sex-specific death rates of
diabetics compared to non-diabetics is significantly higher at virtually
all age groups (Hayward & Lucena, 1965; Hirohata, 1967; Garcia et al.,
1974).
In the West, it is well-established that the commonest
cause of this increased mortality is atherosclerosis and its complic¬
ations (Kessler, 1971; Garcia et al., 197^)• addition to macro-
vascular disease, microangiopathy, in the form of chronic renal failure,
is now the commonest cause of death in diabetics developing the dis¬
ease before the age of 20 years (Knowles, 197^; Kussman et al.f 1976).
In addition to this excess mortality, the management of
diabetes mellitus and its vascular complications places a considerable
burden on the social, financial and medical resources of the community.
As an example, the United States National Health Interview Study in
1965 estimated that over half a million diabetics were disabled in
some way by their disease and that the total cost from loss of earnings,
hospital admissions, out-patient attendances and drugs was almost two
billion dollars/year (Knowles et al., 1976).
The two main long-term complications of diabetes are
atherosclerotic vascular disease and microvascular disease. Though
there is evidence that thrombosis may be involved in the pathogenesis
of both diseases, their pathology and epidemiology appear to be different.
ATHEROSCLEROSIS AND DIABETES MELLITUS
Information on the prevalence of large vessel disease in
diabetes comes from three main sources : death certificates, autopsy
series and epidemiological studies. All three have considerable limit¬
ations. Death certificates are frequently inaccurate and it has been
shown that up to one third of known diabetics have no mention of the
disease on their certificates (Cameron, 1966). Autopsy series are highly
selective and diabetes is difficult to diagnose after death if not suspect¬
ed previously. In addition, pathological evidence of arterial disease
is difficult to quantify and correlates poorly with its clinical manifest¬
ations. Epidemiological studies are not immune from criticism. Definitions
of diabetes or abnormal glucose tolerance have varied widely. Many studies
have been retrospective, with the problem that duration of diabetes is
frequently uncertain since the onset of the disease may be insidious.
In a review of 149 papers related to the vascular complications of
diabetes, only eight had followed up a cohort assembled at the time
that the diagnosis of diabetes was made. Most have been studies of
the prevalence of complications for the available survivors of an
undefined initial population, making results difficult to interpret
(Kaplan & Fernstein, 1973)• However, recent carefully-conducted epi¬
demiological studies such as the Framingham (Garcia et al., 197^0 ant^
Whitehall studies (Fuller et al., 1980) have provided additional inform¬
ation confirming the excess mortality and morbidity from cardiovascular
causes in diabetes.
The frequency and severity of cardiovascular disease in
populations vary widely between different georaphical and ethnic groups
(Keys, 1970). Both autopsy and epidemiological surveys have shown that
the prevalence of cardiovascular disease, though consistently higher in
diabetics than non diabetics, follows the same pattern as in non diabetics
(Robertson & Strong, I968; Keen & Jarrett, 1979)„
Reasons for the excess cardiovascular disease in diabetics
remain obscure. Since diabetes is frequently accompanied by cardiovascular
risk factors such as hypertension, hyperlipidaemia and obesity, doubt
has been expressed as to whether diabetes is an independent risk factor
for arterial disease (Royal College of Physicians, 1976). However, recent
evidence from the Framingham study favours the view that the association
of known cardiovascular risk factors in diabetes does not satisfactorily
account for the excess mortality and morbidity (Kannel & McGee, 1979)o
Ischaemic heart disease
Janeway (1916) and Levine (1922) were the first to record
the association of diabetes and ischaemic heart disease. This impression
was subsequently confirmed by many autopsy (Root et al., 1939) Goldenberg
et al., 1958) and clinical studies (Bryfogle & Bradley, 1957)* Many of
these studies may be criticized on methodological grounds, but modern
prospective population surveys have essentially confirmed their findings
(Garcia et al., 197^; Fuller et al„, 1980). They also show that the normal
male preponderance of ischaemic heart disease is not observed in diabetics
where men and women have the same prevalence„ The reason for the increased
risk in diabetic women is unknown„
Diabetics have a higher mortality following myocardial
infarction than non diabetics (jarrett, 1961; Soler et al., 1975)-
The connexion between diabetes and ischaemic heart disease is further
suggested by the finding that patients with a proven myocardial infarction
have a high prevalence of abnormal glucose tolerance tests (Sowten,
1962; Bengtsson et al., 1973) which persists for months after the acute
event. There is now evidence that patients with only mild glucose in¬
tolerance have an increased risk of ischaemic heart disease. The
Whitehall study has shown that men with impaired glucose tolerance
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(defined as a 2h blood glucose following a 50g glucose load of 5A
to 6.1 mmol/l) have approximately double the risk of death from ischaemic
heart disease as subjects with strictly normal glucose tolerance (Fuller
et al., 1980).
Peripheral vascular disease
The prevalence of clinical vascular disease in the lower
extremities (generally defined as intermittent claudication, absence
of pulses and gangrene) is considerably higher in diabetics than non
diabetics (Kramer, 1932; Bryfogle & Bradley, 1957), and conversely,
the frequency of diabetes among patients with peripheral vascular disease
is higher than the prevalence of diabetes in the general population (Bell,
1957; Gensler et al., 1965). The reported high prevalence of gangrene
in these studies could have been due to infection in the pre-antibiotic
era, though more recent surveys confirm that peripheral vascular disease
is still commoner in the diabetic (Kahn et al., 1971; Garcia et al., 197^)•
Cerebrovascular disease
Autopsy studies have suggested that atherosclerotic cerebro¬
vascular disease is more common in diabetes (Baker et al., 1961; Grunnet,
1963)0 The Pramingham study has clearly shown an increased mortality and
morbidity from cerebrovascular accidents in diabetics (Garcia et al., 197^)>
though in a cohort study from the Joslin Clinic suggested that the increas¬
ed risk of cerebrovascular accidents was confined to women only (Kessler,
I97l)o These studies make no distinction between thrombotic and haemorrh-
agic strokes. Since diabetics appear to have a higher prevalence of hyper¬
tension than non diabetics (Pell & D'Alonzo, 1967; Garcia et al., I97^)>
a proportion of the increased cerebrovascular risk is likely to be due
to hypertensive rather than occlusive mechanisms.
5
ARTERIAL DISEASE
The Pathogenesis of Arterial Thrombosis
Thrombosis has been considered as the response of the
vessel wall to injury (Mustard & Packham, 1977), this response varying
according to the type of vessel involved. In arteries, a "white thrombus"
is formed, consisting mainly of aggregated platelets enmeshed in fibrin
(Poole & French, 1961; French, 1969). Venous thrombi have a much smaller
platelet contribution but are largely made up of erythrocytes, leucocytes
and fibrin (chandler, 1969; Paterson, 1969).
The initiating event in arterial thrombosis appears to be
endothelial damage, since a normal vascular endothelium is essentially non-
thrombogenic (Nalbandian & Henrv, 1978). Experimentally, thrombosis can be
induced by injuring the vessel wall by a variety of mechanical, electr¬
ical and chemical insults, but the mechanisms whereby the endothelium
is damaged in vivo is uncertain,, Mechanical stress, secondary to the
repeated passive distension and contraction of arteries - "vessel
fatigue" - has been invoked as a possibility (Duguid, 1976). Studies
of extracorporeal shunts in pigs (Murphy et al., 1962; Mustard et al.,
1962) have shown that deposition of thrombi occur principally at sites
of turbulence. Collisions between platelets in these areas may cause
release of proteolytic enzymes and permeability factors which results
in endothelial damage ( Mustard et al., 1965; Jorgensen et al., 1972,
1973). The development of fissures in an atheromatous plaque may also
provide a thrombogenic surface (Friedman & Van den Bovenkamp, 1966)°
Primates have been shown to develop endothelial lesions when fed high
cholesterol diets (Vesselinovitch & Getz, 197^0 or made homocystein-
aemic (Harker et al., 197^ ). In addition, testosterone has been shown
to cause damage to rabbit endothelium (Gaynor, 1973), but the relevance of
all these studies to human pathology is uncertain.
Arterial Thrombosis and Atheroma
Atheroma secondary to thrombosis
Rokitansky (I852) was the first to suggest that atheroma
might result from the deposition of blood elements. This view was
vigorously attacked by his contemporaries, notably Virchow (i860).
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Rokitansky's "encrustation" theory was revived by Duguid (19^6; 19^8)
who provided evidence that atheromatous plaque formation was the con¬
sequence of mural thrombi which became incorporated in the vessel wall
and organized to cause intimal thickening. Evidence from animal exper¬
iments and detailed human pathological studies have tended to confirm
Duguid's thrombogenic theory (Roberts & Ferrans, 1976; Woalf, 1978)°
On the basis of animal studies and tissue cultures of
smooth muscle cells, Ross and Glomset (1976) have proposed a mechanism
whereby endothelial damage leads to the formation of an atheromatous
plaque. It is suggested that repeated endothelial damage results in
platelet adhesion, with subsequent aggregation. Platelets release a
mitogenic factor, characterized as a polypeptide of I3000daltons mol¬
ecular weight (Antonaides et al., 1975; Busch et al., 1976). This
factor appears to be very similar to a polypeptide isolated from bovine
pituitary glands (Gospodarowicz, 197^), and triggers the proliferation
of cultured smooth muscle cells (Rutherford & Ross, 1976). The importance
of platelets in atherogenesis is suggested by the fact that experimental
animal models do not form atheromatous lesions if the animals are made
thrombocytopenic (Friedman et al., 1976) or given antiplatelet agents
such as dipyridamole (Burns et al., 1976). Other smooth muscle mitogens
such as low-density lipoprotein (Fischer-Dzoga & Kuo, 1976), insulin
(Stout et al., 1975) an& growth hormone (Ledet et al., 1976) may also
be important in stimulating smooth muscle cell accumulation in the
arterial intima. It may be that the platelet-derived mitogen is the
"trigger" for smooth muscle cell proliferation, with other factors play¬
ing a supportive role (Ross & Glomset, 1976). In culture, smooth muscle
cells have been shown to produce connective tissue proteins (Ross & Klebanoff,
I97l) and glycosaminoglycans (Wright & Ross, 1975), whch appear to be
able to bind low-density lipoproteins (iverius, 1972). In human biopsy
specimens, atheromatous plaques have been shown to contain fibrinogen
and fibrin, presumably derived from organized thrombus, which is also
capable of binding low-density lipoproteins (Smith & Staples, 1981).
It therefore seems possible that endothelial damage is
followed by platelet adhesion and aggregation. Release of the platelet
mitogen results in proliferation of smooth muscle cells in the arterial
intima, followed by the production of connective tissue and glycosamino¬
glycans and accumulation of lipoproteins to give an atheromatous plaque
(Ross & Glomset, 1976).
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Thrombosis secondary to atheroma
Thrombosis can cause arterial occlusion by several mech¬
anisms. Accumulation of mural thrombus can eventually result in a
complete blockage of the artery (Mitchell & Schwartz, 1965). Alternat¬
ively, mural thrombi may fragment, releasing a shower of platelet micro-
thrombi into the circulation. This possibility has been explored by
Jorgensen et al.(l967)» who found that infusion of adenosine-diphosphate
into the coronary arteries of pigs resulted in the formation of platelet
aggregates, and 36% of the animals died from ventricular fibrillation.
Platelet microemboli have been directly observed in the retinal circulat¬
ion of a few patients with transient ischaemic attacks (Ross Russel, 1961),
but other aterial diseases are impossible to observe directly, and as
Mitchell (l98l) has pointed out, many arterial conditions which present
clinically as stroke, peripheral disease and ischaemic heart disease
may be unrelated to thrombosis. The area of ischaemic heart disease has pro¬
voked the most controversy. Jorgensen et al. (1968) studied the pathology
of patients dying suddenly secondary to presumed coronary artery disease
and concluded that a large number of cases showed no signs of occlusive
thrombi. Roberts and Buja (1972) found occlusive thrombi in over half
of patients dying after myocardial infarction, but in only 8% of those
who died suddenly. On the other hand, Haerem (1972; 197*0 was able to
demonstrate microthrombi in the epicardial arteries of many patients
dying suddenly of coronary artery disease.
A further possible mechanism of sudden coronary death is
that transient platelet aggregation results in release of thromboxane A^,
causing vasoconstriction with resultant myocardial ischaemia precipitating
a fatal arrythmia. Patients with unstable angina have been reported to
have relatively high concentrations of thromboxane B^ (the metabolite
of thromboxane A ) in coronary sinus blood (Hirsh et al., 1981), but
this rise may follow, rather than be responsible for, the ischaemic
episode (Robertson et al., 1981).
In summary, it would appear that the haemostatic system,
and platelets in particular , play an important role in the initiation
of atheroma, and may be responsible for the later occlusive episodes
in an undefined proportion of cases. However, though it is accepted
that platelets are important mediators of thrombosis, it is still un¬
certain whether in vitro hyperactivity results in an increased risk
of thrombosis in vivo.
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MICROANGIOPATHY
The existence in diabetics of degenerative changes in¬
volving retina, kidney and nerves was recognized during the second half
of the I9th Century (McMillan, 1975)• However, it was not until the
introduction of insulin treatment, resulting in the prolongation in
life of young diabetics, that large numbers of diabetics were affected
by these complications. The important concept of a disease of small blood
vessels specific for diabetes was first formulated by Lundbaek (1953)
and involvement of the microcirculation in the retinal, renal and neurol¬
ogical sequelae of diabetes was emphasized by the introduction of the
term "microangiopathy" by Ditzel and Rooth (i955)>
Microvascular disease now accounts for a large proportion
of the mortality and morbidity of diabetic patients„ Diabetic renal
disease is now the commonest cause of death in almost half the patients
developing diabetes before the age of 20 (Knowles, 197^) and in the West,
diabetes is the commonest cause of blindness in adults under the age of
65 (Kahn & Miller, 197^0° Microvascular disease also contributes signif¬
icantly to diabetic peripheral vascular disease (Christensen, 1972) and
may also affect the capillaries supplying the myocardium resulting in
a form of cardiomyopathy (Ledet et al„, 1979).
The pathological basis of microangiopathy was established
by light microscopic studies which demonstrated the characteristic renal
lesion of diabetes - glomerular nodular sclerosis - by Kimmelstein and Wilson
(1936) and the presence of PAS-positive material in the walls of
capillaries in retinal (Priedenwald, 19^9) and renal (McManus, 19^+8)
specimens from diabetic patients. Shortly after the introduction of the
electron microscope, the vessel wall thickening was attributed to an
increase in the capillary basement membrane (Earquar et al0, 1959).
Basement membrane thickening has tended to dominate the thinking behind
diabetic microangiopathy ever since.
In view of the very different pathological appearances in
end-stage renal and retinal disease secondary to diabetes, and the possible
different aetiologies and precipitating factors influencing diabetic
small vessel disease in the various vascular beds of the body, the use of
the term "microangiopathy* to describe possibly quite different processes
has been questioned (Winegrad & Greene, 1978). However, basement membrane
thickening has been described in almost all small vessels in diabetic
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subjects (Reddi, I978), and capillary microaneurysms are not restricted
to the retina, but have also been observed in the glomeruli (Bloodworth,
1978) an(i the myocardium (Factor et al., 1980) of diabetics. Further
support for a unitarian view of diabetic small vessel disease comes from
a number of epidemiological studies which show that the prevalence of
clinically apparent retinopathy, nephropathy and neuropathy are strongly
correlated and all three are closely related to the duration of diabetes
(Pirart, 1978; Jarrett & Keen, 1979; West et al., 1980).
Aetiology and pathogenesis of diabetic microangiopathy
In spite of intensive histological and histochemical studies
over the past three decades, the cause of the characteristic lesions
of diabetes and the relationship between these pathological findings
and the clinical manifestations of diabetes remains unclear. The pro¬
longed controversy and sometimes acrimonious debate concerning the
stage in the evolution of diabetes that basement membrane thickening
occurs (Gundersen et al., 1978; Siperstein et al0, 1978) has tended to
obscure the fact that so little is known of the early functional
changes in the diabetic microvasculature, and of the sequence of events
leading to the loss of an eye or renal failure.
Any theory of the aetiology of diabetic microangiopathy
must reconcile a number of apparent paradoxes. There is now compelling
epidemiological evidence that when asymptomatic individuals with abnormal
glucose tolerance are observed over a number of years, retinopathy is
very rarely observed if the 2hr blood glucose level is less than II.I
mmol/l (Sayegh & Jarrett, 1979; Rushforth et al., 1979). This is in marked
contrast to ischaemic heart disease, where even impaired glucose tolerance
(5.^ - 6.1 mmol/l) results in a two-fold increase in mortality (Fuller
et al., I980). In contradistinction to ischaemic heart disease, there are
only small national differences in nephropathy and retinopathy prevalence
suggesting that environmental factors may be less important in micro¬
angiopathy (jarrett & Keen, 1979). The relationship between metabolic
control and the vascular complications of diabetes is a subject for
a separate thesis, but currently a consensus of opinion favours the view
that good control of blood glucose levels reduces the prevalence of
microvascular disease. Evidence in support of this view has recently
been extensively reviewed by Pirart (1978), Tchobroutsky (1978) a-nd
Skyler (1979).
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On the other hand, microvascular complications are not
inevitable consequences of diabetes, even after years of mediocre meta¬
bolic control. It is well documented that 20 - 40% of patients surviving
more than ^0 years of diabetes have little or no clinically important
evidence of microangiopathy (Oakley et al., 197^; Paz-Guevara et al.,
1975)° After 15 years of diabetes, 60 - 70% of patients have retinopathy
but only 5% develop maculopathy (background retinopathy with oedema of
the macula) and 3 - 10% proliferative retinopathy, the two main causes
of blindness in diabetes (Blakenship & Skyler, 1978) and 59% of a
series of ^0 year survivors had no noteworthy renal disease (Paz-
Guevara, 1975)» raising the possibility that only a subset of patients are
at risk of developing severe complications. Unfortunately, at present
there is no means of identifying this high risk group.
Apart from the duration of diabetes, hypertension appears
to favour the development of retinopathy (jarrett & Keen, 1979; West et
al0, 1980) though whether it accelerates the progression from background
to proliferative retinopathy is not known (West et al0, 1980).
Though there is a tendency for twins with diabetes to have the same
extent of retinopathy (Pyke & Tattersail, 1973) and certain HLA loci
have been reported to occur more commonly in diabetics with proliferative
retinopathy (Dornan et al., I98l) the role of heredity in microvascular
complications remains undetermined.
Growth hormone has been implicated in the pathogenesis
of microvascular disease, notably by the group of Lundbaek(l976)« The
beneficial effect of pituitary ablation on severe proliferative retino¬
pathy, and the finding of abnormal growth hormone secretion in insulin-
dependent diabetics suggest that this hormone could have a direct effect
on the micocirculation in the presence of hyperglycaemia.
Though organs such as eye and kidney have totally different
functions, the early changes of diabetes appear to be remarkably similar.
Direct observation of retinal and conjunctival vessels shows initially
dilatation of venules (Ditzel & Moinat, 1959). The stimulus for this
dilatation is not known but hypoxia has been proposed as one possibility.
At this early stage, retinal blood flow is increased, this abnormality
being partially reversible by tight metabolic control (Kohner, 1976).
In addition, there is a breakdown of the blood-retinal barrier as demon¬
strated by leakage of fluorescein into the vitreous (Cunha-Vaz et al.,
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1978)• Later changes include irreversible arteriolar constriction (Ditzel
& Moinat, 1959), followed by sclerosis of capillaries, arterioles and
venules (Ashton, 19^9). At this stage, areas of non-perfusion of the
retina may be observed on fluorescein angiography (Kohner, 1976), and
microaneurysms and hard exudates with dot and flame haemorrhages develop
to give the appearances described as background retinopathy (Blakenship
& Skyler, 1978). The cause of the areas of capillary non perfusion is
unknown, though microthrombus formation is one factor which may favour
retinal ischaemia. Retinal hypoxia is believed to be a strong stimulus
for new vessel formation(Blakenship & Skyler, 1978) so that capillary
occlusion appears to be of critical importance in the pathogenesis of
proliferative retinopathy,,
The morphology of the kidney is less easy to observe than
the retina. The earliest functional change appears to be an increase in
glomerular filtration rat^ reversible by insulin therapy (Morgensen et
al., 1979). The glomerular filtration rate remains above normal until
the onset of proteinuria when it descends to the normal range before
falling below normal with the onset of renal failure (Morgensen et al.,
1979). As with the increased retinal blood flow, the cause of the in¬
creased glomerular filtration rate is unknown, though an increase in
the surface area of the glomerulus may be involved (Morgensen et al.,
1979). Subsequently, the afferent glomerular arterioles undergo arterio¬
sclerosis (Bell, 1953 ) followed by diffuse and then nodular glomerulo¬
sclerosis (fhrquar et al., 1959).
Similar changes of initial venous dilatation, followed by
arteriolar constriction and sclerosis of small blood vessels has also
been described in the skin of diabetic patients (McMillan, 1975).
Though neuropathy is linked in time with the appearance
of retinopathy and nephropathy it is less certain that a vascular aetiology
underlies the the various neuropathic syndromes of diabetes, where metabolic
factors may be as important (Thomas& Ward, 1975). Nonetheless, the finding
of fibrin-plugged vessels supplying sural nerves taken from patients
with evidence of diabetic neuropathy suggests that neuronal ischaemia
may be involved in certain neuropathies (Timperley et al., 1976).
1 2
GLYC0SYLATION OF HAEMOGLOBIN
Until recently, assessment of long term glycaemic control
of diabetic patients has been severely limited. Determination of urinary
glucose concentrations is notoriously unreliable and problems of sampling.
blood glucose concentrations sufficiently frequently to obtain an accurate
estimation of overall blood glucose control over a prolonged period of
time seemed intractable. This problem has been greatly simplified by the
observation that the concentration of glycosylated haemoglobins correlates
with mean blood glucose levels. Haemoglobin A^c (HbA^ ) is the most
abundant minor component of human haemoglobin A, normally comprising
approximately of the total haemoglobin. Interest in HbAT was stim-
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ulated by the discovery by Rahbai (1968) that this component was two
to three times higher in diabetic compared with non diabetic subjects.
The biosynthesis and chemical structure of HbA^ have recently been review¬
ed by Bunn (l98l). Glucose first condenses with the N-terminal amino
group of the p-chain of haemoglobin to form a Schiff base (pre-HM^ ).
Pre-HbAjc is unstable and can either dissociate to HbA and glucose or
undergo an Amadori reaction to form a more stable ketoamine linkage
(HbAj ). This almost irreversible reaction proceeds slowly and contin¬
uously throughout the lifespan of the erythrocyte, the rate being de¬
pendent on the blood glucose concentration. Other minor components:
HbA , HbA , HbA and HbA are also glycosylated but are quantit-
_Lci JL D -Lcl-j- 2,
atively less important than HbAjc«
A number of methods have been developed to measure glycosylated
haemoglobin. HbA^c elutes more rapidly than HbA on cation exchange chromato¬
graphy. Several minor components of haemoglobin (HbA^a,HbA^_^) elute faster
than HbAjc. When the total fast fraction (HbA^a, HbA^, HbA^c) is measured
together, it is referred to as HbAT or more simply, HbA . A number of"" J_cl~C J-
column chromatographic methods of varying degrees of complexity have been
devized (reviewed by Bunn, 1981). but for routine clinical use, provided
that the pH of the elution buffers and the temperature are carefully
controlled, the microcolumn method (which measures HbA^.) gives satis¬
factory results (Abraham et al., 1978). This is the method employed in
Parts III and IV of this Thesis.
Other methods including isoelectric focussing (Beccaria
et al., 1978) and a colorimetric method (Fluckiger & Winterhalter, 1976)
have also been developed, but column methods remain the most popular.
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A number of reports have confirmed the utility of HbAIc
and HbAj. measurements in the assessment of glycaemic control in diabetic
patients (Koenig et al.f 1976; Ditzel & Kjaergaard, 1978; Boden et al.,
1980). These reports indicate that HbA concentrations correlate well
with glycosuria and mean blood glucose measurements. When poor metabolic
control is improved, HbA^ levels fall towards normal, with a lag period
of 4 - 6 weeks before a plateau is reached, though there is evidence
that levels can rise more rapidly if a period of good control is followed
by high blood glucose levels (Boden et al., 1980).
Measurement of glycosylated haemoglobin has therefore
provided a useful tool, not only for the management of diabetic patients,
but also for the investigation of the relationship between glycaemic
control, other haematological abnormalities and the development of vascular
complications in diabetes.
It is not known whether increased glycosylation of haemoglobin
alters erythrocyte function in diabetes. Though the addition of 2,3-
diphosphoglycerate causes much less of a reduction in oxygen affinity
of HbA^ compared to that of HbA (Bunn & Briehl, 1970), the oxygenation
of intact erythrocytes appears to be only slightly affected by alterations
in HbAT (Bunn, 1981).1c
Non-enzymic glycosylation is not exclusive to haemoglobin,
but is likely to affect many other proteins. Recently, glycosylation
of albumin (Guthrow et al., 1979)> fibrinogen (McVerry et al., 1980a)
erythrocyte membrane protein (Miller et al., 1980), collagen (Rosenberg
et al., 1979) and crystalline lens protein (pande et al., 1979) have
been described in diabetic patients. Whether such biochemical modifications
result in altered function is currently under study. One such experiment
has shown that when glycosylated plasma proteins were injected into
mice, thckening of the glomerular basement membrane resulted compared






The existence of red cells was recognized by the 17th
centuary, but it is doubtful whether platelets were identified until
chromatic aberration of the early compound microscopes was overcome by
Johseph Lister in 1826 (Robb-Smith, 1967). Gulliver (1842), in an append¬
ix to his translation of the works of Gerber, described spheres of 2.5
micron in diameter which were almost certainly platelets. He observed
that these particles adhered to white cells and developed granules on
standing, but believed that they were not involved in fibrin formation.
In the same year, Addison (1842), examining coagulating blood, noted
that "the fluid, i.e. liquor sanguis, contained a great number of minute
molecules or granules". He suggested that they arose from broken-down
white cells and that they could be important in the generation of fibrin.
Also in 18^2, Donne described three blood particles: red cells, white
cells and "des globulins du chyle", the latter being described as 1/300
mm in diameter. Since he used water as a diluent, it is uncertain
that the droplets of chyle were indeed platelets (Robb-Smith, 1967).
The existence of a third particle smaller than red and
white cells was confirmed by Simon (1844) who described them as mol¬
ecules of fibrin and Zimmerman (18^6) who believed that they were
red cell precursors. Wharton Jones (I850) made a detailed study of the
blood vessels of the frog's foot in response to inflammation. He found
that following in jury to the vessel wall "grayish granulous-looking plugs,
composed, apparently, of colourles corpuscles and coagulated fibrin,
are sometimes to be seen to block up an artery". He was therefore prob¬
ably the first to describe in vivo thrombus formation but, as frog plat¬
elets are nucleated, failed to identify the corpuscles as platelets,
believing them to be white cells.
Beale (I864-) considered fibrin to be derived from platelets
"the production of the material we know as fibrin is due to the gradual
death of minute particles of the living matter of the white, and small
colourless corpuscles, which takes place under ordinary circumstances
when blood escapes from the vessels of the living body". Osier (187^)
described platelet clumping and pseudopod formation but confessed "we
know nothing of the origin and destiny of these corpuscles".
Hayem (1878) established the platelet as a separate entity
(l'hematoblaste ), counted them reasonably accurately, recognized their
role in clot formation and retraction but believed that they were red
cell precursors. Progress during the next forty years was consolidated
and amplified by the work of Bizzozero (1882). He damaged guinea pig
blood vessels and showed that the initial stage in thrombus formation
was platelet adhesion and aggregation to the site of injury. He was the
first to use the term platelet (bltltpl&tchen). These observations were
extended by Eberth and Schimmelbusch (1886), who showed that platelet
accumulation occurred before fibrin formation, and introduced the term
"viscous metamorphosis" to describe the shape change induced by platelets
in contact with a damaged blood vessel or foreign surface.
The platelet then fell into obscurity until Wright (1905)
showed clearly that platelets were derived from a bone marrow precursor,
the megakaryocyte. Pratt(l905) devised a more accurate method of count¬
ing platelets and Duke (19IO) demonstrated the first haemorrhagic dis¬
order secondary to a low platelet count.
A further fifty years was to elapse before the enormous
growth in the understanding of platelet histology, biochemistry and
physiology. In spite of these advances, the role of the platelet in
thromboembolic disease is still not fully understood.
PLATELET STRUCTURE AND PHYSIOLOGY
The resting platelet is disc shaped, measuring 2-4 microns
in diameter. Platelet ultrastructure has been extensively investigated
by electron microscopy, notably by the group of White (White, 1971;
White, 1972; White & Gerrard, 1976). The platelet membrane is a triple
layered structure with an equatorial band of microtubules running round
the perimeter close to the surface membrane, which appears to maintain
the platelet's discoid shape. Intracellular structures include a surface
connecting vesicular system (the open cannicular system) and a complex
of dense vacuoles (the dense tubular system) which may represent rem¬
nants of the megakaryocyte endoplasmic reticulum (White, I972). Micro¬
filaments are distributed throughout the cytoplasm, but seem to be
connected to the wall of the surface of the external membrane, and are
believed to be components of the actinomyosin-like contractile system
("thrombosthenin").
At least three types of membrane-bound granules can be demon¬
strated by electron microscopy. Alpha granules, containing fibrinogen,
P -thromboglobulin, platelet factor 4 and. a mitogenic factor; dense
bodies containing calcium, adenosine diphosphate, adenosine triphos¬
phate and serotonin and lysosomal granules (shown with histological
stains) containing acid hydrolases (White, 1971; Day & Holmsen, 1971;
Bentfield & Bainton, 1975)* Mitochondria and glycogen granules are
also present, equipping the cell for glycolysis and aerobic respirat¬
ion.
Platelets are derived from megakaryocytes, which probably share a common
origin with myeloid and erythroid cells (Becher et al., 1963). Once
mature, the megakaryocyte transforms from a spherical to a highly irreg¬
ular shape (Behke, 1969) and fragmentation of the cytoplasm produces
2,000 to 3>000 platelets. This phenomenon occurs when the ploidy number
of the megekaryocytes is between 8 and 32 ( Penington & Streatfield,
1975)t and it is thought that ploidy number at release is a feature
governing size of the platelets( Penington & Streatfield, 1975> Paulus
1975)• Platelets show a marked variation in volume and density in
normal subjects (McDonald et al., 1964; Karpatkin, 1969) though it
is still unclear to what extent dimunition of platelet size occurs
during the life of the platelet is still unclear. The normal platelet
count in man ranges from 250,000 - 500,000/ul and turnover is approx-
imately 3.5 x DO /ml/day (Harker & Finch, 1969). Platelets survive in
the circulation under normal conditions for 9 - II days. Recent evid¬
ence suggests that platelets lose portions of their membrane glycoprot¬
eins whilst in the circulation (George et al„, 1976, 1978)
and loss of platelet surface sialic acid has been shown to accelerate
platelet removal from the circulation (Greenberg et al., 1975).
PLATELET FUNCTION
A diverse range of functions and properties have been attributed
to platelets including storage of substances such as adenosine diphos¬
phate and serotonin, adhesion, aggregation, procoagulant activity, con¬
traction, secretion, prostaglandin synthesis and phagocytosis (Gordon &
Milner, 1976). The following brief review will concentrate on these
properties which-seem most relevant to the mechanisms of thrombosis.
Platelet Adhesion
Following the observations of Bizzozero (1882), Bounameau (1959)
and Hugues (i960) realized that platelets adhered in vivo primarily
'to subendothelial connective tissue. Subsequent investigators establish¬
ed that platelets adhered to several components of the subendothelium
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including collagen fibrils (Kjaerheim&Hovig, 1962; Hugues & Lapiere,
1964), elastin (Hugues, i960) and blood vessel basement membrane
(Baumgartner et al., 1967)0
In vivo adhesion to subendothelium is usually followed by
platelet-platelet interactions (aggregation) leading to the formation
of mural platelet thrombi or platelet plugs0 Electron microscope studies
of this process have shown that the participating platelets become de-
granulated (Kjaerheim & Hovig, 1962). This degranulation was later found
to correspond to the platelet release reaction (Grette, 1962; Holmsen
et al., 1969) which is observed when platelets are aggregated in
vitro.
Von Willebrand factor and platelet adhesion
The role of a plasmatic factor in platelet adhesion was first
recognized following the discovery that the prolonged bleeding time
found in von Willebrand's disease could be corrected by the transfusion
of factor VIII concentrate (Nilsson & Holmberg, 1979). The terminology
and the molecular heterogeneity of the factor VIII:von Willebrand mol¬
ecule are complex, and only a brief resume can be given in this section.
Von Willebrand factor has been the subject of a number of reviews (Bloom,
1977; Koutts et al., 1979; Bloom, 1979). The human factor VIII:von Will¬
ebrand factor has two main biological activities: procoagulant activity
(FVIII:C), the ability to correct the long clotting time of haemophilic
plasma and von Willebrand activity ( VIII:vWF), the ability to cause
platelet retention in a glass bead column or to aggregate platelets in
the presence of the antibiotic ristocetin. Material which precipitates
with heterologous antisera, factor VHI-related antigen (VIIIR:Ag), is
associated with the platelet-related activities (Koutts et al., 1979;
Bloom, 1979).
The factor VIII molecule has proved difficult to purify and
characterize. It is a glycoprotein with repeating covalently linked
subunits of molecular weight 250,000 daltons. The size of the oligomer
in vivo is not certain, but may be between 0.5 x 10^ to 20 x 10 daltons,
the larger oligomers seeming to be most active in promoting platelet
adhesion (Bloom, 1977).
Endothelial cells have been shown to produce VIIIR:Ag, but not
VIII:C activity (jaffe et al., 1973; Tuddenham et al., 1981). This ant¬
igen is also found in platelets, and is released when they undergo
aggregation (Koutts et al., 1978)* In contrast, FVIII:C activity has
never been convincingly been demonstrated in endothelial cells or
platelets, but may be produced in the reticuloendothelial system (Bloom,
I979).
When blood from patients with von Willebrand's disease is pass¬
ed over de-endothelialized rabbit aortas, platelets adhere poorly, part¬
icularly at high shear rates, suggesting a role for VIII:vWf in promoting
platelet adhesion (Weiss et al., 1978). Specific receptors for VIII:vWf
exist on the platelet membrane, and are activated in vitro by ristocetin
(Kao et al., 1979). Factor VIIIR:Ag, in addition to being present in the
plasma, has recently also been demonstrated in the subendothelium of
human umbilical vessels (Rand et al., 1980) and Sakariassen et al. (1979)
have shown that the adherence of platelets to de-endothelialized
human arteries corresponded to the quantity of VIIIRsAg bound to the
subendothelium. However, the relative contributions of plasmatic,
platelet, and subendothelial VIII:vWf to normal haemostasis is not
known. Because of a lack of suitable models which satisfactorily measure
increased platelet adhesion, it is not known whether high levels of
factor VIII:vWf cause an increased risk of thrombus formation (Baton et
al., 1981).
Platelet Aggregation
In I960, Hellem discovered that a substance (R factor) caused
platelets to aggregate in vitro, this factor being identified as aden¬
osine diphosphate by Gaarder et al.(l96l)„ Knowledge of platelet be¬
haviour advanced rapidly with the invention of the platelet aggrego-
meter (Born & Gross, 1962), which enabled the turbimetric measurement
of platelet aggregation under controlled conditions.
Platelets have been found to react to a diverse range of stim¬
uli in a remarkably uniform manner, which has been termed the Basic
Platelet Reaction or BPR (Holmsen, 1976). The BPR may be divided into
three phases: induction, transmission and execution.
Induction
Over fifty substances are capable of inducing platelet aggreg¬
ation in vitro (Mustard & Packham, 1970), though it is likely that
. relatively few are important in vivo. Platelets interact with a large
number of these agents through specific receptor mechanisms (Mills &
Macfarlane, 1976). This diversity of receptor sites is provided by
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the glycoprotein coat of the platelet membrane. Identification of
functional glycoproteins has been facilitated by the study of patients
with inherited bleeding disorders caused by a defect in platelet func¬
tion. Thus, glycoprotein lb (absent in Bernard-Soulier syndrome)is
known to be required for the binding of FVIII:vWf and adhesion to sub-
endothelium, and glycoprotein lib and III (absent in Glanzmann's
thrombasthenia) is required for platelet aggregation and clot retraction.
The characterization of these functional glycoproteins has recently
been reviewed by Nurden and Caen (1979) and Phillips (1980).
Agonists of platelet induction may be divided into two main
groups: macromolecules such as thrombin, collagen and antibody-antigen
complexes; and small molecular weight compounds such as ADP, adrenaline
and serotonin (Mills & Macfarlane, 1976).
Transmission
By a process that is still not fully understood, induction
causes an alteration in the platelet membrane which results in the
mobilization of a transmitter, which is almost certainly calcium, into
the platelet cytosol (Holmsen, 1976). The precise role of calcium is
difficult to establish in spite of extensive studies of calcium flux
into the cell, and of changes in intracellular calcium levels . This
is because calcium is one of the constituents released by the dense bodies,
and the quantity released is greatly in excess of the small changes in
cytoplasmic calcium which probably regulate cell function (Crawford &
Taylor, 1977)• Recent work suggests that one component of the platelet
contractile system, myosin light chain,is phosphorylated by a specific
protein kinase (Daniel & Adelstein, 1976) which is activated by calcium
through a calmodulin subunit (Hathaway & Adelstein, 1979).Phosphorylat¬
ion of the myosin stimulates actomyosin ATPase (Adelson & Conti, 1973).
resulting in contraction (Lebowitz & Cooke, 1978). However, though
myosin phosphorylation is strongly associated with the secretory process,
it seems not to be associated with shape change and aggregation (Haslam
& Lynham,1978).
Another important modulator of platelet reactivity is cyclic
AMP. Agents which induce platelet aggregation tend to reduce cyclic
AMP levels, while inhibition of aggregation increases levels of this
agent (Haslam & Taylor, 1971; Salzman, 1972). However, this is certainly
an oversimplified view, since the ability of various agonists of platelet
aggregation to reduce cyclic AMP levels does not parallel their efficiency
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as aggregating agents (Robison et al., 1971; McDonald & Stuart, 1973).
How cyclic AMP influences platelet aggregation is unknown, though regul¬
ation of cyclic AMP-dependant protein kinases may be important (Booyse
et al., 1976; Steiner, 1976).
Execution
Influx of calcium into the cytosol results in the transformation
of the platelet from a disc to a sphere with long cytoplasmic protrusions,
the so-called platelet shape change ( Born, 1970).,
Shape change is an energy-requiring process (Holmsen et al., 197^)» and
permits interactions between similarly-stimulated platelets and the
liberation of platelet granule contents, the process named the release
reaction by Grette (1962). Day and Holmsen (1971) showed that release
of dense body constituents induced by ADP, adrenaline or low concen¬
trations of thrombin or collagen was not accompanied by release of a
granules whereas higher concentrations of thrombin and collagen caused
release of both granule constituents.
Products released by the platelet release reaction have important
functions in haemostas is and thrombus formation. In addition to ADP,
platelets also release thromboxane A^, a powerful vasoconstrictor and
platelet aggregating agent (see below). Permeability factors (Mustard
et al., 1965) may result in endothelial cell injury (Jorgensen et al.,
1972) and a mitogenic factor (Ross et al., 197^0 are also liberated,
and may be important in the initial stages of atherogenesis (Ross &
Glomset, 1976). Fibrinogen and platelet factor k are also released,
and platelet factor 3 is made available on the platelet surface, thus
favouring coagulation (see below).
Platelets and Coagulation
Blood coagulates more efficiently when platelets are present,
but this coagulant activity is present only after platelets have under¬
gone the release reaction (Marcus, 1969). This activity has been termed
platelet factor 3 (PF3) and appears to be related to phospholipids which
are made available on the platelet surface during the release reaction
(Marcus, I969). PF3 activity is required for the activation of factor X
by IXa, VIII and calcium and also in the reaction in which Xa, V and
calcium convert prothrombin to thrombin (Walsh, 197^)• There is also
evidence that platelets are capable of activating factor XII (in the
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presence of ADP) and of factor XI (inthe presence of collagen),
(Walsh, 197*0.
The platelet release reaction also results in the liber¬
ation of two platelet-specific proteins, p-thromboglobulin and plat¬
elet factor k (Moore et al., 1975 > Niewiarowski & Thomas, 1969)0 Plat¬
elet factor k (PF<^) has antiheparin properties which may be of import¬
ance during heparin therapy, but it could also interact with heparans
produced by the vessel wall (Rosenberg, 1975)* The function of p-thromb¬
oglobulin is uncertain. It is related, though immunologically distinct
from PP4- and recently Rucinski et al0 (1979) have described another
protein closely related to p-thromboglobulin, which they have named
"low-affinity PFV.' Sensitive radioimmunoassays have been developed
for both PF4- and p-thromboglobulin, and these tests have been widely
used as markers of the platelet release reaction in vivo (Zahavi and Kakkar,
1980 ; Kaplan & Owen, 1981).
Prostaglandins, Thromboxanes, Platelets and the Vessel Wall
The realization that prostaglandins might play an important
role in platelet reactions began with the observation that platelets
produce PGEg and PGF^ during aggregation (Smith & Willis, 1970), an^
that this production was blocked by aspirin (Smith & Willis, 1971; Vane,
I97l). Since aspirin had previously been shown to inhibit platelet
aggregation (O'Brien, 1968; Zucker & Peterson, 1968), inhibition of
prostaglandins seemed to provide an explanation of this phenomenon.
However, PGE^and PGF^ were shown to have only minor effects on plat¬
elet aggregation(Shio & Ramwell, 1972). Incubation of platelet micro¬
somes was found to generate an unstable compound with potent pro-aggreg-
atory properties which was named labile aggregation stimulating substance
or LASS (Willis et al., 197*0 •
The group of Samuelsson had previously demonstrated the existence of
an enzme present in sheep vesicular gland preparations (cyclo-oxygenase)
capable of converting arachidonic acid to cyclic endoperoxides and
subsequently that platelets produced two highly unstable endoperoxides
termed PGG and PGH which were potent inducers of platelet aggregation
( Hamberg et al., I97*+a, I97^b), the formation of which was blocked
by aspirin (Hamberg & Samuelsson, 197*0 • The cyclic endoperoxides were
later found to rapidly be transformed into another labile substance,
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thromboxane A , another powerful aggregating agent (Hamberg et al.,
1975), which appears to be more important than LGG^ and PGHp in vivo
(Smith et al., 1976). The exact mode of action of thomboxane on
platelet aggregation is uncertain, opinions differing as to whether
it acts by potentiating the release of intraplatelet ADP (Zucker, 1980)
or whether it has a separate effect on intracellular calcium transport
(Gerrard & White, 1978). Thromboxane A^ is also a powerful vasoconstrict¬
or and is rapidly degraded into the less active compound, thromboxane
(Hamberg et al., 1975).
In 1976, an arachidonic acid derivative produced by vessel wall
preparations with potent platelet inhibitory and vasodilatory properties
was identified (Moncada et al., 1976, 1977). Initially named PGX, the
substance was finally called prostacyclin or PGI,,. Like thromboxane A^,
PGI^ is formed from a,rachidonic acid by the action of cyclo-oxygenase,
and this process is inhibited by aspirin (Moncada et al., 1977).
The principal effect of PGIg appears to be an increase in
cyclic AMP (Gorman et al., 1977)° Like thromboxane A^ , PGIg has a
short half-life in plasma, being degraded to the stable form, 6-keto-
PGF.J. , which has only minor effects on the inhibition of platelet
function (Johnson et al., 1976).
Following the discovery of PGI^, the concept has arisen that
this prostaglandin is the physiological medium that protects the vessel
wall from the accumulation of platelet aggregates, and explains the
relative non-thrombotic surface provided by the endothelial cell mono¬
layer. It is suggested that, under normal circumstances, a delicate
balance exists between platelet thromboxane production and vessel wall
PGI production, with an increase in thromboxane relative to PGI
production resulting in thrombus formation (Moncada & Vane, 1979).
Complete acceptance of this attractive hypothesis is hindered by two
lines of evidence. Firstly, thrombin and collagen, likely to be import¬
ant inducers of platelet aggregation in vivo, have been shown to be
capable of aggregating platelets after inhibition of platelet cyclo-
oxygenase, suggesting prostaglandin independent pathways of platelet
aggregation ( Zucker & Peterson, 1970; Packham et al., 1977)° Secondly,
congenital cyclo-oxygenase deficiency leads to only a mild bleeding
disorder (Malmsten et al., 1975) and- ingestion of high doses of aspirin
which block both platelet thromboxane and vessel wall prostacyclin
production result in a prolonged bleeding time (Preston et al„, I98l),
suggesting that in the absence of prostaglandins, the balance of haemo-
stasis favours haemorrhage rather than thrombosis.
TESTS OF PLATELET FUNCTION
In comparison with the sophisticated techniques which
have been used to study platelet biochemistry, physiology and pharmo-
cology, tests currently used to assess platelet behaviour in clinical
studies are relatively primitive. The majority of these tests are per¬
formed in vitro and generally measure platelet-surface interactions
("adhesion") or platelet-platelet interactions ("aggregation"),
though measurements of platelet survival and plasma levels of certain
platelet-specific proteins ( p-thromboglobulin and PF^) have also been
used to assess platelet function in thrombotic conditions.
The relation between these different tests and their rel¬
evance to thrombogenesis has not yet been clearly established; lack
of standardization of these tests has made comparison of results between
different laboratories difficult, and may explain many of the dis¬
crepancies which have been reported.
In Vitro Tests
Platelet adhesion
These tests have been divided into two groups : those
which measure platelet adhesion alone, and those which measure adhes¬
ion-aggregation (Bowie& Owren, 1978). Tests of adhesion alone include
exposure of blood or platelet-rich plasma to glass slides or cover
slips, rotating glass tubes coated with collagen or other proteins
whereas adhesion-aggregation is measured by exposing blood or platelet-
rich plasma to rotating glass bulbs or by filtration through glass
wool or glass bead columns. These methods are reviewed fully by
Meyer (1972) and Bowie and Owren (1978). Largely because of its simpli¬
city, the glass bead method has been most extensively. Native or anti-
coagulated blood, or platelet-rich plasma is passed through a plastic
tube filled with glass beads of a standard size and the percentage of
platelets retained in the column is calculated from the platelet counts
before and after the filtration„ The test is influenced by many factors
such as haematocrit, anticoagulant, temperature, flow rate through the
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and even the type of plastic used to make the column (Meyer, 1972;
Bowie & Owren, 1978)„ In spite of these technical problems, there is
general agreement that platelet adhesion (more correctly termed
platelet retention) is reduced in patients with von Willebrand's
disease. However, results in patients with thrombotic diseases are
contradictory, both raised and normal retention having been reported
(Meyer, 1972). A notable exception is diabetes mellitus, where in¬
creased platelet retention has frequently been described. The sig¬
nificance of this finding will be discussed more fully in Part V ,
Section 2.
Platelet aggregation
The most widely used test of platelet aggregation was
first described by Born and Gross (1962) and O'Brien (1962). Gitrated
platelet-rich plasma is placed in a transparent cuvette and light
transmission through the platelet suspension is recorded. Upon addition
of an aggregating agent to the stirred platelet suspension, aggregate
formation increases the light transmission in a manner proportional
to the rate and extent of platelet aggregation. Different inducers
of platelet aggregation produce different shapes of aggregation traces.
For example, adenosine diphosphate and adrenaline produce single,
reversible curves at low concentrations, but at higher concentrations
of inducer, a biphasic response is obtained, the second irreversible
phase being parallelled by the release reaction (Zucker & Peterson,
1970). This second phase of platelet aggregation is only observed when
the extracellular calcium concentration is low (e.g„ citrated platelet
rich plasma), and its in vivo relevance has been questioned (Mustard et
al., 1975; Macfarlane & Mills, 1975). Arachidonic acid (Kinlough-Rathbone
et al., 1976) and ristocetin (Howard, 1975) also are capable of aggregat¬
ing platelets and inducing a 'biphasic response in the aggregometer.
This second phase can be abolished by the addition of non-steroidal
anti-inflammatory drugs such as aspirin and indomethacin by inhibition
of platelet eyelo-oxygenase (Roth & Majerus, 1975)= When collagen is
added to platelet-rich plasma, a lag phase is followed by a single
aggregation curve, which is associated with release of adenosine di¬
phosphate and thromboxane A^ (Smith et al„, 1976).
Quantification of platelet aggregation curves has not
been standardized. The majority of authors measure the maximum change,
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the time taken to reach maximum change and the initial rate of change
of light transmittence. However, a number of investigators have tried
to analyze aggregation mathematically (Skoza. et al., 1967; Projmovic,
1978). Mathematical treatment of platelet aggregation curves will be
discussed more fully in Part III, Section 2 of this Thesis.
Platelet aggregation, as assessed in the aggregometer, is
influenced by a large number of technical factors such as size and shape
of stir bars, temperature, concentration of calcium, pH and "temporal
drift" - the variation in aggregability with time after blood sampling.
In addition, smoking, excercise, mental stress and menstruation in women
may causeaggregation curves to change markedly. These variables are
reviewed extensively by Sixma, (1972), Packham et al., (1978) and
Projmovic (1978). Unless such factors are carefully controlled, spurious
results may arise. These technical problems may in part explain the
lack of agreement between different clinical studies. For example,
increased sensitivity to aggregating agents has been described in patients
with stable ischaemic heart disease (O'Brien et al., 1966; Goldenfarb
et al., 1971; Dreyfuss & Zahavi 1973) but not by others (Enticknap et
alo, 1969; Steele et al., 1973).
Other tests which measure platelet aggregation in vitro
including screen filtration (Swank, 1968) and membrane capacitance (Bicher,
I97l) bo not appear to offer advantages over the conventional aggregometer
technique, and have not been widely adopted. Platelet electrophoresis is
an interesting though laborious technique. Changes in electrophoretic
mobility have been reported in platelets from patients with ischaemic
heart disease by Hampton and Mitchell (197*0 'bu't others have failed
to find this abnormality (Grottum, 1968).
In Vivo Tests
Bleeding time
This simple test can be made reasonably reproducible,
particularly if the technique modified by Mielke et al. (1969) is used.
Lengthening of the bleedingtime occurs in certain quantitive and
quantitive plateIt disorders such as von Willebrand's disease and
thrombasthenia, but the technique has not been widely used in thrombotic
states (Hirsh et al., 1978).
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Platelet survival
This approach to the study of platelet behaviour will
be discussed in greater detail in Part III, Section I.
Though time-consuming, it offers the advantage of assessment of the
platelet -vessel wall interaction, rather than of the platelet in isolation.
Platelet aggregate formation
In this technique, blood is taken into anticoagulant
(EDTA) with and without formalin. The two samples are centrifuge! to
sediment any platelet aggregates fixed by the formalin, leaving the
remaining platelets in suspension. Platelet counts of formalinized
and unformalinized platelet-rich plasmaare compared to give an estimate
of platelet aggregates (Wu & Hoak 197*0° It is not certain if this
simple test does really measure circulating platelet aggregates, or
whether it reflects in vitro activation of platelets during blood
collection. The test appears to be abnormal during acute thrombosis,
returning to normal a few days after the acute episode (Dougherty et
al., 1977).
Beta-thromboglobulin and platelet factor ^
Plasma measurements of these two proteins have been used
extensively as tests of "in vivo" release of platelets in a wide
variety of thombotic disorders (reviewed by Zahavi & Kakkar, 1980;
Kaplan & Owen, I98l). Both tests readily yield false positives unless
blood collection and processing are performed scrupulously to avoid
in vitro platelet release. Though a correlation between raised p-thrombo-
globulin levels and shortened platelet survival has been described
(Ludlam et al., 1979; Doyle et al., 1980), neither the administration
of sulphinpyrazone (Ludlam et al., 1979; Han et al., 1979) nor aspirin
and dipyridamole (Han et al., 1979). both of which prolonged platelet
survival, reduced p-thromboglobulin levels, suggesting that
plasma levels of p- thromboglobulin and platelet survival do not
neccessarily record the same phenomenon.
SECTION 3 THE COAGULATION SYSTEM
the coagulation system
HISTORICAL
In I666 Malphigi observed when blood was allowed to clot,
and the clot was washed, a mass of white fibres remained (Pickering,
1928). Ruysh (1707) discovered that the elastic material obtained by
whipping blood was similar to that obtained by washing clots (Pick¬
ering, 1928) and this material was named fibrin (la fibrine) by
Chaptal (l795)«
Hewson (1770) showed that coagulation could be inhibited
by neutral salts such as sodium sulphate. Arthus and Pages (1890)
established the importance of calcium in fibrin formation and from the
work of Hammarsten (l899)» Schmidt (I872) and Morawitz (1905) the
known clotting factors were named and the so-called "classical" theory
of blood coagulation emerged (Fig i).
In essence the theory proposed two separate inactive comp¬
onents (prothrombin and fibrinogen) triggered into a two-stage reaction
by an activator (thromboplastin) released by cellular damage, a concept
which remained unchallenged for nearly 50 years.
An advance was made possible by the introduction by Quick
(1935) of the one-stage prothrombin time test, which was based on the
assumption that if calcium, thromboplastin and fibrinogen were present
in excess, the clotting time would be a reflection of the prothrombin
concentration. In 19^3 Quick observed that stored human plasma devel¬
oped a prolonged prothrombin time, which was corrected by the addition
of dicoumarized dog plasma. This led Quick to propose that prothrombin
consisted of a labile fraction (fraction a) and a stable fraction (fract¬
ion B) reduced by dicoumarin. In 19^7> publishing work performed in
19^-, Owren described a patient whose plasma had a prolonged prothrom¬
bin time which was corrected by addition of a small amount of normal
plasma from prothrombin had been removed by adsorption. Owren named
the new component factorV, which represented Quick's labile factor.
The stable factor was finally designated factor VII by Koller et al.
(l95l)o The identification of factors V and VII did not greatly alter
the classical theory, but a problem arose when it was appreciated that
haemophilic patients had a prolonged clotting time in glass tubes, but
a normal prothrombin timec Weil (1906) had previously shown that normal
blood could correct the long clotting time of haemophilic blood, and
I
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this observation was later confirmed by Pohle and Taylor (1937) and- .
Minot and Taylor (19^7) who found that the correction in clotting time
was produced by a plasma fraction free of fibrinogen and containing
only traces of prothrombin This factor was termed antihaemophilic
factor, and was followed by a series of reports of patients with coag¬
ulation abnormalities resulting in the identification of Christmas fact¬
or (Biggs et al., 1952; Aggeler et al„, 1952), plasma thromboplastin
antecedent (Rosenthal et al., 1953)> Hageman factor (Ratnoff & Colopy,
1955). Stuart-Prower factor (Telfer et al., 1956; Hougie et al., 1957)
and fibrin stabilizing factor (Lorand & Jacobsen, 1958)• The confusion
over the nomenclature of these factors was resolved by an International
Committee who assigned a Roman numeral to each factor (Macfarlane, 1972).
More recently, the discovery of two other coagulation factor defects,
Fletcher factor (Hathaway et al., 1965) and Fitzgerald factor (Waldman
et al., 1975) have provided additional information concerning the
initial events in surface-mediated coagulation. A list of the synonyms
and their internationally agreed names are shown in Table I„
ACTIVATION OF THE COAGULATION SYSTEM
Blood coagulation is customarily divided into three phases:
the intrinsic system, involving activation of factor X following cont¬
act with a foreign surface; the extrinsic system, which is the system
which is activated when blood is exposed to damaged tissues; and the
common pathway which is the sequence of events following activation
of factor X to the formation of a fibrin clot.
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Activation of the Intrinsic Coagulation System
The intrinsic pathway of coagulation is initiated by
surface contact. The contact system of plasma proteins consists of four
principal proteins: factors XI and XII, prekallikrein and high-molecul¬
ar kininogen. Interaction of these substances results not only in the
activation of the coagulation system, but also the kinin and fibrinoly¬
tic pathways, though the precise mode of the activation process is not
yet fully undersood. Probable mechanisms are reviewed more fully by
Ogston and Bennett (1978) and Cochrane et al. (1980).
When plasma comes into contact with a negatively-charged
surface, the four molecules assemble on the surface, leading to the
generation of active enzymes and the conversion of high-molecular
kininogen to bradykinin. A number of negatively-charged substances
of possible biological importance are capable of inducing contact act¬
ivation, including collagen (wilner et al., 1968) and vascular basement
membrane (Cochrane et al., 1972). Once bound to the surface, factor XII
is more susceptible to activation by proteolytic cleavage (e.g. by
kallikrein; Griffin, 1978) and XI activation is enhanced by surface-
bound XII and high-molecular kininogen (Cochrane et al., 1980). Kallikrein,
generated at the surface from prekallikrein by Xlla, in its turn amplif¬
ies the reaction by activation of additional factor XII (Cochrane &
Revac (1979). Activated factor XII also activates plasminogen ( Niewiarowski
& Prou-Wartelle, 1959).
Factor XIa is a serine protease that converts factor IX
to IXa (Davie & Ratnoff, 1964). The next zymogen to be activated in the
sequence is factor X which also requires calcium ions, phospholipid and
factor VIII. The role of factor VIII in factor X activation is not clear,
but may serve as a regulatory protein enhancing the rate of factor X
activation, in the same way that factor V accelerates the conversion
of prothrombin (Esnouf, 1977)°
Activation of the Extrinsic Coagulation System
The active component of tissue factor is known to be a
lipoprotein complex (Nemerson & Pitlick,1972). Tissue factor acts by
activation of factor VII,a process which is accelerated by the presence
of a number of enzymes such as factor Xa, thrombin, fragments of factor
XII and plasmin (Bennett, 1977). Factor Vila, tissue factor and calcium
ions result in the activation of factor X (Nemerson & Pitlick, 1972).
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Activation of the Common Pathway
Activation of factor X by either the intrinsic system or
the extrinsic system is achieved by the same mechanism (jesty et al.,
197^)• Conversion of prothrombin to thrombin requires factor Xa,
phospholipid, calcium ions and factor V. This process is reviewed ex¬
tensively by Esnouf (1977) and Bennett (1977), Activation of factors
XII, XI, IX, and possibly VII is accomplished by a common mechanism
(Rosenberg, 1975)* These factors circulate as inactive precursors which
are activated when a proteolytic enzyme with serine at its active
centre is released by cleavage of bonds. This system of amplification
was postulated as the classical cascade or waterfall concept of coagulat¬
ion in I9&4- independently by Macfarlane and Davie and Ratnoff and sur¬
vives with only minor modifications.
The interaction of thrombin with fibrinogen to form fibrin
monomer starts the final stage of fibrin formation. Fibrinogen is a
glycoprotein of molecular weight approximately 3^0,000 daltons. Its
molecular configuration is still debated (Gaffney, 1977; Dolittle,
I98Q). Conversion of fibrinogen to fibrin involves the cleavage of
the small polypeptides A and B (Bailey & Bettelheim, 1955; Bailey et
al., I95l)« The resulting soluble protein (fibrin monomer) polymerizes
to fibrin polymer, a process which is accelerated by the presence of
calcium (Boyer et al., 1972). The fibrin clot is rendered more rigid
by the formation ofY-glutamyl-£ -lysine links between adjacent fibrin
molecules by the action of factor XIII (Lorand & Jacobsen, 1958).
INHIBITORS OF COAGULATION
Powerful mechanisms exist in the circulation for limiting
fibrin formation. At least four different antithrombins have been des¬
cribed. These include the protease inhibitors of-j.-antitrypsin (Gans &
Tan, 1967), a2-macroglobulin ( Steinbuch et al., 1967 ) and c-j- ester¬
ase inhibitor (Ratnoff et al., 1969) but the cx^-globulin termed anti-
thrombin III is responsible for the largest part of antithrombin act¬
ivity in plasma (Lane et al., 1975). Antithrombin III, being the major
antithrombin in plasma is also the plasma protein through which heparin
exerts its effect (Barrowcliffe et al., 1978). In addition to its
antithrombin properties, in the presence of heparin, antithrombin III
inhibits the serine proteases plasmin, the clotting factors Xlla
XIa, IXa and particularly Xa (Rosenberg, 1975).
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Coagulation and Arterial Thrombosis
Since impairment of the coagulation system leads to haem¬
orrhage, it might seem reasonable to search for evidence of hypercoag¬
ulability in patients with thrombotic disorders. In general, such a
search has proved disappointing, particularly in the case of arterial
disease (Davis & McNicol, 1978; Hirsh, I98l). Though many studies have
attempted to demonstrate an association between raised levels of coag¬
ulation factors and arterial disease, the significance of these results
may be questioned, since such a relationship may be incidental rather
than causal. In contrast to the haemorrhagic disorders, few congenital
abnormalities of haemostasis have been shown to result in an increased
risk of thrombosis, with the notable exception of antithrombin deficiency.
A number of families with hereditary antithrombin III deficiency have
been described, with a high prevalence of venous (Egeberg, 1965; Marcin-
iak et al., 197^0 an(i possibly also arterial disease (Mackie et al.,
1978).
Though several plasma proteins such as fibrinogen, factor
VIII and Q^-antitrypsin rise following tissue injury e.g. myocardial
infarction (Brozovic, 1977; Hirsh, 1981), these changes are transient,
and therefore appear unlikely to provoke further arterial disease, but
could favour venous thromboembolism during convalescence.
Longstanding coagulation abnormalities associated with an
increased risk of arterial disease are relatively few. Low levels of
antithrombin III have been described in patients with stable ischaemic
heart disease (innerfield et al., 1976; Yue et al., 1976)° Fibrinogen
concentrations are raised in young patients with ischaemic heart disease
(Ogston & Ogston, I966) and more recently, the level of fibrinogen has
been shown to correspond to the severity of angiographically-proven
coronary artery disease (Lowe et al., 1980). However, it cannot be
certain that these changes are not merely secondary phenomena, and may
be of no pathogenetic significance.
More direct evidence for direct involvement of the coag¬
ulation system in arterial thrombosis has recently been published„
Preliminary results of the Northwick Park prospective study of cardio¬
vascular disease in the community (Meade et al., 1980) has shown that
the mean recruitment levels of factors VII, VIII coagulant activity
and fibrinogen were significantly higher in those who died of cardio¬
vascular disease compared to those who survived.
SECTION 4 THE FIBRINOLYTIC SYSTEM
THE FIBRINOLYTIC SYSTEM
HISTORICAL
Mammalian blood contains an enzyme system capable of diss¬
olving blood clots - the fibrinolytic system. Like the coagulation
system, a complex arrangement of inter-related pathways have been
described, though the precise physiological and pathological signif¬
icance of the process is not fully understood.
Morgagni (1769) and Hunter (1793) were aware that blood
remained fluid in the blood vessels after sudden or violent death.
Green (I887) discovered that fibrin formed from ox blood dissolved
after incubation with saline, and that the resulting solution could
not be clotted by thrombin. The term fibrinolysis (la fibrinolyse)
was coined by Dastre (1893) an<3- Hedin (1903) demonstrated that the
ability to lyse clots resided in the globulin fraction of serum.
Milstone (19^1) showed that a substance produced by streptococci re¬
quired a factor present in human serum to lyse blood clots. This lytic
factor was studied by Kaplan (l9^+) and Ghristensen (19^5) wh° con¬
cluded that it was an enzyme precursor which was activated by the strept¬
ococcal fluid. Subsequently, this precursor was named plasminogen,the
enzyme plasmin and the streptococcal factor streptokinase (Christensen
& Macleod, 19^5)* These historical aspects have been reviewed more
extensively by Astrup (1956) and McNicol and Douglas (1972)0
COMPONENTS OF THE FIBRINOLYTIC SYSTEM
Plasminogen
Human plasminogen is a single chain glycoprotein, with a
molecular weight of approximately 90,000 daltons (Soktrup et al.,
1978). Native plasminogen has an NH^-terminal glutamic acid (Glu-
plasminogen) but it is readily converted by plasmin digestion to mod¬
ified forms with NH2-terminal lysine, valine or methionine (Wallen &
Wiman, 1970, Wallen & Wiman, 1972). The biological significance of
these two forms is uncertain, but it seems that virtually all the
normal circulating plasminogen in man is in the Glu-plasminogen form
(Collen et al., 1975). Plasminogen contains an arginyl-valine bond




Plasminogen activators occur in the blood and in many diff¬
erent tissues and body fluids such urine, saliva and semen (Astrup,
1966, McNicol & Douglas, I9?E). A small amount of plasminogen activity
can be detected in normal blood (Mtillertz, 1953), but levels rise foll¬
owing various stimuli such as strenuous exercise, stress or venous
occlusion (Brozovic, 1977)• This activity originates mainly from the
vessel wall (Todd, 1964). Recent studies have shown that cultured
vascular endothelial cells are capable of synthesizing plasminogen
activator (Levin & Loskutoff, 1979) though inhibitors of activation
are also produced. Loskutoff (1979) has shown that when endothelial
cells are stimulated with thrombin, plasminogen activator is markedly
reduced, which may have important implications during thrombus format¬
ion in vivo.
Plasminogen activator activity can also be induced by con¬
tact activation of factor XII (Niewiarowski & Prou-Wartelle, 1959).
This so-called "intrinsic" fibrinolysis, to distinguish it from plas¬
minogen activation by tissue or vascular activator ("extrinsic" fibrin¬
olysis; Collen, 1980) requires the presence of other proteins, one of
which has been termed Hageman factor cofactor (Ogston et al., 1969)°
Various pathways involving factor XII, high molecular kininogen, pre-
kallikrein and contact activation have been proposed (Kaplan et al.,
1976, Ogston & Bennett, 1978), though the precise mechanisms and physiol¬
ogical importance of intrinsic plasminogen activation is unknown.
Inhibitors of Fibrinolysis
Inhibitors of plasminogen activation
Inhibitors of intrinsic plasminogen activation include c^
inactivator (Kluft, 1977), an inhibitor of Xlla-induced fibrinolysis
(Hedner & Martisson, 1978) and eC2-macroglobulin (McConnell, 1972).
Since the physiological role of the intrinsic pathway of activation
is unknown, the importance of these inhibitors in vivo remains conject¬
ural. Inhibitors of the extrinsic pathway have also been described,
but their existance has not been definitely established (Collen, 1980).
Inhibitors of plasmin
Antiplasmins have been more fully characterized than inhib-
itors of plasminogen activation. The principal physiological inhibitor
of plasmin appears to be a2~antiplasmin (Collen, 1976, Mttllertz &
Clemmensen, 1976). A number of other substances possess antiplasmin
activity including Q^-macroglobulin (Ganrot, 1967), Cf^--antitrypsin
(Rimon et al., 1966), antithrombin III (Highsmith & Rosenberg, 197^0
and c-j. esterase inhibitor (Ratnoff et al., 1979).
Mechanisms of Fibrinolysis
The mechanisms of fibrinolysis in vivo remain controversial,
and a number of hypotheses have been proposed to explain how fibrinoly¬
sis is localized to the fibrin clot. Alkjaersig et al. (1959) have
suggested that plasminogen is adsorbed to polymerizing fibrin and con¬
verted to an active enzyme by activators which diffuse into the clot.
In this environment, plasmin could act relatively free of inhibitors.
Ambrus and Markus (i960) proposed that plasmin-inhibitor complexes,
formed in the circulation dissociate in the presence of fibrin, since
plasmin has a higher affinity for fibrin than for its inhibitors.
Chesterman et al. (1972) have advanced the hypothesis that the activ¬
ators bind selectively to fibrin and convert plasminogen, which diffuses
into the clot, to plasmin. A more recent hypothesis, based on a molecul¬
ar model, has been formulated by Collen (1980). He has proposed that
plasminogen binds to fibrin by its lysine-binding sites. Tissue plas¬
minogen activator also binds strongly to fibrin, thereby activating the
fibrin-bound plasminogen. Since the fibrin-bound plasmin which results
has a relatively short half-life (10 s ), effective clot lysis depends
on a continuous replacement at the clot surface of inactivated plasmin
molecules (complexed with Cf^-antiplasmin) by plasminogen molecules.
Whatever mechanism is responsible for clot and thrombus
dissolution in vivo, many other factors may be important such as age
of thrombus, site (arterial or venous) presence of blood cells and the
extent of fibrin cross-linking (Kernoff & McNicol, 197?)• The existence
of other plasmin-independent fibrinolytic mechanisms has also been





When fibrin is exposed to plasmin, digestion occurs con¬
tinuously over long periods, forming a variety of degradation products
which vary in size and properties (Marder et al., 1969; Marder & Schul-
man, 1969). These products are referred to collectively as fibrin degrad¬
ation products (FDP), fibrinolytic split products (FSP) or fibrin-fibrin-
ogen related antigen (FR-antigen). Fibrin is initially split to yield
fragment X (MW 270,000) and low molecular fragments A, B and G. Fragment
X is split to fragment Y (MW 165,000) and fragment D (MW 85,000). Finally,
fragment Y is digested to fragments D (MW 85,000) and E (MW 55,000),
(Marder et al„, 1969; Marder & Schulman, 1969). Fragment X is slowly
clottable by thrombin, but the final products of plasmin digestion are
non-clottable (Pizzo et al„, 1972).
Fibrinolysis and Thrombotic Disease
Some authors have proposed that fibrinolysis is in dynamic
equilibrium with blood clotting, and that in health fibrin deposition
and lysis occurs continuously as a part of the normal maintenance of
blood vessels (Nolf, 1908; Astrup, 1956). In support of this view is
the observation that plasminogen activator activ¬
ity is present in non-stressed blood (Mtlllertz, 1953). However, turn¬
over studies with radiolabelled fibrinogen and plasminogen show that
low grade intravascular coagulation and/or fibrinolysis
is very low or non-existent (Collen et al., 1972; Harker & Slichter,
197*0 •
Though a partial deficiency of plasminogen associated with
recurrent thrombosis has been described (Aoki et al„, 1978), other
patients have low or absent levels of functional plasminogen without
thrombotic problems (jacobsen, 1968; Aoki et al., 1978) suggesting
that non-plasmin dependent fibrinolytic pathways may be important.
Plasminogen levels are not generally reduced in arterial thrombotic
diseases (Ogston & Ogston, 1966; Harker & Slichter, 197*0» Though
plasminogen turnover is increased in patients with venous thrombosis,
it is unaltered in arterial thromboembolic disease (Harker & Slichter,
1974)0 A few patients with a deficiency of inactivators of plasminogen
activator (Nilsson et al0, 1961; Pandolfi et alc, 1970) an4 reduction
in antiplasmin (Naeye, I96l) associated with severe thrombotic disease
have been described, but such cases seem to be very rare.
Apart from these uncommon deficiency states, the evidence for
impaired fibrinolysis as a contributing factor to thrombosis is less
convincing. Reduced fibrinolytic activity, measured by a variety of
techniques such as spontaneous activity, stimulation by venous occlus¬
ion and quantity released by vein wall biopsies, has been reported in
a variety of conditions including coronary artery disease (Chakrabarti
et al., 1968), peripheral vascular disease (Nestel, 1959)» cerebral
vascular disease (Pilgeram, 197^0 an6 oral contraceptive usage (Astedt
et al., I973)» However, the significance of these studies may be quest¬
ioned, since the reduced fibrinolytic activity may have been secondary
to the thrombotic condition. Recently, two prospective studies suggest
that reduced fibrinolytic activity may identify which patients are at
risk of thrombotic disease. Reduced fibrinolytic activity was found to
be the most powerful predictor of deep vein thrombosis in women under¬
going gynaecological surgery (Clayton et al„, 1976) and preliminary
results from the Northwick Park prospective study of cardiovascular
death suggested that fibrinolytic activity at the onset of the study
tended to be lower in subjects dying from cardiovascular causes compared
with the survivors, though this difference did not achieve statistical
significance (Meade et al., 1980).
PART II THE HAEMOSTATIC SYSTEM IN DIABETES MELLITUS
3 7
THE HAEMOSTATIC SYSTEM IN DIABETES MELLITUS
This initial study was designed to assess the extent of
platelet, coagulation and fibrinolytic system abnormalities in a
representative sample of ambulant patients attending a diabetic clinic
in comparison with a non-diabetic control group. The battery of tests
was selected to give the maximum information on the haemostatic system,
with a balance between proceedures performed on the morning of venesects
ion and others which could be performed on frozen plasma samples.
For ease of presentation, the sections concerning platelet
aggregation, tests of coagulation and tests of fibrinolysis will be
considered separately.
SECTION I PLATELET AGGREGATION AND DIABETES MELLITUS
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INTRODUCTION
A wide range of abnormalities of platelet behaviour have
been described in diabetic patients and have been extensively reviewed
by Bern (1978), Colwell et al. (1978) and Jones and Peterson (l98l).
This section concerns platelet aggregation; other aspects of platelet
function in diabetes will be discussed in Partlll, Sections I and 2
and in Part V, Section 2.
Aggregation in vitro is perhaps the most intensively
studied aspect of platelet behaviour in diabetes. The most commonly
used aggregating agent used has been ADP, though aggregation to adrenal¬
ine, collagen and arachidonic acid have also been studied. The earliest
studies used a system whereby aggregation of recalcified PRP was observed
visually in a rotating Chandler's loop or disc. Szirtes (1970) and
Rathbone et al. (1970) found that the time taken to produce visible
platelet aggregates was shorter in diabetic subjects than controls,
and that this abnormality was most marked in patients with vascular
disease. These results could be interpreted as evidence of increased
thrombin generation in the PRP from diabetics rather than hyperaggreg-
ability of platelets per se, but subsequent reports of abnormal aggreg¬
ation measured using the platelet aggregometer ( a system independent
of the coagulation system) began to appear. To date, results have been
somewhat contradictory. The majority of authors have reported that
diabetics with evidence of severe microvascular disease have an abnormally
low threshold or an increased extent of the second phase of aggregation
induced by ADP (Heath et al.,I97I» Kwaan et al„, 1972a; Leone et al.,
1974; Passa et al., 197^; Bensoussan et al., 1975; O'Malley et al.,
1975) in both insulin dependent and non-insulin dependent patients.
The group of Colwell have been able to demonstrate enhanced second
phase aggregation to ADP and adrenaline in 'latent' diabetics, defined
as asymptomatic individuals with abnormal glucose tolerance (Sagel et
al., 1975; Colwell et al., 1976; Colwell et al., 1977) "but in contrast,
Davis et al. (197^) were unable to demonstrate any differences in the
extent of ADP induced aggegation between men with and without abnormal
glucose tolerance. Recently, Petersen and Gormsen (1978) were unable
to demonstrate any differences between ADP induced aggregation of
insulin dependent diabetics with and without retinopathy and non
diabetic controls.
In general, these studies have involved groups of patients
with a high prevalence of severe microvascular complications. The present
study was designed to assess platelet aggregation in a representative





Thirty-four diabetics (20 men, Ik women) were chosen from
those patients attending the Aberdeen Diabetic Out-Patient Clinic.
Selection criteria included abnormal glucose tolerance (see below) and
a willingness to participate in the study (which frequently involved
loss of a morning's work).No age criteria were imposed, though patients
taking regularly drugs other than insulin or oral hypoglycaemic agents
and pregnant diabetics were excluded from the study0
Six patients were chemical diabetics (defined as asympto¬
matic individuals with an Increment Index of more than 2.^6 in response
to an intravenous glucose tolerance test (Duncan, 1956). The remainder
were clinical diabetics as defined by Fitzgerald and Keen (196^).
Eighteen were treated with insulin, Ik with oral hypoglycaemic agents
and two were controlled on diet alone.
Thirty-four non-diabetic subjects (22 men, 12 women) were
selected as controls from laboratory and medical staff of Aberdeen Royal
Infirmary and staff of the Macaulay Institute for Soil Research, Aberdeen.
All controls had a fasting plasma glucose level of less than 6.1 mmol/l
and none were receiving regular medication.
Subjects were asked to abstain from all drugs apart fomm
diabetic treatment for at least Ik days prior to the test. Informed
consent was obtained from all taking part in the study.
After an overnight fast, subjects attended the ward. Diabet¬
ics postponed their morning tablets or insulin until the test was com¬
pleted. While resting supine, a history and examination was undertaken.
Specific enquiries were made to elicit a past or present history of
angina, dyspnoea, myocardial infarction, claudication, stroke, hyper¬
tension, vascular surgery and smoking. Blood pressure was measured
and peripheral pulses were palpated. A search for femoral, carotid
and vertebral bruits was made and a I2-lead electrocardiograph (ECG)
was performed. The retinae were inspected by direct ophthalmoscopy
(pupils undilated) and finally the subjects' height and weight were
measured.
A diagnosis of ischaemic heart disease (iHD) was based
on a history of myocardial infarction confirmed by EGG or a rise in
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cardiac enzymes, cardiac failure or angina or ischaemic changes on the
EGG (Q waves, T inversion, S-T depression >2 mm); peripheral vascular
disease (PVD) as a history of arterial surgery of the lower limbs, inter¬
mittent claudication, presence of femoral bruits or absence of more
than two leg pulses; and cerebrovascular disease (CVD) as a history
of stroke of presumed thromboembolic origin, transient ischaemic
attacks or presence of carotid or vertebral bruits. An obesity
index was calculated by dividing the subject's weight by an ideal
weight standardized for height, sex and age from tables compiled by
Kemsley et al. (1962).
After 15 min resting supine, ^5ml blood was removed
from an antecubital vein, using minimal venous stasis and a 19 gauge
needle„
REAGENTS
Adenosine 5' Diphosphate Grade I Sodium Salt (Sigma Chemical Co.,
St„ Louis, Missouri) was dissolved in barbital-saline buffer, pH 7.35
(Sagel et al„, 1975) "to give a 2.1 mM stock solution which was aliquotted
into polythene containers and frozen at -20°G until use. After thawing,
any unused solution was discarded,, The stock solution was renewed every
three months. Fresh dilutions of the stock were prepared daily.
Epinephrine (Sigma Chemical Go.) was dissolved in O.IM hydrochloric
acid to give a stock solution of I0c5mM which was aliquotted and frozen
until use at -20°C. The stock was renewed weekly. Fresh dilutions of
the stock were made up in barbital-saline buffer, pH 7°35> each day.
Collagen Fibrils (Hormon-Chemie, Munich, W. Germany) were stored in
suspension at 4°C and dilutions were made daily, using glycine buffer,
pH 2.8.
METHODS
Platelet Count was performed according to the method of Brecher and
Cronkite (1950). 0.1ml of the sample (either anticoagulated blood or
platelet-rich plasma (PRP) ) was pipetted into a plastic tube contain¬
ing I.9ml of a freshly prepared 1% aqueous solution of ammonium oxalate.
The contents of the tube were gently mixed, and when whole blood was
used, left to stand for IOmin to allow haemolysis of the erythrocytes
to occur. A small volume of the well mixed platelet suspension was
transferred to loth chambers of an improved Neubauer counting chamber'
(Hawksley & Sons Ltd., Lancing, Sussex). The chamber was left in a
damp Petri dish for a minimum of 20 min to allow the platelets to
settle. The platelets were then counted using phase contrast micro¬
scopy. A minimum of 200 platelets were counted on each side of the
chamber and the average of the two counts (x 100) was taken as the
O
platelet count /mm . When the count in the two sides differed by more
than 1%, the counts were repeated using a fresh chamber.
Platelet Aggregation Venous blood was anticoagulated with I.29M
trisodium citrate in a ratio of I : 19 to give a final concentration
of 0.06^-mmol/l. The citrated blood was centrifuged at 250 g for 10 min.
The resulting PRP was removed using a plastic pipette and placed in
an unstoppered polypropylene tube. Care was taken to wipe the sides
of the tube after centrifugation, to avoid erythrocyte contamination
of the PRP. The buffy coat was left undisturbed and the remaining red
cells and plasma were centrifuged at 1,700 g for a further 10 min to
obtain platelet-poor plasma (PPP), which was pipetted into a clean
tube. 0.1ml PRP was removed for platelet count and the remainder was
transferred into disposable acrylic cuvettes (ADG Instruments Ltd.,
Crawley, Surrey) with a capacity of 0.2ml, using an automatic pipette
with disposable polypropylene tips, 0.2ml PPP being placed in a similar
cuvette. To each was added a 3m® x Imm disposable siliconized stir
bar (ADG Instruments Ltd.). Centrifugation and storage of the samples
were at room temperature.
The twin-channel platelet aggregometer (ADG Instruments
Ltd.) was connected to a twin-channel chart recorder (Smith Instruments
Ltd., Wembley ). Fifteen min before the start of the experiment,the
aggregometer was switched on to warm the heating block to 37°G, and the
stirring speed was set at 1,200 rpm . The optical transmission of
PRP was arbitrarily set at 0% and that of PPP at 100%. Since the light
transmission of plasma from diabetic subjects varied owing to lipaemia,
the instrument settings required adjustment for each subject studied,
but were not altered during a single run. Chart speed was set at IOmm/min
On a single day, only one subject was studied (diabetic
or control). In parallel with the subject's aggregation response, to
act as a control for the aggregating agents, a second sample of PRP
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was tested in the second channel. This PRP was provided by one of
two non-diabetic subjects, the same two donors being used thoughout
the experiment.
Three min before aggregation, a sample of PRP was incubated
at 37°G in a water bath. The cuvette was removed after exactly 3min,
the sides dried, and placed in the aggregometer. The aggregating
agent was added using a Terumo Micro Syringe (25ul capacity, Glass
Appliances Ltd., Aberdeen), taking care to avoid air bubbles. Aggregat¬
ion was followed for 3 min. Serially increasing concentrations of each
agent were added until a biphasic response (ADP, adrenaline) or a
monophasic response (collagen) was obtained up to 3 min after addition
of the aggregating agent (Figs. 2, 3» ^)° The sensitivity of the platelets
to each aggregating agent was defined as the threshold concentration
required to produce a biphasic (ADP, adrenaline) or monophasic (collagen)
response within 3 min of addition of the aggregating agent (o'Malley
et al., 1975)°
Determination of the threshold ADP concentration was start¬
ed precisely 20 min after venepuncture and was completed within 20 min.
Between 40 and 60 min the threshold for collagen was determined, followed
by adrenaline between 60 and 80 min. The time taken to complete the
experiment never exceeded 80 min from venesection.
Statistics To compare results obtained in diabetics and controls,
in view of the near normal distribution of the threshold concentrations
and platelet counts, Student's t test for non-paired data was employed.
In view of the smaller numbers involved, Wilcoxon's rank
sign test for non-paired data was used to compare the results obtained
from different diabetic sub-groups.
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RESULTS
CLINICAL DATA (Tables 2 and. 3)
Age The mean age of the diabetics was 47.1 years (SD 1 I6.7)
which was significantly older than that of the controls (39.1 1 10.7
years; p < 0.025). The age distributions are shown in Fig. 5.
Obesity The mean obesity index of the diabetics was 112.4 1 15.4,
which was not significantly different from that of the controls
(107 i 10.7; P <0.05). The distributions of obesity index are shown
in Fig. 5.
Blood Pressure The mean systolic blood pressure of the diabetics
was significantly (p < 0.025) higher than that of the controls (l42 t
25 compared to 129 1 20 mmHg), but the mean diastolic pressures were
not significantly different (84 ± 12 compared to 82 - II mmHg; p>0.05).
As can be seen from Fig. 6, only two diabetics and one control had
diastolic blood pressures above 100 mmHg.
Smoking Eight diabetics and six controls were regular cigarette
smokers.
Vascular Disease None of the controls had clinical evidence of athero¬
sclerotic vascular disease. The prevalence of macrovascular disease of
the./diabetics ;is shown in Table 2. Fourteen of the 34 diabetics had
clinically evident large vessel disease. Only two diabetics had severe
microvascular disease, one with proliferative retinopathy, and one
with a severe peripheral neuropathy. No diabetic had proteinuria detect¬
able by test strips (Labstix, Ames Co.). Since fluorescein angiography
was not performed on these patients, and ophthalmological examination
was carried out with the patients' pupils undilated, no separation was
made between absence of retinopathy and minimal background changes.
PLATELET TESTS
The results of platelet counts and platelet aggregation
are summarized in Table 4.
Whole Blood Count There was no significant differences in mean
platelet counts between diabetics and controls. Similarly, there were
no differences between diabetics with and without vascular disease, or
between insulin dependent and non-insulin dependent diabetics.
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PRP Platelet Count The mean platelet count of PRP was slightly, but
significantly (p40.05) lower than that of the controls, but there
were no significant differences between diabetics with and without
vascular complications and between those on insulin and those on oral
therapy.
ADP Threshold From Fig. 7 it can be seen that there was no difference
in the threshold concentration of ADP required to produce a biphasic
response in diabetics and controls, or between the different diabetic
sub groups.
Adrenaline Threshold As shown in Fig. 8, the threshold concentration
of adrenaline required to produce a biphasic response was similar
in diabetics and controls, and in the diabetic sub groups.
Collagen Threshold The threshold concentration of collagen required
to produce platelet aggregation was similar in diabetics and non-
diabetics, with no significant differences between those with and with¬
out vascular disease, and between those on insulin and those on oral
therapy (Fig 9).
In diabetic subjects Nos. 12, 15 and 17 no second phase
response was obtained to ADP and adrenaline and their platelets
did not aggregate in response to collagen. Though subjects had been
specifically requested to refrain from taking aspirin-containing drugs,
this would appear to be the most likely explanation for the lack of
response. In four diabetics and four controls it was not possible to
determine the threshold for collagen, in four controls the threshold
for adrenaline and in three controls the threshold for ADP could not
be determined within the allotted 20 min timespan.
Aggregation Control The thresholds for a single normal donor were
measured 60 times over the time of the study, in parallel with the
diabetic and non-diabetic subjects. Mean t SD threshold concentration
for ADP was 0.91 1 0.22 uM (range 0.6-1.6), for adrenaline 0.29 1 0.15 uM
(range O.I-O.7) and for collagen 0.37 1 0.13 ug/ml (range 0.2-0.7), giving
coefficients of variations of 24.2, 5I«7 an4 35«6% respectively.
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DISCUSSION
This study was unable to show significant differences in
the threshold concentrations of ADP, adrenaline and collagen required
to produce primary (collagen) or secondary (ADP and adrenaline) platelet
aggregation in a group of ambulant diabetic out-patients compared to
non-diabetic controls. The diabetic group were significantly older than
the controls, which might have been expected to exaggerate any differences
between the two groups (lecrubier et al., 1980). The diabetics had a
significantly higher systolic blood pressure, but were otherwise well-
matched for diastolic blood pressure, obesity and cigarette smoking.
In spite of careful standardization of conditions of
rest, nutrition, temperature of centrifugation and aggregation, and
timing of venesection and platelet aggregation, using the same non-
diabetic control on 60 occasions, the coefficient of variation for
ADP, adrenaline and collagen was wide. Similar day-to-day variability
has been reported by others (Harrison et al., 1967; Goldenfarb et al.,
I97l)o The cause of this variability is not known, but could include
minor differences in the shape of stir bars or cuvettes (Coller & Gralnick,
1976) or ill-defined factors such as mental stress (Harrison et al.,
1967).
The mean platelet count of PRP was significantly lower
in diabetics than in controls, though the platelet counts in whole
blood were similar. This difference has not been reported previously.
Blood from diabetic subjects appears to contain a higher proportion
of megathrombocytes than non-diabetics (Garg et al., 1972; Colwell et
al., 1977) and it is possible that during centrifugation some of these
denser platelets may have been discarded in the buffy coat. A second
possibility is that sedimentation of platelets from diabetics was
accelerated by the higher concentration of plasma fibrinogen in these
subjects (see Part II, Section 2). The effect of fibrinogen on platelet
sedimentation is not known, though this plasma component appears to
be the most important determinant of erythrocyte sedimentation under
normal conditions (Zacharski, 1976). Whatever the reason, the lower
platelet count of PRP from diabetic subjects may have obscured any
difference between the groups, since platelet aggregability increases
with increasing platelet count (Born & Hume, 1967; O'Brien, I97l)«
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In the present study, the platelet counts of PRP were not adjusted to
a constant number since it was decided to attempt to complete aggreg¬
ation studies within 80 min of venesection to minimize the known changes
in platelet aggregability with time 'temporal drift' (Hardisty et al.,
1970; Warlow et al., I97/+i Rossi & Louis, 1975). This time limit precluded
the determination and adjustment of platelet count by visual methods.
However, the difference in mean platelet counts between diabetics and
controls was small (approximately 70 x IO^/l) and when the platelet
count of the PRP of the 60 control ADP-induced aggregations using the
same donor were correlated with the threshold concentration of ADP, only
a weak correlation was found (r - 0.27; p>0.05). This suggests that
variation in platelet count was not the only factor causing the relatively
large coefficients in variation. It follows that any abnormality of
platelet aggregation in the diabetic group would have to be considerable
to obtain statistically different results from the controls.
In view of the essentially negative findings in this part
of the study, the technique of platelet aggregation used in Part III,
Section 2 was considerably modified to include standardized PRP platelet
counts and a kinetic analysis of the data in an attempt to increase the
sensitivity of the method.
SECTION II THE COAGULATION SYSTEM AND DIABETES MELLITUS
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INTRODUCTION
In comparison with the intense interest aroused hy
platelets and the fibrinolytic system in diabetes, the coagulation
system has attracted less attention. Early studies described abnormalities
of various global tests of coagulation including shortened whole blood
clotting, recalcification and thromboplastin times, and increased prothrombin
and antiheparin activities, suggesting that diabetic blood may be
in a hypercoagulable state (Egeberg, 1963; Valdorf-Hansen, 1967; Ghanen
et al., I97l).
A number of investigators have shown that plasma fibrinogen
concentrations are raised in diabetics, particularly in those patients
with severe retinopathy or nephropathy ( Egeberg, 1963; Mayne et al.,
1970; Aimer & Nilsson, 1975)* However, there is less agreement concerning
the levels of the other coagulation factors„ Factor VIII:C levels
have been reported to be increased (fOgeberg et al.,1963; Mayne et al.,
1970) though others have failed to confirm these findings (Bensoussan
et al., I975)« Abnormalities of factor VIII (VIII:C and VIII:vWF) will
be discussed more fully in Part V , Sections I and 2.
Egeberg (1963) reported raised levels of factor V, but
normal levels of factors II, VII, IX, XI and XII whereas Valdorf-Hansen
found increased concentrations of factor VII in diabetics with nephro¬
pathy and severe retinopathy.
The majority of these studies have been fragmentary. The
present study was designed to measure a wide range of coagulation
factors, and to relate any abnormalities to the presence of macro-





Diabetics and controls were those already described in
the preceeding Section.
REAGENTS
Human Fibrinogen (Kabi Grade L, AB Kabi, Stockholm, Sweden) was
dissolved in distilled water to give a concentration of IOg/l and
stored in aliquots at - 20°C until use„
Fibreglass (Tyglass fabric quality No. Y83, Fothergill & Harvey Ltd.,
Manchester) was cut into pieces approximately 30cm x 30cm. The pieces
were heated without boiling in a mixture containing three parts
concentrated sulphuric acid to one part concentrated nitric acid for
10 min to remove the fabric plasticizer. The squares were washed free
of acid with distilled water, air dried and cut into 4cm x 4cm squares.
Folin-Ciocalteu's Phenol Reagent (BDH Chemicals Ltd., Poole, Dorset)
was purchased every two months to ensure fresh reagent and stored
in the dark until use.
Bovine Thrombin (Parke Davis, Detroit, Michigan) was reconstituted
with the addition of the supplied diluent to give a final concentration
of 50 NIHu/ml.Aliquots were stored at - 20°C until use,
Platelet Substitute (Platelin, General Diagnostics, New Jersey) was
reconstituted to maker's instructions with distilled water.
Barbital Saline Buffer 2„06g barbitone sodium, 2.76g barbitone
and 7.3g sodium chloride were dissolved in distilled water and the
pH adjusted to 7°5 with IN hydrochloric acid. The volume was made up
to II with distilled water.
BLOOD SAMPLES
Plasma Pool 20ml venous blood was removed from each of 20 healthy
male volunteers aged 20 - 30 years. The blood was placed in tubes
containing trisodium citrate to give a final concentration of 0.I29M.
The tubes were mixed and chilled on ice for 5 mi-n "then centrifuge! at
1,000 g for 10 min. The resulting plasma was pooled in a chilled plastic
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beaker and gently mixed0 Aliquots were stored at - 70°C until use„ Once
thawed, any unused plasma was discarded„
Gitrated Plasma (0.I29M) was used for the estimations of prothrombin
times, partial thromboplastin times and coagulation factor assays„
After venesection, the blood was cooled for 5 before centrifugat-
ion and the plasma was stored in small aliquots at - 20°G
(partial thromboplastin time, factors VII, X, XI, XII) and at
- 70°G (factors II, V, VIII, IX)„
Oxalated Plasma was used for measurement of fibrinogen by adding
blood to a tube containing dry potassium oxalate in a concentration of
2mg/ml blood. Thereafter the anticoagulated blood was treated in the same
way as the citrated blood, ana stored at - 20°Go
ASSAYS OF THE COAGULATION SYSTEM
Whole Blood Clotting Time was based on the method of Lee and White
(1913). One ml venous blood was placed in a triplicate set of poly¬
propylene tubes. The tubes were incubated at 37°C and one tube was
tilted every 30 s until clotting occurred. The second tube and then
the third tube were treated in the same way until clotting occurred,
the clotting time being taken as that of the third tube.
Partial Thromboplastin Time (PTT) was based on the method of Langdell
et al. (I953)» 0.5ml platelet substitute (reconstituted)was added to
2ml kaolin suspension (_5mg/dl) and the mixture was kept on ice. O.Iml
of this mixture was added to a glass tube with O.Iml test plasma,
warmed at 37°0 for 60 s and then 0.025M calcium chloride was added.
The tube was gently tilted until clotting occurred. The average time
in seconds for the plasma to clot after addition of calcium chloride
in duplicate tubes was taken as the PTT. A PTT ratio was obtained
by dividing the test PTT by a PTT using the normal plasma pool.
Prothrombin Time (PT) was a modification of the method of Quick(l935)•
A saline extract of brain thromboppastin was thawed and kept on ice.
O.Iml test plasma was mixed with the same volume of brain thromboplastin.
After incubation at 37°C ^or 60 s , calcium chloride (0.1 ml of 0.025M)
was added. The tube was tilted until clotting occurred. PT and PT
ratios were expressed in the same way as for the PTT.
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Factor VIII and IX assays were "based on the method of Breckenridge
and Ratnoff (1962). 0.1ml kaolin/platelet substitute and 0.1ml
factor deficient plasma were incubated at 37°C for 8 min (factor
deficient plasmas provided by General Diagnostics, Thame, Oxon)„
The test plasma was diluted I : 20 with barbital-saline buffer, pH 7„5„
After 8 min the diluted test plasma was added to the tube in the water-
bath and mixed. 0.1ml 0o025M calcium chloride was added and the clotting
time recorded. In order to obtain a standard curve, dilutions of the
normal plasma pool (i :I0, I : 20, I : 10, I : 80) were made and clotting
times were established as described above. The standard curve was
drawn on double log paper and the test plasma was read off the curve
(expressed as per cent normal pool).
Factors XI and XII were assayed by a similar method to that described
for factors VIII and IX with the following modifications : kaolin/
platelet substitute mixture and the diluted test plasma were incubated
for 2 min at 37°C when 0.1ml factor deficient plasma was added and the
tube left for a further 6 min. Calcium chloride was then added and
the clotting time recorded.
Factor X was measured using the method described by Denson (1961).
0.1ml factor deficient plasma was mixed with 0.1ml diluted test plasma
(i : 20). 0.1ml reconstituted Russell's viper venom/cephalin reagent
(General Diagnostics) was added, the tube mixed and after 30 s 0.1
ml calcium chloride was added, the time taken to clot being recorded.
Factors VII, V and II were assayed using a modification of the method
described by Denson (1966). 0.1 ml factor deficient plasma was added
to a glass tube and 0.1 ml test plasma (diluted I : 20) was added and
after 30 s calcium thromboplastin (Behringwerk AG, Marburg-Lahn,
W. Germany) was added. The time taken to clot was measured.
Fibrinogen was measured using a modification (Ogston & Ogston, 1966)
of the method of Ratnoff and Menzie (l95l)° To 0.25ml oxalated plasma
was added 1.5ml 0.I5M saline in a plastic tube. 0.2ml bovine thrombin
(50 NIHu/ml) was added and the plasma allowed to clot for 15 min at
37°C. The clot was filtered through the fibre glass square, rinsed
with saline, dried and boiled for IOmin in 0.2N sodium hydroxide.
The solution was cooled and 6ml 12.5% aqueous solution of sodium
carbonate followed by Iml Folin Giocalteu's reagent (diluted I : 2
with distilled water) were added and mixed thoroughly. The solution
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was left for 15 min and then centrifuged for 5 min at 1000 g before
reading in a spectrophotometer at a wavelength of 690nm. The optical
density of the solution was read and the concentration of fibrinogen
read from a standard curve using purified human fibrinogen.
STATISTICS
Results between diabetics and controls were compared using
Student's t test for unpaired samples„ In view of the smaller numbers
involved and the non-parametric nature of some of the data, comparisons
between diabetic sub groups were made using the Wilcoxon rank sign test
for non-paired data. Correlations were calculated using linear regression,
the results being expressed as the correlation coefficient r.
RESULTS
The results of the coagulation studies are summarized in
Table 5. The distribution of the individual coagulation factors which
were significantly different in diabetics and controls are shown in
Fig. 10.
WHOLE BLOOD CLOTTING TIME
There was no significant difference between diabetics and
controls, between diabetics with and without vascular disease and between
insulin and non-insulin diabetics.
PARTIAL THROMBOPLASTIN TIME
There was no significant difference between diabetics and
controls, or between the different diabetic sub groups„
FIBRINOGEN
Fibrinogen concentrations were significantly higher in
diabetics compared with controls (p <0.005). However, there were no
statistically significant differences between the diabetic sub groups.
Fibrinogen concentrations did not correlate significantly with age, duration
of diabetes or obesity index ( Table 6).
FACTOR II
Levels of factor II (prothrombin) were significantly higher
in diabetics (p<0.00l), but there were no statistically significant
differences between diabetic sub groups and factor II levels did not
correlate significantly with age,duration of diabetes or obesity index
(Table 6).
FACTOR V
Diabetics had significantly higher levels of factor V than
controls (p<0.00l). There were no statistically significant differences
between diabetic sub groups, and there was no significant correlation
with age, duration of diabetes or obesity index (Table 6).
FACTOR VIII
VIII:C activity was significantly higher in diabetics
than controls (p <.0.02) though there were no significant differences
between the different diabetic sub groups, and no significant correlation
was found in relation to age, duration of diabetes or obesity index.
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FACTOR IX
There was no significant difference between diabetics and
controls, or between different diabetic sub groups,
FACTOR X
There was no significant difference between diabetics and
controls or between different diabetic sub groups,
FACTOR XI
Factor XI levels were significantly lower in diabetics
than controls (p <0,00l), but there were no significant differences
between diabetic sub groups. There was no significant correlation between
factor XI levels and age, duration of diabetes or obesity index (Table 6).
FACTOR XII
There was no significant difference between diabetics and
controls, or between different diabetic sub groups.
DISCUSSION
This study has shown significantly increased levels of
fibrinogen and factors II, V, VII and VIII in diabetic patients compared
with controls. Levels of factor XI were found to be significantly lower
in diabetics than controls, whereas there were no significant differences
in PTT ratio, whole blood clotting time and levels of factors IX,X and
XII. The abnormalities were not statistically significantly related to
the presence or absence of macrovascular disease, type of treatment,
obesity, age or duration of diabetes. However there was a tendency for
levels of fibrinogen and factor VII to be highest in patients with
evidence of large vessel disease, though these differences failed to
reach statistical significance. It is possible that with larger numbers
of patients would produce significant differences.
One possible explanation for the raised coagulation factor
levels is that the diabetics were significantly older than the controls,
and levels of factors V and VII tend to increase with age in normal
subjects (Hamilton et al.,197^). However, no significant correlation
between any of the clotting, factor levels and age of the diabetics was
found, making this explanation less likely.
An unexpected finding was the significantly lower levels
of factor XI in diabetics compared with controls. Prom Table 5 it
can be seen that factor XII levels were appreciably lower in both
diabetics and controls. These findings may reflect activation of
the intrinsic coagulation system followed by inactivation during
blood collection and it may be that contact activation of diabetic
plasma occurs more readily than control plasma.
This study confirms earlier reports that fibrinogen concen¬
trations of fibrinogen are increased in diabetics (Egeberg, 1963; Mayne
et al., 1970; Aimer & Nilsson, 1975). More recently, in a large popul¬
ation study, Fuller et al. (1979) found that fibrinogen concentrations
were related to the presence of retinopathy. On the other hand, de Silva
et al; (1979) in another large study found no relation with the presence
of micro- or macrovascular complications, but fibrinogen concentrations
appeared to be increased in patients who were receiving sulphonylureas.
The results of the present study are more in keeping with that of Fuller
et al. (1979).
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The cause of these alterations in the coagulation system
is not known. One possibility which does not seem to have been explored
systematically is that the degree of metabolic control influences the
results. The present study was not designed to answer this point;
Part V of this Thesis provides evidence that levels of certain coag¬
ulation factors are at least partly dependent on the degree of glycaemic
control of the diabetes0
Radiolabelling experiments have shown that fibrinogen
consumption is increased in diabetic patients (Ferguson et al., 1975;
Jones & Peterson,1979)• This shortened fibrinogen survival was prolonged
when hyperglycaemia was controlled, but fibrinogen taken and labelled
during the hyperglycaemic period had a near-normal survival when infused
during euglycaemic conditions, suggesting that the fibrinogen molecule
is not itself modified during hyperglycaemia. Interestingly, Coller
et al.(l978) have described a correlation between the concentration
of fibrinogen and the level of Hb Aj. Since the fibrinolytic system
appears to be attenuated in diabetes (see Part II, Section 3 ) the
cause of the increased fibrinogen disappearance is not certain, though
the overall catabolic rate of plasma proteins appears to be increased
in diabetics (Parving et al., 1975) and increased vascular permeability
might also play a role (Parving, 1976) in increasing the rate of
clearance. Increased fibrin formation and accelerated fibrin degradation
in diabetes is suggested by the finding of increased soluble fibrin
complexes (Tsianos & Stathakis, I980). Measurement of the kinetics
of other coagulation factors has not yet been applied to the study
of thromboembolic disorders, but could yield additional information
on the mechanisms of coagulation factor abnormalities in diabetes.
The biological significance of the changes described in
this Section are uncertain. Raised fibrinogen levels may be important
in increasing whole blood viscosity in diabetic patients (McMillan,
1976). Raised levels of individual coagulation factors are generally
not believed to indicate a tendency to arterial thrombosis (Davis &
McNicol, 1978; Hirsh, 1981). However, in a large prospective study,
Meade et al. (1980) have shown that factor VIIIsC, fibrinogen
and particularly factor VII were significantly increased in subjects
dying of cardiovascular causes compared to survivors. It is of interest
that these same factors were found to be increased in the present
study. Prospective trials are required to determine if these alterations
are of predictive value in the development of diabetic vascular complications.
SECTION 3 THE FIBRINOLYTIC SYSTEM AND DIABETES MELLITUS
INTRODUCTION
The fibrinolytic system has been the subject of a number
of studies in diabetic patients, though results show a remarkable
lack of unanimity. Hathorn et al. (l96l), Fearnley et al. (1963) and
Aimer and Nilsson (I975) have reported low levels of fibrinolytic
activity as measured by euglobulin clot lysis or fibrin plate technique
On the other hand, others (Denborough & Paterson, 1962; McKay & Hume,
196^; Tanser, 1967) found no differences between diabetics and controls
whereas Cash and McGill (1969) found increased spontaneous fibrinolytic
activity in young insulin-dependent diabetics.
When the fibrinolytic system is stressed, by excercise
(Cash & McGill, 1969). subcutaneous injection of adrenaline (Tanser,
1967) or venous occlusion (Aimer & Nilsson, I975)> "the normal rise
in fibrinolytic activity appears to be reduced in diabetic subjects
and using a histochemical technique, Aimer and Nilsson(l975) have
reported that biopsies of arteries and veins from diabetic patients
are deficient in vascular activator.
In addition to plasminogen activator production, other
abnormalities of components of the fibrinolytic enzyme system have
been reported. Concentrations of the antiplasmins a^-macroglobulin
and a^-antitrypsin have been reported to be raised in diabetic
subjects (Ganrot et al„, 1967; Aimer & Nilsson, 1975; Jonsson & Wales,
1976). Antithrombin III, which is more important for its inhibition
of activation of the coagulation system (Part I, Section 3) has been
variously reported as low (Banerjee et al., 197^)> increased (Fuller
et al., 1979) or normal (Zucker et al„, 1979) in diabetic patients.
The majority of these studies measured only one or two of these
components. The aim of the present study was to measure a wide screen




Diabetics and. controls were those previously described
in the preceeding Sections.
REAGENTS
Casein (Hammerstein quality, Hopkins & Williams, Chadwell Heath, Essex)
was prepared as a 4% solution by suspending 4g in 70ml borate-saline
buffer, pH 7»^» Two ml IN sodium hydroxide was added and the solution
was stirred until the casein was dissolved. The pH was adjusted to 7.4
with IN sodium hydroxide and the volume made up to 100ml with borate-
saline buffer. The solution was stored at 4°C for up to one week.
Tyrosine Standard was obtained from BDH Chemicals Ltd.
Streptokinase (Varidase, Lederle Laboratories, New York) was dissolved
in 0.I5M saline to give a concentration of 2,000 Christensen u/ml.
The solution was stored in small aliquots at - 20°C until use.
Borate-Saline Buffer was prepared by dissolving 4.77g of disodium
borate in 250ml distilled water (solution A). I2.40g boric acid and
2.92g sodium chloride were dissolved in distilled water and made up
to II (solution B). Approximately 20ml solution A were added to solution
B and the proportions adjusted to give a pH of 7»^°
ASSAYS OF THE FIBRINOLYTIC SYSTEM
Euglobulin Clot Lysis Time (ELT) was based on the method described
by Nilsson and Olow (1962). 0.5ml fresh citrated plasma and 9.5ml
0.014% acetic acid were added to a glass tube, the contents mixed and
stood on ice for IOmin. The resulting precipitate was centrifuged at
1000 g for 5 min, the supernatant decanted off and the euglobulin
precipitate resuspended by the addition of 0.15ml Tris buffer (pH 7»*0
and emulsification using an orange stick. 0„I5ml of the suspension
was placed in a glass tube and 0.15ml bovine thrombin was added (2 NIHu/ml).
The contents were mixed and the tube transferred to a time recorder
(Carmanan Instruments Ltd., Glasgow). The time taken for the clot
to lyse was taken as the ELT. Results were expressed using a line
obtained by plotting the log of the lysis time in min against arbitrary
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units of fibrinolytic activity, IOu being equated, with a lysis time
of 50 min (Sherry et al„, 1959).
Plasminogen was estimated by a modification (Alkjaersig et al., 1959a)
of the caseinolytic method of Remmert and Cohen (19^9). 0„5ml 0.6N
hydrochloric acid was added to 0.5ml oxalated plasma and the mixture
was left to stand at room temperature for 15 min. 0.5ml 0.6N sodium
hydroxide, Iml borate-saline buffer (pH 7.^), 0.5ml streptokinase
(2,000u/ml) and 2ml casein were added and mixed thoroughly. Two ml
samples were removed at 2 and 62 min and added to 2ml 10% trichloro¬
acetic acid to precipitate the unhydrolyzed casein. The precipitate
was left for 20 min and then centrifuged at 1,000 g for 5 min. One
ml supernatant was removed and mixed in a glass tube with I.5ml 5%
trichloroacetic acid and 5^1 0.5N sodium hydroxide. I.5ml Folin
Ciocalteu's reagent was added and the mixture allowed to stand for 15
min. The optical density of the 2 min sample was read against the 62
min sample at a wavelength of 680nm. With each batch of plasmas, Iml
of a standard solution containing ^-OOug/ml tyrosine in place of plasma
and hydrochloric acid was also processed. Results were expressed in
casein units (Alkjaersig et al., 1959b), one unit being the amount of
proteolytic enzyme which produces I80ug of tyrosine-like material
from the casein in 60 min.
(^-Antitrypsin, a^-Macroglobulin, C^-Esterase Inhibitor and Antithrombin III
were assayed by the quantitative single radial immunodiffusion technique
(Mancini et al„, 1965). Commercially prepared immunodiffusion plates
and standardized reference sera were obtained from Behringwerke AG.
Serum was used for estimations of d^-macroglobulin and c^-esterase
inhibitor and oxalated plasma for d^-antitrypsin and antithrombin III
assays. The standard serumor plasma was diluted with 0.I5M saline to
give three concentrations of known antigen , from which a
standard curve was obtained. 5U1 of each sample to be tested was pipetted
into a well on the immunodiffusion plate, which was left covered at
room temperature when the area of precipitation was measured, read off
the standard curve, results being expressed as mg/dl.
STATISTICS




The results are summarized in Table 7.
ELT
The mean resting ELT was not significantly different between
diabetics and controls, and there were no significant differences between
the different diabetic sub groups. However, in diabetic subjects, ELT
was found to be negatively correlated with obesity index (Table 8).
a ^-antitrypsin
The concentrations of Q^-antitrypsin in diabetics did
not differ significantly from controls. Levels were not significantly
related to the presence of vascular complications, type of treatment,
obesity index, duration of diabetes or age.
q ^-macroglobulin
Levels were significantly higher in the diabetics compared
with the controls (p <0.05). There were no significant differences
between those with and without vascular complications. Concentrations
were significantly higher in insulin dependent compared with non-insulin dependent
diabetics (p<0.0l) The age of the patient was inversely correlated with
the q^-macroglobulin level (Table 8).
Antithrombin III
Diabetics had significantly lower levels than controls
(p <0.00l), but this abnormality appeared to be unrelated to the
presence of vascular disease. Concentrations of antithrombin III were
significantly lower in non-insulin dependent diabetics compared to
those on insulin (p<0.02). Levels were also inversely correlated with
age (Table 8).
Cj-esterase inhibitor
Levels were significantly higher in diabetics (p<0.00l),
but this increase appeared to be unrelated to the presence of vascular
disease , age, duration of diabetes, treatment or obesity.
Plasminogen
No significant differences between diabetics and controls,
or between any of the diabetic sub groups, were observed.
DISCUSSION
This study has shown that the diabetic subjects had signif¬
icantly increased concentrations of a -macroglobulin and c -esterase
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inhibitor and reduced levels of immunologically detectable antithrombin
III compared to controls. In contrast, resting ELT and levels of a^-
antitrypsin were not significantly different from controls.
The finding of increased a^-macroglobulin concentrations
in diabetics is in agreement with others (Ganrot, 1967; Aimer & Nilsson,
1975; Jonsson & Wales, 1976), but a new observation is that levels
were higher in insulin dependent diabetics compared to non-insulin
dependent patients. Though a^-macroglobulin has been shown to increase
with age in normal subjects (Hamilton et al., 1974b), in the present
study diabetics showed an inverse relationship, presumably because
of the lower age of the insulin dependent patients. The relationship
of a^-macroglobulin concentrations with age is shown in Fig. II.
Raised levels of c^ esterase inhibitor have not previously
been reported in diabetes. This elevation was not related to age of
the patients, but appeared to be related to the presence of vascular
complications.
The lower levels of antithrombin III may be explained
by the greater age of the diabetics compared to controls since there
was a significant negative correlation with age in the diabetic group.
However, it should be noted that like a,p-macroglobulin, abnormal
levels were found in insulin-dependent diabetics compared to those
on oral therapy.
ELT was not significantly different in diabetics compared
to controls. From the results, it can be seen that the standard deviations
for this test were wide. It is possible that some of the abnormal
results of resting ELT reported by others may be caused by a preponderance
of obese subjects in the diabetic group, since the present study confirms
earlier reports that obese subjects have lower fibrinolytic activity
(Ogston & McAndrew, 1964). It may also be that release of fibrinolytic
activators after a stimulus such as venous occlusion may be a more valid
test of overall firinolytic potential.
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As with the coagulation system, the reasons for the changes
found in this and other studies is uncertain. Plasma proteins such as
fibrinogen, factor VIII,and a^-antitrypsin rise, and antithrombin III
levels fall following a wide variety of conditions involving tissue
injury and are commonly referred to as acute phase reactants. Unfortunately,
use of this term obscures the fact that it is not known by what
mechanisms such changes take place„ In diabetes, such changes could
be merely secondary to an injured vascular tree (caused by atheroma
or microangiopathy) Alternatively, there may be a more direct metabolic
explanation, since it has been shown that in isolated rat liver experiments,
infusions of insulin, Cortisol and growth hormone in physiolological
quantities increased the synthesis of fibrinogen andaT and a„-glyco-
proteins, suggesting that hormonal factors may be of importance (John
& Miller, 1969).
Whether such changes have any influence on the develop¬
ment of vascular complications is also unknown. C^-esterase inhibitor
is a relatively minor antiplasmin (Part I, Section 3) and patients
with inherited antithrombin III deficiency have levels less than 60%
of normal before thrombotic problems are encountered (Marciniak et
al., 197*0 so that it may be more logical to regard these abnormalities
as markers of tissue damage rather than factors of pathogenetic sig¬
nificance. On the other hand, a^-macroglobulin is responsible for
a considerable proportion of the increased whole blood viscosity
found in diabetics (Skovberg et al., 1966) and it has been suggested
that one effect of the increased concentrations of a^-macroglobulin
in diabetics is to inhibit the action of leukocyte proteases which
normally degrade the basement membrane, thus contributing to the
thickening characteristic of microangiopathy (Brownlee, 1976).
PART III PLATELET MEMBRANE ABNORMALITIES IN DIABETES MELLITUS
SECTION I PLATELET SURVIVAL IN DIABETES MELLITUS
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PLATELET SURVIVAL
In vitro tests of platelet function may be criticized
since they are performed under unphysiological conditions and their
relevance to platelet behaviour in vivo is uncertain. An alternative
approach has been to study the disappearance of radiolabeled platelets
from the circulation. Two radioisotopic approaches have been employed
in the study of platelet survival. In one, a cohort of platelets is
labelled; in the other, a mixed population of circulating platelets
is labelled ( a 'random' or 'population' label).
Though cohort labelling should theoretically produce
more accurate and easily analyzed data, no satisfactory cohort label
32 32exists for platelets. Attempts with P, P-diisopropyl fluorophosphate
(DF32?), 35S or ^Selenomethionine have not proved satisfactory, since
the period which they remain available for labelling megakaryocytes
is long compared to platelet lifespan ( for reviews see Aster, 1971;
Gardner, 1972; Harker, 1978). Thus labelled platelets continue to
appear during the time platelets are being removed from circulation,
making results difficult to interprete.
32
Random labels, such as P-orthophosphate , DEP labelled
32 3 I^ 14with P, H and C and C-serotonin have been extensively tested,
but problems with elution or reutilization of the label, or toxicity
to the subjects has led to most investigators abandoning_ these techniques
in human studies. In I977» an international committee concluded that
-^Cr-sodium chromate was the only isotope suitable for platelet survival
studies (Panel on Diagnostic Applications of Radioisotopes in Hematology,
1977). Since this date, "^"''In, complexed with hydroxyquinoline has been
used as a platelet marker, with the advantages over -^Cr that much
smaller quantities of blood need to be removed for platelet labelling
- as little as 26ml (Hawker et al., 1978), labelling efficiency appears
to be superior to "^Cr (Scheffel et al., 1977) an<^ finally the high
energy permits the in vivo imaging of labelled platelets using a gamma
camera (Scheffel et al„, 1977). However, the relative high cost, the
short half-life of the isotope (2.8 days) and the problems associated
with the high energy radiation has limited the use of ^^In to special¬
ized centres, and -^Cr is at present used by the majority of laboratories
measuring platelet survival. The method first described by Aas and Gardner
(1958) was subsequently modified by Aster and Jandl (196^-), resulting
in improved recovery and viability of the labelled platelets.
Though widely used, the technique has important limitations.
Repeated estimations of Cr-labelled platelet survival are not desirable
because of radiation hazards and are contraindicated during pregnancy.
A minimum of 100ml of blood must be removed to obtain sufficient platelets
for labelling (Abrahamsen, 1968a). The proceedure of labelling requires
considerable attention to detail to avoid platelet damage and is
time consuming (in the author's experience the proceedure takes at
least 3h). Veins may be compromized owing to the large cannula required
to remove the blood (of particular importance in diabetic patients where
access to veins is frequently difficult). Finally, facilities for handling
radioisotopes are required.
ASPIRIN LABELLING TECHNIQ.UE
First described by Stuart et al. (l975)» this method
appeared to offer an attractive alternative to established techniques.
The procedure makes use of the fact that acetyl salicylic acid irrevers¬
ibly inhibits the capacity of the platelet to convert arachidonic acid
to the endoperoxides PGG^and PGH^ (see Part I, Section Z), by acetylating
platelet cyclo-oxygenase (Roth et al., 1975)* This inhibition persists
throughout the life of the platelet. As a by-product of thromboxanes
produced from the cyclic endoperoxides, malondialdehyde (MDA) is formed
(Smith et al., 1976), which can be estimated colorimetrically by
reaction with thiobarbituric acid (Sirmhuber & Yu, 1958). Reappearance
of MDA should therefore parallel the entry of new platelets into
the circulation unlabelled with aspirin.
The present study was designed to evaluate this new
method and to compare platelet survival in diabetic and control subjects.
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MATERIALS
N-e thylmaleimide (Sigma Chemical Co.) was dissolved in phosphate-saline
buffer, pK 7„^ to give a 20mM solution. Aliquots were placed in
polythene tubes and stored at - 20°C until use.
Phosphate-Saline Buffer was prepared by mixing I8ml solution A(23.^g
sodium dihydrogen phosphate/l distilled water) with 82 ml solution B
(2I„3g disodium hydrogen phosphate/l distilled water). An equal volume
of 0.I.5M saline was added to produce a buffer of 0.I5M and a pH of 7°^»
Sodium Thiobarbiturate was produced by dissolving jiOOmg 2-thiobarbituric
acid (Sigma Chemical Co.) in 10ml 2.5N sodium hydroxide with gentle
warming. The pH was adjusted to 7«^ with IN hydrochloric acid and the
volume was made up to 50ml with distilled water. The solution was
stored out of the light and was made up fresh for each estimation of
platelet survival.
Magnetic Stirrers were made from cylindrical magnets 3mm long x
2mm diameter (Sheffield Magnet Co., Sheffield). The magnet was
placed inside a 3mm length of polythene tubing gauge No. BP 270
(Portex Ltd., Kent) and the ends were sealed with silicone rubber sol¬
ution (Dow Corning Corp.).
I>I>3,3-tetraethoxypropane (TEP) was obtained from BDH Ltd.
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STANDARD CURVE FOR MALONDIAhDEHYDE
METHOD
The principle of the procedure employs the fact that acid
hydrolysis of I mole of 1,1,3,3-tetraethoxypropane (TEP) yields
one mole of MDA and four moles of ethanol (Sinnhuber & Yu, 1958) <>
The method used was a modification of that described by
Kwon & Watts (1963). TEP was not subjected to overnight hydrolysis
since MDA polymers may form, with loss of reactivity with thio-
barbituric acid (Gutteridge, 1975) » 220.49mg TEP were added to a
II stoppered glass flask. One ml IN hydrochloric acid was added and
the volume was made up to exactly II with distilled water, giving
_3
a concentration of TEP of I x 10 M, This stock solution was stored
O
at 4 C until use,
Dilutions of the stock solution were made with distilled
water, to give final concentrations ranging from 0.428 to 0.005 x 10
Duplicate Iml samples of each concentration were placed in glass
centrifuge tubes and Iml of distilled water treated in the same way
acted as blank. 0.2ml 20% aqueous solution of trichloroacetic acid and
0.2ml of the sodium thiobarbiturate solution were added. The tubes
were agitated , boiled in a water bath (marbles were used as condensors)
for 15 min, cooled and centrifuged at 1,700 g for 10 min. The optical
density of the solutions was read at 532nm against distilled water,
using a Pye Unicam SP 1800 spectrophotometer.
RESULTS AND COMMENTS
The results of a typical experiment are shown in Table 9.
When the concentration of MDA was plotted against optical density,
a linear curve was obtained throughout the range of concentrations
used, with the line passing through zero (Figo 12).
The molar absorptivity E (defined as the optical density
produced by one mole in a one cm light path) was calculated from the
curve to be 1.55 x IO5, which corresponds exactly to that obtained
by Placer et al (1966) for MDA. The amount of MDA in a sample may
therefore be calculated by the formula :
MDA (nmol) = V x ODj^g
0oI55 (Placer et al., 1966)
where V is the final volume of the test solution, is the optical
density at 532nm „
However, since the standard curve was linear within the
limits of optical density used in the platelet survival experiments,
optical density was used to compare the results of MDA assays, results
being expressed as OD/lO^ platelets.
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EFFECT OF STORAGE OF REAGENTS IN MALONDIALDEHYDE ASSAY
INTRODUCTION
The assay system as originally described by Stuart et
al. (1975) was found to be unsatisfactory., Using the mixture of
perchloric acid and thiobarbituric acid, the final pink solution
was frequently turbid in spite of prolonged centrifugation, making
optical density readings unreliable. The same problem was also described
by Okuma et al„ (l97l) who clarified the solution with addition of
alkali and Biosolv, a commercial solvent„ This has the disadvantages
of diluting the chromagen (resulting in loss of sensitivity) and
also increases its lability (Okuma et al„, I97l)» Placer et al. (1966)
overcame the problem by adding a pyridine/n-butanol mixture but this
is volatile, emitting toxic fumes. A further consideration is that
Gutteridge et al. (197^) have shown that when fatty acids are boiled
with thiobarbituric acid and percloric acid (as in the Stuart assay)
MDA may be formed in the absence of an oxidating agent such as n-ethyl
maleimide.
To avoid these problems, a modification of the method of
Flower et al. (1973) was used. In this technique, trichloroacetic acid
is substituted for the perchloric acid to precipitate the protein. To
avoid auto-oxidation of fatty acids, the platelet proteins were first
precipitated with the trichloroacetic acid. The solution was centrifuge!
and the supernatant was boiled with the sodium thiobarbiturate. No
problems with turbidity were encountered with this method.
The following experiment was designed to determine whether
the modified reagents used in the MDA assay, and the standard solution
of MDA derived from TEP were stable on storage.
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METHODS
One per cent sodium thiobarbiturate and 20% trichloro¬
acetic acid were kept in stoppered glass bottles at room temperature„
A solution of MDA (0„3 x I0~^M) was made from TEP as previously describ¬
ed and was stored throughout the experiment at 4°C„ The MDA assay
was performed in duplicate as described in the previous experiments
At daily intervals, the assay was repeated, using the same solution
of MDA and the same reagents,
RESULTS AMD COMMENTS
The results over a two week period are shown in Table 10.
The resulting chromagen did not decline over the two week period,
suggesting that the reagents are sufficiently stable over this time.
Thus, one batch of reagents is adequate to measure platelet
survival. During this time, the sodium barbiturate produced a white-
brown precipitate. However, this did not effect the efficiency of the
assay. The coefficient of variance for this experiment was Io3%>
suggesting that the method is highly reproducible.
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DAY-TO-DAY VARIABILITY IN PLATELET MALONDIALDEHYDE PRODUCTION
INTRODUCTION
The accurate estimation of platelet lifespan by the MDA
technique depends on a reliable baseline before the administration
of aspirin. The following experiment was designed to assess day-to¬
day variability in platelet MDA production by normal subjects.
SUBJECTS
Four subjects (2 men, 2 women) volunteered to take part
in the study. None had taken drugs within the preceeding two weeks
and were in apparent good health. The women were not menstruating at
the time of the study.
METHODS
Nine ml of venous blood was removed from each subject at
intervals of several days and placed in a plastic tube containing
Iml 0.077M EDTA (ethylenediamine tetraacetic acid, pH 7«^)° The blood
was gently mixed and centrifuged at 250 g for 10 min to obtain PRP,
which was removed using a plastic pipette. The platelet count of the
PRP was performed as previously described. Duplicate Iml samples were
placed in polypropylene conical centrifuge tubes and centrifuged at
1000 gfor 12.5 min ho obtain platelet buttons. The supernatant was re¬
moved by inversion of the tubes which were allowed to stand for 2 min
to drain off the remaining PRP. The sides of the tubes were carefully
dried with filter paper and Iml phosphate buffer, pH 7°^> added to
each tube. The tubes were placed in a waterbath at 37°C which was
placed above a magnetic stirrer. The polythene-coated magnets were
used to resuspend the platelets for 4 min then 0.1ml 20mM n-ethyl
maleimide was added and the tubes stirred for a further minute. The
magnets were then removed and the tubes maintained at 37°G for exactly
30 min, when the reaction was stopped by the addition of 0.2ml 20%
trichloroacetic acid. The tubes were centrifuged for 15 min at 1,000 g
and Iml of the supernatant was placed in a glass centrifuge tube.
0.2ml of 1% sodium thiobarbiturate was added and the tubes were placed
in a boiling waterbath for 15 min, cooled and centrifuged at 1,000 g
for a further 10 min. The optical density of the resulting pink solution
was read at 532nm, using a Pye Unicam SP 1800 and Icm light path silica
cells.against distilled water. For each estimation, a reagent blank was
7 1
also read. Results were expressed as optical density/10^ platelets.
RESULTS AND COMMENTS
The results of five sets of estimations spread over one
week are shown in Table II„ The coefficients of variation for the
four subjects were 2*22%, 2.77%,5°20% and 5.00% respectively.
It can be seen that though inter-individual differences between
subjects were quite marked, MDA production remained constant for
each individual. Variability was approximately twice as high in the
two female subjects as in the males. This prompted a study on the in¬
fluence of the menstrual study on platelet MDA production (Tindall et
al.,1981a) which found that production drops by approximately one
third following the onset of menstruation, rising back to normal
after three to four da,ys. The reason for these changes is not known,
but does impose a serious limitation on this method of measuring platelet
lifespan.
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PLATELET SURVIVAL IN DIABETIC PATIENTS USING AN ASPIRIN LABELLING TECHNIQUE
INTRODUCTION
Platelet survival has been reported to be shortened in a
variety of thromboembolic conditions including acute (Abrahamsen, 1968b)
and recurrent venous thrombosis (Harker & Slichter, 197*1), rheumatic valve
disease (Steele et al,f 1971) > acute myocardial infarction (Abrahamsen, 1968b)
and following replacement of diseased heart valves with the older types
of prosthetic valves (Harker & Slichter, 1972, 197^; Weily et al., 197^)•
In this latter study, shortened platelet survival was related to the
frequency of embolic events. In stable ischaemic heart disease, results
have been less consistent, with normal (Abrahamsen, 1968b; Kutti &
Weinfeld, I97l) and shortened (Murphy & Mustard, 1962) platelet survival
having been described,, Two recent studies have shown that platelet
survival is shortened in the presence of angiographically proven cor¬
onary artery disease (Steele et al., 1973; Richie & Harker, 1977)°
Since measurement of platelet survival would appear to
be a useful method to detect an increased tendency to arterial thrombo¬
embolism, it is perhaps surprising that few investigators have used
this technique in diabetic patients. Abrahamsen (1968b) siudied 28
patients with maturity onset and juvenile onset diabetes,, using ^"Cr.
Maturity onset diabetics did not differ from non diabetic controls;
juvenile onset patients had slightly reduced survival times and those
with micro- or macrovascular complications had significantly shorter
platelet survival times than controls. Ferguson et al. (l975)» using
^Se, studied eight insulin dependent diabetics without vascular
complications, and also found platelet survival to be shortened com¬
pared to controls. Finally, Dassin et al„ (1978) found increased
platelet consumption in one third of 31 insulin dependent diabetics
using ~^Cr, but this shortening could not be related to the degree
of vascular complications„
The present study measured platelet survival in twelve
diabetics and twelve controls, using the aspirin technique.
MATERIALS AND METHODS
Subjects
Twelve non-diabetic controls (7 men, 5 women) and 12
diabetics (7 men, 5 women) were studied. The controls were healthy
laboratory and medical staff with a mean age of 30*8 years (range 23-
49 years). The diabetics were clinical diabetics using the criteria
of Fitzgerald and Keen (1964). The mean age was 39.4 years (range 16-
65). Clinical details of the diabetic patients are shown on Table 12.
None of the subjects was taking any medications known to influence
platelet behaviour, and in particular, aspirin-containing drugs were
avoided for at least two weeks prior to the study. None of the women
were menstruating during estimation of platelet survival. All blood
samples were removed under non-fasting conditions (MDA production
does not alter with a rise in plasma glucose (Tindall et al., 1981b).
Methods
MDA production of n-ethyl maleimide stimulated platelets
was performed as described in the preceeding Chapter. The subject
was then given 600mg soluble aspirin and MDA production was measured
at daily intervals until values exceeded 80% of pre-aspirin levels.
Results were expressed as a percentage of the pre-aspirin level and plotted
against time in days. For each subject, a straight line was computed
using linear regression analysis and the platelet survival time was
expressed as the time in days an extrapolation of the line intersected
100% of the pre-aspirin level (Fig 13).
Statistics
Platelet survival times were compared using Wilcoxon's




As can "be seen from Fig. lA-, recovery of MDA production
after the first day was linear up to 80% of pre-aspirin levels in
"both diabetics and controls. As shown in Fig. 15, platelet survival
of the diabetic patients was significantly shorter than that of the
controls (p <0.0l), the mean values being 6.92 days and 9.05 days
respectively. Shortened platelet survival did not seem to be related
to the presence of vascular complications as mean platelet survival
time of the six diabetics without vascular complications were not
significantly different from those with vascular disease (Table 13).
Shortened platelet survival was not significantly correlated with
age of the diabetic (r -O.O67, P > 0.05) or duration of diabetes
(r 0.263, P >0.05).
DISCUSSION
Using a non-isotopic method for measurement of platelet
survival, survival times were significantly shorter than those of controls.
This finding seemed not to be related to the presence of vascular complic¬
ations or to the duration of diabetes, though the numbers of patients
studied was too small for detailed statistical analysis. The mean age
of the diabetics was slightly greater than the controls. Platelet
survival has been reported to decrease with age (Abrahamsen, 1968b),
but this would seem to be an unlikely explanation of the present findings
since in this study, no significant correlation with age was found and
one of the shortest platelet survivals in the series was in a 20 year
old diabetic. Assessment of metabolic control was not made in this
study; it remains speculative that shortened platelet survival is
related to poor metabolic control.
Advantages of the aspirin-labelling technique include its
simplicity, low cost and, since it does not expose the subject under
study to radioactivity, may be particularly useful in children and dur¬
ing pregnancy, and for studies which demand repeated measurements of
platelet survival. The results obtained correlate reasonably closely
with the standard "^Cr method (de Haas et al., 1979; Roncucci et al.,
1979; Tindall et al., 1981c) in normal and thromboembolic conditions.
Since the aspirin-labelling method actually measures the
rate of platelet production rather than platelet removal, this technique
I
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reflects platelet survival when the rate of the two processes is the
same, that is, when the platelet count remains constant. Some authors
have preferred to refer to the aspirin-labelling technique as "platelet
regeneration time" (Roncucci et al., 1979) or "platelet production time"
(de Haas et al., 1979)° In this paper, the term platelet survival has
been retained to simplify the terminology.
Unlike the radioisotopic methods, the aspirin-labelling
technique can not be used when a subject is taking drugs which interfere
with MDA production (e.g. non-steroidal antiinflammatory drugs), though
recently Tindall et al. (l98lc) have shown that valid platelet survival results
can be obtained if recovery of MDA production is measured immediately
after discontinuation of the drug. Under these conditions, the results
obtained appear to refer to the survival of platelets during the period
of drug administration.
A more practical problem of the technique is that the sens¬
itivity of the colorimetric assay is relatively low. As can be seen from
Fig. 12, the limits of detection are reached at approximately IOpmol/ml
and the useful range is between 50 - 400pmol/ml. Consequently, a washed
platelet system must be used since in the presence of plasma proteins
MDA production is undetectable (personal observation; Catalano et al.,
1981). Modifications of the method have been introduced by a number of
investigators. The substitution of arachidonic acid for n-ethyl maleimide
has been reported to increase the sensitivity of the assay 10-fold (de
Haas et al., 1979) but platelet washing is still required. The fluoro-
metric assay of MDA described by McMillan et al. (1977) has permitted
the measurement of MDA in PRP after thrombin-stimulation, thus avoiding
possible artefacts during a washing procedure (Tindall et al., I98lb).
The cause of shortened platelet survival in diabetes is
not known. Previous studies have been in agreement with the present
results which found no clear relation to the presence of clinically
detectable vascular disease. In an extension of the present study,
Tindall et al. (1981b) found that a group of 40 insulin-dependent
diabetics (20 with severe retinopathy and 20 with minor background
changes only) had highly significantly shorter platelet survival times
than 40 controls, but there was no statistical difference between the
two diabetic sub-groups. These results, as with the present study, may be
interpreted as either clinically undetected vascular damage or potentially
reversible metabolic factors are responsible for these changes. In this
regard, it has recently been shown that shortened fibrinogen survival in
diabetics can be prolonged by tight control of hyperglycaemia (Jones &
Peterson, 1979).
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As with the causes of the shortened platelet survival, the
mechanism of removal of platelets prematurely from the circulation in
diabetes and other thromboembolic conditions is incompletely understood.
Reimers et al. (1973) have shown that thrombin-degranulated rabbit
platelets have a normal lifespan. This suggests that platelets can
undergo reversible aggregation in vivo and continue to circulate
normally. Changes of the platelet membrane seem more important in
determining lifespan. When sialic acid was removed from the surface
glycoproteins of rabbit platelets ,platelet survival was markedly reduced
(Greenberg et al., 1975)• Experiments by George et al. (1976, 1978)
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show that when surface glycoproteins are marked with I-diazotized
diiodosulfanilic acid, radioactivity is lost more rapidly than •^"'"Cr,
This apparent membrane loss may occur during reversible adhesion to
the vessel wall and thus modify the platelet so that it is removed from
circulation by the reticuloendothelial system. If this hypothesis is
correct, it would appear logical to search for membrane abnormalities
in the platelets of diabetic subjects, which was the aim of the
next experiments reported in this Thesis.
SECTION 2 FIBRINOGEN BINDING AND ADP-INDUCED AGGREGATION IN PLATELETS
FROM DIABETIC SUBJECTS
FIBRINOGEN BINDING AND ADP-INDUCED AGGREGATION IN PLATELETS FROM
DIABETIC SUBJECTS
INTRODUCTION
Evidence that in vitro platelet aggregation is increased
in certain groups of diabetic subjects has been presented in Part II,
Section I of this Thesis. However, what causes this hyperaggregability
is not known. A plasma factor, found in plasma from diabetic subjects,
which enhanced the second phase of ADP-induced aggregation when added
to control PRP has been described (Kwaan et al., 1972a; Leone et al.,
1974; Colwell et al., 1977)* On the other hand, these observations have
not been confirmed by others, who concluded that the abnormality was
intrinsic to the platelet itself (Bensoussan et al., 1975; Coller et al.,
It has been stated that only the second phase of ADP-induced
platelet aggregation is enhanced in diabetes (Colwell et al., 1978);
it is certainly this aspect of platelet aggregation that has received
most attention, and it has been related to an increased production of
proaggregatory arachidonic acid derivatives such as thromboxane A^
(Ziboh et al., 1979; Halushka et al., 1981). Recently, an increase
in ADP-induced platelet shape change has been described in diabetics,
particularly those with retinopathy (Porta et al., 1980) which implies
that an earlier stage in platelet activation may also be affected.
Fibrinogen is an essential co-factor for ADP-induced
aggegation of human platelets (Born & Cross, 1964; Niewiarowski et al.,
1977). Mustard et al. (1978) demonstrated that I2^I-fibrinogen became
associated with human platelets during ADP-induced shape change and
aggregation. Subsequent studies demonstrated the existence of specific
and saturable receptors for fibrinogen which became exposed on the
platelet surface in the presence of ADP or adrenaline, and that the
binding required divalent cations such as calcium or magnesium (Marguerie
et al., 1979, 1980; Peerschke et al., 1980; Bennett & Vilaire, 1979).
Peerschke et al. (1980) have proposed that a relationship exists between
the quantity of fibrinogen bound and platelet aggregability. This
study investigated the possibility that the hyperaggregability of





Sixteen diabetics (l2 men, 4 women) were selected from
those patients attending the Diabetic Clinic at Hopital St Louis.
Clinical details of the patients are shown in Table 14. The mean
age was 40.9 years (range 21 - 42 years). The extent of retinopathy
was assessed by retinal fundoscopy and fluorescein angiography. The
diabetics were separated into two groups on the basis of retinal
appearances : eight had no or minimal retinal changes (less than five
microaneurysms in each eye) and were termed "background retinopathy".
Eight were chosen because of severe retinopathy which required photo¬
coagulation treatment (one maculopathy and seven with proliferative
retinopathy). Diagnosis of diabetes was based on the criteria of Keenet al(l979)
Nine non-diabetic controls (7 men, 2 women) were selected
from medical and laboratory staff. Mean age was 27.2 years (range 24 - 42
years). All were in good health at the time of study and had no family
history of diabetes.
Neither diabetics nor controls were receiving any drugs known
to affect platelet function for two weeks prior to the tests. None of
the female subjects were taking oral contraceptives.
REAGENTS
Acid Citrate Dextrose was prepared by dissolving 0.8g citric acid,
2.2g trisodium citrate and 2.45g glucose in distilled water and making
the volume up to 100ml .
Platelet Washing Buffer was made by dissolving 7«56g citric acid, 0.9g
glucose, 0.373g potassium chloride, 0.294g calcium chloride (2HpO),
0.203g magnesium chloride and 6g sodium chloride in 700ml distilled
water. The pH was adjusted to 6.5 with 2N sodium hydroxide and the
volume made up to II with distilled water to give a buffer containing
36mM citric acid, 5^ glucose, potassium chloride, 2mM calcium
chloride, ImM magnesium chloride and I03mM sodium chloride.
Reaction Buffer was made by dissolving 8g sodium chloride, 0.2g
potassium chloride, Ig sodium bicarbonate, 0.05g sodium dihydrogen
phosphate, 0.43g calcium chloride (2H^o), 0.203g magnesium chloride
and Ig glucose in 700ml distilled water. The pH was adjusted to 7.35
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with IN hydrochloric acid and made up to II with distilled water, giving
a buffer containing I37mM sodium chloride, 2.7mM potassium chloride,
IOmM sodium bicarbonate, 0.3mM sodium dihydrogen, 2mM calcium chloride,
ImM magnesium chloride and 5.5mM glucose.
Bovine Serum Albumin, Gohn fraction V, was obtained from Sigma Chemical
Co..The albumin was dissolved in reaction buffer to give a stock solution
of 3.5mg/ml which was stored in small aliquots at - 20°C until use.
Apyrase was obtained from Sigma Chemical Co. It was dissolved in the
washing buffer to give a solution of 5mg/ml. Each lot was tested before
use, since some lots possessed platelet aggregatory properties due to
impurities. The stock solution of apyrase was divided into small aliquots
and frozen at - 20°C.
Prostaglandin E^. (pgej.) was a gift from Dr J. Pike, the Upjohn Co., Michigan.
The PGEj was originally stored at - 20°C in 70%ethanol 30% water at
a concentration of Img/ml. This solution was diluted to a concentration
of 7ug/ml in the washing buffer and frozen in small aliquots at - 20°C.
Heparin (choay, Paris) was kept at 4°C, at a concentration of 5>000U/ml.
Adenosine 5* Diphosphate Grade I Sodium Salt (Sigma Chemical Co.) was
dissolved in Tris buffer (0.I5M, pH 7-35) and stored at a concentration
of I x 10 M in small aliquots at - 20°C until required.
ADP stock was changed every three months and the washing and reaction
buffers were freshly prepared at weekly intervals.
METHODS
Platelet Separation
After informed consent, blood was removed from all subjects
within 2h after breakfast. Diabetics received their normal antidiabetic
therapy on the morning of the test. For platelet aggregation studies,
PRP was prepared from 20ml citrated blood (0.128m) by centrifugation
at 120 g for 10 min. After aspiration of PRP, PPP was produced by
centrifuging the remainder at 1,200 g for 15 min. The platelet count
of the PRP was determined by the method of Brecher and Cronkite (1950) as
previously described (Part II, Section i), and the PRP was diluted with
PPP to give a platelet count between 250 - 300 x IO^/l.
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Washed platelets for fibrinogen binding studies were pro¬
duced by taking the blood into acid citrate dextrose in a ratio of 4.5
volumes blood to one volume anticoagulant. Blood was taken into two
polythene conical 50ml tubes containing the anticoagulant, 250ul of
apyrase stock (final concentration, 25ug/ml) and 50ul of PGE^ stock
(final concentration , 20nM ). The contents of the tube were mixed
carefully and the blood poured into 5ml plastic tubes. PRP was produced
by centrifugation at I20g for IOmin, pooled in conical plastic tubes
(capacity I2ml) and the PRP was centrifuged at 1,200 g for 10 min. The
resulting platelet pellet was resuspended by decanting off the PPP
and adding Iml volumes of the washing buffer and agitating gently with
an automatic pipette with a polythene tip. Care was taken to leave
any erythrocytes at the bottom of the tube. The resuspended platelets
were transferred to a fresh conical tube, the volume made up to 10ml
with fresh washing buffer and the tube was recentrifuged at 1,200 g
for a further 10 min. The first washing buffer contained 5U/ml heparin
which was omitted for the second wash. Both washing buffers contained
bovine serum albumin in a concentration of 3»5mg/ml. The platelet
button was finally resuspended in the reaction buffer containing
3.5mg bovine serum albumin, and the platelet count was adjusted to
1.5 x 10 /ul. All manipulations were performed at room temperature.
Platelet Aggregation
Aggregation was performed using a dual-channel aggregometer
(Payton Associates, Scarborough, Ontario) adjusted to give a stirring speed
of 900rpm. Samples of 0.5ml were used, and the sensitivity of the
recorder was adjusted so that PRP and PPP corresponded to 10% and 90%
light transmittence respectively. Chart speed was set at IOcm/min.
Aggregation was started one h. following venesection. 0.5ml samples
of PRP were warmed at 37°C for exactly one min in the heating block
without stirring. After 45s incubation the sample was stirred by adding
a stir bar and at 60s the ADP was added, using a microsyringe. For
each experiment, ADP stock was diluted to a concentration of 1.25 x 10
with 0.I5M saline. This was added to the PRP in small volumes to
give a range of ADP concentrations from 0.5 x 10 to 3 x TO M (final
concentrations). For example, IOul added to 500ul PRP was equivalent to
a concentration of 2.5x10 ^M, I2ul to a concentration of 3«0uM.
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Platelet aggregation was followed for 30s, and for each subject,
five to seven concentrations of ADP were tested.
Analysis of the results was performed using the method of
Zuzel et al. (l979a). For each aggregation curve, a tangent was drawn
through the steepest part of the curve (Fig. 16). The reciprocal of the
initial rate of aggregation obtained from the tangent was plotted
against the reciprocal of the ADP concentration to give a linear dose-
response Lineweaver-Burk plot as shown in Fig. I7.(Skoza et al., 1967).
The intercept on the horizontal axis was used to obtain the reciprocal
of the K^. This constant may be defined as the concentration of ADP
required to produce half-maximal aggregation (v ), where V is themax' max
theoretical maximal aggregation rate produced by an infinite concentration
of ADP. All aggregation studies were performed within A-h of blood collection.
Fibrinogen Binding
Fibrinogen binding was performed using the method of Lee et
Jp C
a>l. (l98l). I-radiolabelled fibrinogen was purchased from the Centre
Nationale de Transfusion Sanguine (Orsay, France). This fibrinogen had
been purified using the method of Jaques (19^3),and consisted of greater
than 96% clottable protein following the addition of I NIHu of purified
thrombin and incubation at 37°G for one hr (Lee et al., I98l). The
purified fibrinogen was iodinated with carrier-free (^ ) Na I (New
England Nuclear Co.) by the chloramine T method (Hunter & Greenwood,
1962). The ^^I-fibrinogen was greater than 96% precipitable in 20%
trichloracetic acid and approximately 9^%> clottable with thrombin.
Preparations varied between 100 and 300uCi/mg protein. The labelled
fibrinogen was diluted 50-fold in reaction buffer containing 3.5rog/ml
of bovine serum albumin and frozen at -20°C. Immediately before use,
the thawed fibrinogen was centrifuged at 12,000 g for 10 min as a
precaution to eliminate aggregates. No contamination of the preparation
by factor VHI-related antigen could be detected by Immunoelectrophoresis
using a monospecific antibody to factor Vll-related antigen (Lee et al.,
1981). At a concentration of ^mg/ml, the fibrinogen did not support
ristocetin-induced platelet aggregation using formalin-fixed platelets
and when applied to ^-12% exponential acrylamide slab gels under reduced
conditions, no radioactive bands in the position of reduced factor VIII
and cold insoluble globulin were observed (Lee et al., 1981).
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Fibrinogen binding to platelets was carried out at room
temperature, using freshly-washed platelet suspensions0 The incubation
mixture contained 360ul of a suspension of platelets in reaction buffer
at a concentration of 1.5 x IO^/ul, 4_50ul of reaction buffer containing
3.5 mg/ml bovine serum albumin, 4j5ul of I-fibrinogen (300ug/ml)
which was immediately followed by ^jjul of ADP. The total volume for
each point in the assay was therefore 900ul and contained 30mg/ml
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I-fibrinogen, IOuM ADP and 6 x 10 platelets. Upon the addition of
ADP (zero time), the solution was gently mixed by swirling and left to
stand. Parallel incubations without ADP served as controls for the determin¬
ation of non-specific binding. At 5> 15» an(i 30min after the addition of
ADP, triplicate samples of 250ul were taken from each reaction mixture
and carefully layered onto Iml cold 20% w/w sucrose in reaction buffer
containing bovine serum albumin (3.5ms/ml)« The tubes were immediately
centrifuged at 12,000 g for 2 min in an Eppendorf centrifuge to separate
125the platelets from the free I-fibrinogen. The supernatant was carefully
removed without disturbing the platelet pellet. The radioactivity in
each pellet was counted in a GG 4000 Gamma counter (intertechnique
Roche Bioelectronique, Velizy, France). Total radioactivity was
calculated from duplicate samples taken from each incubation mixture.
The radioactivity that was present in the pellet was expressed as the per¬
centage of the total counts in the 250ul sample of the incubation
mixture. Non-specific binding was obtained from parallel samples
in which no ADP was added, and subtracted from the total to give
specific binding.
Haemoglobin A^ was measured using the micro-column kit produced
by Biorad Laboratories (Richmond, California) by the Department of
Clinical Chemistry at Hopital St Louis. The upper limit in non-diabetic
subjects in this laboratory is less than 7»5%°
Statistics
Results were compared using Wilcoxon's rank sign for





For ease of presentation, the results of platelet aggregation
are shown as l/Km° Thus, the higher the i/K » the more sensitive are the
platelets to the aggregating effect of ADP. Aggregation was not performed
on one control owing to clotting of the blood sample, and in one control
and one diabetic (with background retinopathy) non-linear dose response
curves were obtained. These results were therefore excluded from the
analysis. The i/K of "the 15 diabetics was significantly increased
compared to the controls (p <0.05). The diabetics with severe retinopathy
had significantly (p <0.05) higher i/K than the controls though differences
between controls and diabetics with background retinopathy, and between
those diabetics with and without severe retinopathy approached, but
did not reach statistical significance (Fig. 18).
i/K hid not correlate significantly with age (r 0.26), or to
duration of diabetes (r 0.^-0), but there was a highly significant correl¬
ation with the concentration of HbA^ as can be seen in Fig. 19 (r 0.79»
p <O.OOl).
Fibrinogen binding
The mean percentage platelet-bound fibrinogen was higher
in diabetics compared with controls at 5> 15 anh 30 min after the addition
of IOuM ADP (Fig. 20). When the controls were compared with the eight
diabetics with severe retinopathy, this difference reached statistical
difference.at 15 min (p <.0.05). Increased fibrinogen binding did not
correlate significantly with age of the diabetics (r 0.10), duration
of the diabetes (r O.Ol) or to the concentration of HbA^. (r - O.25).
In addition, fibrinogen binding did not significantly correlate with
ADP-induced aggregation, as expressed by i/K (r 0.15). All correlations
were calculated with specific fibrinogen binding at 15 min.
DISCUSSION
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This study reports the preliminary finding that I-
fibrinogen binding to washed platelets is enhanced in diabetes. In
common with many other abnormalities of platelet function described
in this condition, there was an appreciable overlap in the percentage
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of fibrinogen bound between diabetics and non-diabetics, and the increase
was most evident in those diabetics with severe retinopathy. The exper¬
imental system employed does not permit the distinction between increased
fibrinogen binding due to an increased affinity of the platelet receptor
for fibrinogen from an increased number of these binding sites. To
elucidate this problem, Scatchard analysis of the binding data would
be required (Marguerie et al., 1979, 1980; Bennett & Vilaire, 1979).
Such studies require considerable quantities of platelets, which acre
generally obtained from pooled blood bank donations. The present study
required 100ml from each subject. Since diabetics have been reported
to have increased numbers of megathrombocytes in the peripheral blood
(Garg et al., 1972, Golwell et al., 1977), a shift in the frequency
distribution of platelet volume towards larger platelets might result
in increased numbers of binding sites. Since fibrinogen binding sites
can be unmasked in the absence of ATP by the proteolytic enzyme
chymotrypsin (Mustard et al., 1979) and that chymotrypsin-treated platelets
bind increased quantities of fibrinogen when stimulated with ADP compared
to untreated platelets, it is tempting to speculate that in vivo platlet
damage might result in the exposure of fibrinogen binding sites.
Platelet sensitivity to ADP-induced aggregation, as expressed
by i/Km, was increased in the diabetic patients. l/Km is obtained from a
kinetic analysis of the velocity of the primary wave of platelet aggreg¬
ation in response to a range of ADP concentrations. Primary ADP-induced
platelet aggregation is generally regarded as normal in diabetic sub¬
jects (Colwell et al., 1978),. This phase of aggregation is relatively
difficult to quantify using a fixed low concentration of ADP, in view
of the wide range of responses encountered. The technique described in
this study uses a kinetic analysis of the aggregation curves produced
by a range of ADP concentrations. By adjusting this range according
to the responses obtained, platelets with widely different sensitivities
to ADP may be compared. Since the result is not dependent on a single
fixed concentration, pipetting errors may be minimized. A final advantage
is that a series of aggregation velocities can be expressed as a single
value, making comparisons between subjects simpler. Use of the Lineweaver-
Burk plot, originally devized for analysis of enzyme kinetics, should
not be taken to imply that platelet aggregation obeys Michaelis-Mentqn
kinetics since it is likely that aggregation is considerably more complex.
However, it would appear to be a useful method for the quantification
of platelet aggregation.
Support for the view that enhanced aggregation is not con¬
fined to the second phase in diabetes is given by Porta et al. (1980)
who found platelet shape change in response to ADP was increased in
diabetes. If both shape change and primary aggregation are increased
in diabetes, this argues for an abnormality in the aggregation response
before the release reaction. It is therefore possible that the enhanced
second phase reported by many authors, and enhanced platelet production of
thromooxanes (ziboh et al., 1979; Halushka et al,, I98l) could in part
be secondary to this phenomenon. The report that when platelets from
diabetic patients with retinopathy were incubated with dihomo-gamma-
linoleic acid (a precursor of PGE^ which does not cause platelet
aggregation) the quantity of MDA produced was not significantly different
from control platelets (Zuzel et al., 1979b) is also compatible with
this hypothesis.
The present study found a strongly significant correlation
between platelet aggregation (as expressed by i/K^) and HbA^..
was also higher in the diabetics with severe retinopathy compared with
background changes only, but since the mean HbA^ was virtually identical
in the two groups (II.2 1 0.7 SEM and II.5 1 1.3% respectively), it
seems possible that the relation between increased primary aggregation
and diabetic control found in this study is independent of retinopathy.
The relation between platelet function and metabolic control of diabetes
will be discussed further in Part V of this Thesis.
Sensitivity of platelets from diabetic subjects was not
found to be significantly correlated with the extent of fibrinogen
binding. It has been recently been shown that ADP-induced platelet
aggregation may be dissociated from fibrinogen binding. Whereas the
platelets of type I Glanzmann's thrombasthenia do not aggregate in
response to ADP and do not bind fibrinogen (Bennett & Vilaire, 1979).
the platelets of type II thrombasthenia do not aggregate with ADP
but fibrinogen binding is only slightly subnormal (Lee et al., 1981).
However, a more likely explanation is that the experimental conditions
used for the study of platelet aggregation and fibrinogen binding
were different : fibrinogen binding of washed platelets was measured
under static conditions at room temperature at room temperature
whereas aggregation was measured in stirred PRP at 37°C.
In conclusion,this study suggests that the platelet
membrane may be altered in diabetic patients, as shown by increased
fibrinogen binding. This abnormality seemed to be related to the
presence of severe retinopathy. Sensitivity of platelets to ADP
was also found to be abnormal in diabetics, and appeared to be related
to the quality of metabolic control.
PART IV PLATELETS AND PROSTAGLANDINS IN DIABETES MELLITUS
SECTION I PROSTACYCLIN PRODUCTION BY VASCULAR ENDOTHELIAL CELLS IN THE
PRESENCE OF SERUM FROM DIABETIC AND CONTROL SUBJECTS
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PROSTACYCLIN PRODUCTION BY VASCULAR ENDOTHELIAL CELLS CULTURED IN THE
PRESENCE OF SERUM FROM DIABETIC AND CONTROL SUBJECTS
INTRODUCTION
As with other aspects of platelet behaviour in diabetes,
there have been discordant findings when the thromboxane-prostacyclin
system has been studied. Stuart et al (1979) reported that MDA ( a
by-product of the thromboxane pathway) production was increased in the
platelets from pregnant diabetics compared to non-diabetics and Ziboh
et al. (1979) and Halushka et al. (1981) found that increased quantities
of thromboxane B^ were synthesized when PRP from diabetics was incubated
with arachidonic acid, the latter authors reporting a positive correl¬
ation between the amount of thromboxane and the blood glucose at the
time of study.
On the other hand, Davis et al. (1979) were unable to
detect significant differences in the plasma levels of thromboxane
between diabetics and controls and Tindall et al. (1981b) found that
thrombin-stimulated PRP from diabetics produced significantly less
MDA than the controls. The situation is further complicated by the
suggestion that the half-life of thromboxane A^ is longer in the
plasma of diabetic subjects compared with controls (Lagarde et al., 1980).
Similar disagreements are encountered when prostacyclin
(PGIg) production is considered. When PGI^ production by segments
of vein (silberbauer et al., 1979) or artery (Johnson et al., 1979)
from diabetics was measured by bioassay, PGI^-like activity was reduced
compared with biopsies from non-diabetic controls. However, Davis et al.
(l98l)were unable to find significant differences between diabetics
and controls, though there was a trend towards lower levels in diabetics
with proliferative retinopathy. Plasma levels of 6-keto-PGFjQ ( a
stable metabolite of PGI-,) have been reported to be reduced (using
gas-liquid chromatography) in diabetics with proliferative retinopathy
(Dollery et al., 1979), though when a radioimmunological technique was
used, no significant differences were observed (Davis et al., I979» I98l).
Experiments using rats made diabetic with streptozotocin
have shown that thromboxane production was slightly increased (Gerrard
et al., 1980) and PGI2 production by vascular segments was reduced
(Carreras et al., 1980; Gerrard et al., 1980; Harrison et al., 1980)
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Moreover, these abnormalities were reversed when the animals were treated
with insulin (Harrison et al., 1980) or pancreatic islet cell transplant¬
ation (Gerrard et al., 1980), which suggests that poor diabetic control
may be one factor contributing to reduced production.
In patients with severe and progressive proliferative
retinopathy, hypophysectomy has been shown to slow the deterioration
of vision (Lundbaek et al., 1969). Such hypophysectomized patients do
not appear to show the same platelet hyperaggregability as non-hypophy-
sectomized patients with proliferative retinopathy (Passa et al., 1974).
The aim of the present study was to test the hypothesis
that serum from diabetic subjects with proliferative retinopathy contains
factors which alter the synthesis or release of PGIg from the vascular




Fifteen diabetics (13 men, 2 women) were studied. All were
insulin dependent diabetics with proliferative retinopathy confirmed
by indirect ophthalmoscopy by an experienced ophthalmologist. Clinical
details of the patients are shown in Table 15. Mean age at the time
of study was 48.8 years (range 33 - 63 years), with a meantime since
diagnosis of 24.2 years (0 - 41 years). Five patients had previously
been surgically hypophysectomized and repeated pituitary function
tests following surgery confirmed absence of anterior pituitary
function. All were receiving hormone replacement therapy with Cortisol
and thyroxine at the time of study.
Fifteen healthy non-diabetic controls (13 men, 2 women)
were chosen from the medical staff. The mean age was 28.7 years (range
22 - 56 years). Smoking habits were similar to the diabetics (four smoked
10 - 20 and four 5 - 10 cigarettes/day). The controls were matched for
sex with the diabetics. None of the subjects were taking medications
known to influence platelet function or prostaglandin production for
at least two weeks prior to the tests.
Preparation of Human Serum
Two-hr post-prandial venous blood samples were taken into
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two 50ml sterile glass tubes, The blood was incubated at 37°G for 2hr,
then centrifuged at 2,000 g for 20 min at room temperature. The result¬
ing serum was filtered through first0.45u then 0.22u filters (Millipore,




Foetal Calf Serum was obtained from Biomerieux (Marcy l'Etoile, France)
and was decomplemented by warming at 56°C for 30 min. Thereafter, it
was stored at 4°C until use.
Cord Buffer was made by dissolving 80g sodium chloride, I.4g disodium
hydrogen phosphate (7 H^o), 3g potassium chloride, 20g glucose and
0.2g potassium dihydrogen phosphate in II distilled water. This resulted
in a buffer of pH 6.5 which was filtered through 0.22u Millipore filters
(Millipore, Molsheim, France) and stored in aliquots at - 20°C until
required. Before use,Colomycin-Penicillin (Roger Belion, Neuilly,France)
6,000U/ml was added.
Collagenase (type CLS 4196) was obtained from Mallet Chemicals (Roissy,
France). 0.4g of the crystalline powder was added to 100ml cord buffer
at 4°C and the mixture stirred at 4°C for 10 min to obtain dissolution
of the collagenase. The solution was then made up to 200ml with cord
buffer, giving a final concentration of 0.2%. The solution was then cent¬
rifuged at 3,000 g for 30 min at 4°C, the pH adjusted to 7.4 with
O.IN sodium hydroxide and passed through first 0.8u and then 0.22u
Millipore filters. It was then stored in aliquots at -20°C until required.
Culture Buffer was prepared by adding to medium MI99 (Biomerieux) the
following products : penicillin IOOU/ml, streptomycin IOOmg/ml, Fungizone
2.5mg/ml, HEPES (hydroxy-2-ethyl-piperazinyl-I-2-ethane-sulphonic acid)
I5mM, L-glutamine 2mM and I3mM sodium bicarbonate (all from Flobio,
Paris). The solution was filtered through 0.22u Millipore and stored at4°C.
Methods
Culture of Endothelial Cells was performed according to the method of
Jaffe et al„ (l973a)« Shortly after birth, the umbilical cord was severed
from the placenta and placed in a sterile container filled with 50ml
cord buffer. The container was kept at 4°C,until required. Cords which
had been traumatized, or that were less than I5cm were discarded.
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Thereafter, the umbilical cord was inspected and clamp marks at each
end of the cord were cut off. The umbilical vein was cannulated and
rinsed two times with cord buffer. The vein was then filled with collagen-
ase solution, the two ends secured by clamping the plastic cannulae,
and the cord immersed in 0.I.5M saline at 37°G for 6-8 min, keeping the
ends out of the saline. The cord was then gently massaged to complete
detachment of the endothelial cells and the vein was drained into a
sterile plastic 50ml centrifuge tube and the vein was rinsed with 30ml
cord buffer. Each tube contained 10ml MI99 with 20% foetal calf serum
to neutralize the remaining collagenase. The cells were centrifuged at
250 g for 10 min, the supernatant was discarded and the cells resuspended
in the culture buffer with 20% foetal calf serum„ After a further
centrifugation the cells were resuspended in culture buffer with
20% calf serum. A cell count was made using a Neubauer counting chamber
and the count was adjusted to 100,000/ml. The cell suspension was then
added to sterile 60mm diameter plastic Petri dishes (Falcon Plastics,
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Oxnard, California) at a concentration of 40,000/ciru All manipulations
were performed under a sterile hood. The cultures were incubated at 37 °C
and in an atmosphere of 5% carbon dioxide, using an incubator produced
by Forma Scientific (Marietta, Ohio). After 24 h , the culture was removed
and replaced with fresh culture medium, 20% human serum replacing the foetal
calf serum (implantation of the endothelial cells on the plastic dishes
was found to be less efficient when human serum was used). The culture
medium was changed every 48 hr until the endothelial cells reached
confluence (7-9 days)„ Cultures were assessed for purity initially by
transmission electron microscopy (endothelial cells being recognized by
their morphological characteristics and by the presence of Weibel-Palade
bodies; Jaffe et al., I973a) an4 routinely by phase contrast microscopy.
Cultures which did not reach confluence by nine days, and those which were
contaminated with fibroblasts were discarded.
Stimulation of Endothelial Cells
When the cells had reached confluence, thrombin-stimulated
release of PGL, was performed using a modification of the method of
Weksler et al. (1978). The cultures were gently rinsed with two volumes
of buffer A (sodium chloride I50mM, potassium chloride 5^M, calcium
chloride I„8mM, magnesium chloride ImM, glucose 5^ and hepes iomm,
pH 7.6). One ml buffer A containing 0.1 NIHu/ml bovine thrombin was
then added to the cultures. (Roche bovine thrombin 5 >000 NIHu was
dissolved in jjml imidazole buffered saline (0.04m, pH 7°^) an4 the
solution was added to 5ml glycerol, giving a final concentration of
500 NIHu/ml,, The thrombin was divided into small aliquots and stored
_ 9o°c until use. A fresh dilution of thrombin was prepared for
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each experiment) The Petri dish was then placed on a rotating horizontal
platform (100 rpm ) for exactly 2 min. The supernatant was then
removed and placed in a plastic tube standing in an ice bath. All
manipulations were performed at room temperature. After measurement
of PGI^-like activity, the remaining supernatant was frozen at - 20°G
until required for the measurement of 6-keto-PGF^ concentrations.
The endothelial cells were detached from the Petri dishes at the end
of the experiment by incubation with cord buffer containing 0.02%
EDTA (Biomerieux) for 20 min and counted using a Neubauer chamber.
PGI^-like Activity
PGI^-like activity was measured by the inhibitory effect
of the supernatant on ADP-induced platelet aggregation. Non-fasting
venous blood (the same donor was used for all experiments) was taken
into trisodium citrate to give a final citrate concentration of 0.I29M.
The platelet count of the PRP was measured by the method of Brecher and
Cronkite (l950) and the platelet count was adjusted to 250 - 300 x 10^/l
with PPP. Platelet aggregation was performed using a Labintec aggrego-
meter (Marseille, France), with a stirring speed of I,I00rpm. 0.1ml of
supernatant was added to 0.4ml PRP in the aggregometer cuvette and incubat¬
ed without stirring for 45 s at 37°C. The PRP was then stirred for 15
s before 2uM ADP (final concentration) was added. The chart speed was
25.2cm/min. The initial rate of aggregation was measured by drawing a
tangent through the steepest part of the aggregation curve and was
expressed as cm/min (the sensitivity of the recorder)having been set
so that PRP and PPP corresponded to 10% and 90% respectively).
PGI^-like activity was expressed as a percentage of the inhibition of
the initial rate of aggregation compared with a control aggegation curve
using 0.4ml PRP and 0.1ml buffer A containing 0.1 NIHu/ml thrombin.
Since PGI^ is labile even at 0°G, care was taken to complete the estimation
of PGI^-like activity within 5 min of stimulating the endothelial cells with
thrombin, though preliminary experiments showed that activity remained
stable on ice for up to 10 min.
6-Keto-PGFla
The frozen supernatants were incubated at 37 °C for 15 min
to ensure complete conversion of PGI^ to 6-keto-PGFja „ The concentration
of 6-keto-PGFjQ in the supernatant was measured in duplicate by radio¬
immunoassay, using the kit supplied by New England Nuclear (Boston,
Massachussets). Results were expressed as the quantity of 6-keto-PGF^
produced in ng/Petri dish.
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Ideal Weight was calculated using the Metropolitan Life Assurance Go.
tables (Documenta Geigy, 1970).
Haemoglobin Aj was measured using the microcolumn kit produced by Biorad
laboratories (Richmond, California) by the Department of Clinical Chemistry
at Hopital St Louis.
Serum Creatinine was measured by autoanalyzer.
Statistics
Results between diabetics and controls were compared using
Wilcoxon's rank sign test for paired samples. Correlations were calculated
using Kendall's rank sign test.
RESULTS
No difference was observed in the time that cells cultured
in diabetic serum reached confluence compared with those grown in control
serum, though cells obtained from different umbilical cords reached con¬
fluence between seven to nine days. At confluence, the cultures were
indistinguishable on phase-contrast microscopy. A typical endothelial cell
monolayer is shown in Plate I. Moreover, the number of cells/culture dish
was similar in endothelial cells grown in the presence of diabetic or control
serum (Table 16).
As shown in Fig. 21, the PGIg-like activity produced by
endothelial cells cultured in the presence of sera from the diabetic subjects
was significantly less than that of cells cultured in control sera (mean - SEM
21.9 t ^.8 compared with 28.3 1 5-1%; p<0.05). Similarly, 6-keto-PGF^
concentrations were significantly lower in cells grown in diabetic compared
with control sera (3.15 - 0.68ng/dish compared with 3*9^ - 0.9Ing/dish;
p<0.05).
The correlation between the concentration of 6-keto-PGF-j.^
and PGI^-like activity for each sample of supernatant is shown in Fig. 22,
the correlation being statistically significant ( T 0.52; p<0.00l). It
may also be seen that the correlation between bioassay and radioimmunoassay
was closer in supernatants derived from endothelial cells grown in diabetic
compared with control serum. As shown in Fig. 22, the range of PGI^-like
activities and 6-keto-PGF^ concentrations was wide. For this reason, results
were also expressed as a ratio :
Pro(^uction (PGI^-like activity or 6-keto-PGF^ concentration) by endo-
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thelial cells cultured in diabetic serum divided by PGI^ production of the
cells grown in the corresponding control serum. The ratios for the 15 pairs
of sera are shown in Fig. 23.
When the rank of the 6-keto-PGF^ratios for the 15 diabetics
was correlated with the rank for the PGI^-like activity, the relationship
was non-significant, though when only the 10 diabetics who had not been
hypophysectomized were considered, a significant correlation was found
(T0.5I; p <0.05).
There was a statistically significant relationship between
the 6-keto-PGF^ ratios and the concentration of HbA^, a higher HbA^ being
associated with a lower production of 6-keto-PGF^ (t 0.49; p<0.05)» as
shown in Fig. 24. There were no significant correlations between the 6-keto-
PGFj^ ratios and age, duration of diabetes or serum creatinine levels, and the
ratios were not different when hypophysectomized were compared with non-
hypophysectomized diabetics (Fig. 23).
DISCUSSION
The results of this study indicate that when human endo¬
thelial cells were cultured in the presence of serum of diabetics with
proliferative retinopathy, thrombin-induced release of PGIg was significantly
diminished compared with cells grown in control serum. Moreover, this re¬
duced capacity to generate PGI^ appeared to be related to the degree
of diabetic control, as assessed by the concentration of glycosylated
haemoglobin.
This phenomenon seems unlikely to be accounted for by a
non-specific effect on cellular growth or proliferation, since cells
cultured in diabetic serum had the same morphology on light microscopy,
reached confluence at the same time and had similar cell counts at
confluence compared with cells grown in control serum.
It is possible that substances other than PGIg with platelet-
inhibitory properties are released from endothelial cells. A significant
correlation was found between PGI^-like activity and concentrations
of 6-keto-PGFja(, suggesting that the platelet-inhibiting properties
of the supernatant were parallelled by the concentration of 6-keto-
PGFjq in the more specific radioimmunoassay.
Thrombin-induced PGI^, release is dose-related and time-
dependent (Szervionke et al., 1979). The concentration of thrombin
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(o.I NIHu/ml) and the time of incubation (2 min) used in the present
study were chosen as a compromise, since preliminary experiments showed
that higher concentrations of thrombin in buffer A induced aggregation
when added to PRP, thus partially masking the inhibitory effect of
PGIg) while longer incubation times resulted in loss of -like
activity.
Differences in PGI„ production between cells grown in
diabetic compared with controls though statistically significant, were
relatively small. An important limitation of the method is that to
avoid cytotoxicity, the proportion of serum that can be added to the
culture should not exceed 20% so that any possible inhibitory factors
in the serum are diluted by I : 5* In addition, as can be observed
in Fig. 22, there was a considerable range of both PGIp-Uke activity
and 6-keto-PGF concentrations produced by endothelial cells cultured
in both diabetic and control serum. This variation in PGI^ production
in endothelial cells obtained from different umbilical cords cultured
under the same conditions has been previously observed by others
(Baenzinger et al., 1979); the cause of this variability is unknown.
As Gerrard et al. (1980) have pointed out, even a relatively minor
shift in the balance between proaggregatory thromboxane and inhibitory
PGI^ production could increase the risk of thrombosis.
The finding of reduced PGI2 production by human endothelial
cells is compatible with animal studies which showed that reduced
vessel wall production of PGIg in diabetic rats was reversible by
insulin injections or islet cell transplantation (Harrison et al., 1980;
Gerrard et al., 1980). These studies suggest that metabolic factors may
be involved. Since all the patients in the present study had proliferative
retinopathy, it is possible that their serum contained inhibitory
factors found only in patients with proliferative retinopathy.
However, the finding of a significant correlation between the
reduction in 6-keto-PGFIQ concentration and HbA^ argues for glycaemic
control being of importance in the regulation of PGI^ production. The
effect of glucose on the production of 6-keto-PGF^a concentrations
produced by thrombin-stimulated endothelial cells will be considered
in the following Section.
There were no obvious differences in cellular growth,
morphology, or PGI^ production by endothelial cells cultured in serum
from hypophysectomized compared with non-hypophysectomized diabetics.
The growth factor obtained from bovine pituitary glands seems not
to be essential for the growth of normal endothelial cells in culture
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(Gajdusek et al., 1980). However, if this factor is absent during
several sub-cultures, the morphology and function of the cells are
modified (Vlodavsky et al„, 1979)• The present study used primary
cultures only, and the results suggest that absent pituitary function
does not influence endothelial cell growth under these conditions„
In conclusion, the results of this study show that
production from thrombin-stimulated endothelial cells grown in
serum from diabetics with proliferative retinopathy is reduced compared
with cells cultured in non-diabetic serum, This inhibition seemed to
be related to the degree of glycaemic control of the diabetes.
SECTION 2 INFLUENCE OF GLUCOSE CONCENTRATION ON PGI,, PRODUCTION
BY CULTURED VASCULAR ENDOTHELIAL CELLS
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INFLUENCE OF GLUCOSE CONCENTRATION ON PGI^ PRODUCTION BY CULTURED
VASCULAR ENDOTHELIAL CELLS.
INTRODUCTION
The results obtained in the previous Section suggest a
possible relationship between PGI2 production and the degree of glycaemic
control of the diabetic serum. That glucose can influence prostaglandin
synthesis was shown by Tannerbaum et al. (1979) who reported that
glucose inhibited the production of PGE2 and PGF2q by the isolated rat
renal papilla preparation in a dose-related manner.
The aim of the present study was to assess the effect
of different concentrations of glucose in the culture medium on PGI^
production by endothelial cells. In view of the good correlation between
PGI^-like activity and concentration of 6-keto-PGFIa reported in the
previous Section, 6-keto-PGFja only was measured in these experiments.
METHODS
Endothelial cells derived from human umbilical veins
of non-diabetic women were cultured as described in the preceeding
Chapter, though in the present experiments, 35mm diameter Petri dishes
were used. The culture medium was MI99 with antibiotics and 20% human
serum as previously described. The same batch of serum from a non-diabetic
subject was used throughout these experiments. Immediately before use,
the culture medium was supplemented with a range of concentrations
of glucose : (no extra glucose added), II.OmM, l6.5mM» 22mM, 27.5nM
and (final concentrations).
The culture medium of each culture was changed every 48h
until the cultures reached confluence (7-9 days), when thrombin-stimulated
PGI2 release was performed (o.I NIH u/ml) as described in the preceeding
Section. Two different protocols were performed :
Protocol A
Endothelial cells from a single umbilical cord were seeded
on six 35mm diameter Petri dishes. After implantation with MI99 con¬
taining 20% foetal calf serum for 24h, the culture medium was changed
to that containing 20% human serum containing the six glucose concentrat¬
ions as described above. At confluence, the cultures were rinsed twice
with buffer A, then 0.5ral buffer A with 0.1 NIHu/ml thrombin was added,
cultures being agitated for 2 min. The supernatant was then removed and
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immediately frozen at - 20°C until measurements of 6-keto-PGF^.^ concentr¬
ations were performed. Three separate experiments using the endothelial
cells from three different umbilical cords were carried out.
Protocol B
The endothelial cells from a single umbilical cord were
implanted into ten 35mm diameter Petri dishes using MI99 and foetal
calf serum as described above. After 2^h, the culture medium was changed
to MI99 containing 20% human serum. Five dishes were cultured in a
medium containing 5.5mM glucose, the remainder were cultured with a
glucose concentration of 22.0mmol/l. When the cells reached confluence,
thrombin-induced PGI„ release was performed as described in protocol A,
but with incubation times of 30s , I min, 2 min, 5 min and 10 min.
For each incubation, one dish cultured in 5.5mM glucose and in the other,
22mM glucose were tested. The supernatants were stored at - 20°G until
required. Three experiments using endothelial cells from three different
umbilical cords were performed.
6-kexo-PGF.r concentrationsla
The concentration of 6-keto-PGFjQ of each supernatant was




There was no difference in the light microscopic appearance,
or in the time taken to reach confluence, of endothelial cells grown in
glucose-supplemented media. However, at the highest concentration of glucose
tested (38.5mM) there was a tendency for cells to become detached when
they reached confluence. The results of the concentrations of 6-keto-PGFlQ
produced by the thrombin-stimulated cells are shown in Table 17. There
were no consistent differences between cells cultured in the various
glucose-supplemented media, though there was a tendency to increased
levels from cells cultured in media containing 38.5mM glucose.
Protocol B
As for Protocol B, there were no differences in morphology
or time taken to reach confluence between endothelial cells cultured in
media containing 5.5 and 22mM glucose. The results are shown in Table 18
and the means from the three different cell cultures are presented in Fig. 25.
At both concentrations of glucose, there was a time-dependent increase
in the production of 6-keto-PGFIa. Howevever, there were no consistent
differences between endothelial cells grown in medium containing 5.5mM
and 22mM glucose.
DISCUSSION
These results indicate that raised glucose concentrations
do not appear to directly inhibit PGI2 production by thrombin-stimulated
endothelial cells. Indeed, at 38.5i™ol/l glucose, there was a tendency
to increased PGI^ release. This stimulatory effect may have been due
to cell injury secondary to the increased osmolarity of the culture
medium. Toxicity at this glucose concentration is also suggested by
instability of cell attachment to the Petri dish. Concentrations of
plasma glucose over 40mmol/l are frequently encountered during diabetic
ketoacidosis and non-ketotic hyperosmolar states (see Part V, Section i).
The results of the present in vitro study suggest that such high glucose
concentrations are directly toxic to the endothelial cells, and could
be one factor causing endothelial damage in vivo.
The inhibitory factor described in the preceeding 1
may have been caused by glycosylated serum proteins, rather than glucose
directly. This appears to be unlikely, since in vitro glycosylation of
proteins such as albumin proceeds rapidly (Dolhoffer & Wieland, 1979)
at 37°C, making it probable that a proportion of serum proteins were
glycosylated in the culture medium during incubation with the endothelial
cells. Certain non-esterified fatty acids such as linoleic acid have
been shown to be potent inhibitors of PGI2 synthesis when added to endo¬
thelial cell cultures (Spector et al., 1980). Non-esterified fatty
acids were not measured in the present study. Though total amounts
of these fatty acids are increased in the serum of insulin-dependent
diabetics, there appears to be no major alteration in the relative conc¬
entrations of individual fatty acids '(Schrade et al., 1963) which could
account for the results observed in the preceeding Section.
SECTION 3 EFFECT OF SERUM FROM WELL AND POORLY-CONTROLLED DIABETICS
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EFFECT OF SERUM FROM WELL AND POORLY-CONTROLLED DIABETICS ON PGI2
PRODUCTION BY CULTURED VASCULAR ENDOTHELIAL CELLS
INTRODUCTION
In the preceeding Section, it was concluded that a high
glucose concentration was not the factor responsible for the reduction
in PGIg production by endothelial cells cultured in serum from diabetics
with proliferative retinopathy„ The experiments described in this Section
were designed to measure 6-keto-PGF production by endothelial cells




Sixteen male insulin-dependent diabetics were selected for
the study. None had symptoms or signs of macro or microvascular disease.
Eight were considered to have good glycaemic control and eight had poor
control of their diabetes. Good control was defined as an HbA^ at the
time of venesection of less than 8.5% (upper limit of normal in this
laboratory is less than 7-5%) anh poor control was defined as an HbA
of 12.0$ or more. Diabetics over the age of 50 years, and those taking
drugs other than insulin were not included in the study.
After informed consent, non-fasting venous blood was removed
from the patients. Serum was prepared as described in Section.I of this
Part. The filtered serum was stored at ,"+°G until required in
sterile glass containers. All sera were used within 3 weeks.
Endothelial Cell Culture and 6-keto-PGF-^ production
Endothelial cells derived from the umbilical vein of non-
diabetic women were cultured as described in the previous Sections.
After implantation in 35mm diameter plastic Petri dishes using MI99
containing 20$ foetal calf serum for 24h, the medium was replaced with
MI99 with 20$ diabetic serum. For each experiment, two Petri dishes
contained endothelial cells cultured in serum from a poorly-controlled
diabetic, and two contained cells cultured in serum from a well-controlled
diabetic. The pairs of diabetics were otherwise matched as closely as
possible for age and duration of diabetes.
When the cells reached confluence, the cultures were
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rinsed twice and stimulated with 0.5ml buffer A containing 0.1 NIHu/ml
bovine thrombin as described in Section I. After 2 min agitation, the
supernatant was removed and stored at - 20°G until required.
6-keto-PGFT
la
Each supernatant was assayed in duplicate for 6-keto-PGFj
concentration, using the radioimmunoassay provided by New England Nuclear
(Boston). For each diabetic serum, results are expressed as the mean
6-keto-PGF production (ng/culture dish) by duplicate endothelial
cultures.
Haemoglobin A^ and Blood Glucose
HbA^ concentrations (microcolumn technique, Bioraa lab¬
oratories) and the blood glucose (glucose oxidase technique) were
measured at the same time that blood was removed to obtain serum.
Statistics
Comparison of the results between groups was made using
Wilcoxon's rank sign test for paired samples, and correlations were
made with Kendall's rank correlation test.
RESULTS
Details of the eight pairs of diabetics are shown in Table
19. Well and poorly diabetics were closely ■ matched for age and duration
of diabetes. In addition, per cent ideal weight (calculated from Metropol¬
itan Life Assurance Tables, Documenta Geigy, 1970) was similar in well-
controlled (mean 100.I, range 86-114%) and poorly controlled (mean 96.0,
tange 86-107%) diabetics.
As shown in Table 19, both post-prandial blood glucose
and HbAj. concentrations were significantly higher in poorly controlled
compared with well-controlled diabetics (p <0.0l).
Results of 6-keto-PGFj.^ production by endothelial cells
cultured in serum from well-controlled and poorly-controlled diabetics
are shown in Fig. 26. Though the mean value of 6-keto-PGF^ was
slightly higher in the group of well-controlled compared with the
poorly-controlled group (o.77ng/dish compared with 0.69ng/dish) this
difference was not statistically significant. There was no difference
either in the cell morphology or in the time the cells took to reach
confluence between endothelial cells cultured in serum from well or
poorly controlled diabetics.
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When 6-keto-PGFjQ production was related to the duration
of diabetes, irrespective of the quality of diabetic control, the
highest values of 6-keto-PGF^ tended to be produced by cells cultured
in serum from those diabetics with the shortest duration of diabetes
(Fig.27 ). Using Kendall's rank correlation test, this correlation
did not reach statistical significance ( t - 0.275, p > 0.05). However,
when the diabetics were arbitrarily divided into two groups on the basis of
duration of diabetes, cells cultured in serum from those diabetics with
a duration of diabetes less than eight years had significantly higher
6-keto-PGF^a production (p <0.05) compared with those sera from diabetics
with a duration greter than eight years (Fig. 28).
DISCUSSION
These results show that PGI^ production by endothelial cells
cultured in the serum from poorly-controlled diabetics did not differ
significantly from that produced by cells grown in serum from well-
controlled patients. However, an inverse relationship between 6-keto-
PGF^a concentration and the duration of diabetes was found. It
is therefore possible that severe vascular complications require to
be present before the depressor effect of diabetic serum on PGIg products
ion is observed, the metabolic control of the diabetes having a relatively
minor effect. Since the extent and severity of vascular complications
correlate with the duration of diabetes (Pirart, 1978; Jarrett & Keen,
1979), it may be that patients described in this Section with the longest
duration of diabetes had subclinical vascular disease, resulting in sera
which depressed PGI^ production.
The nature of this factor remains to be determined. Since
serum was used for all the endothelial cell cultures described in this
Thesis, it is possible that an inhibitor of PGIg production is released
from platelets, or formed during blood coagulation during preparation
of the serum. In this regard, p-thromboglobulin has been shown to bind
to bovine endothelial cells in culture and to inhibit PGI^ synthesis
of these cells (Hope et al., 1979). Though the plasma concentrations
of p-thromboglobulin are frequently increased in diabetics, particularly
in those with microvascular complications (Burrows et al., 1978; Preston
et al., 1978) it is not known whether serum concentrations of p-thrombo-
globulin are higher in diabetics compared with controls. Further experiments
are required to establish whether endothelial cells cultured in a medium
supplemented with platelet-poor plasma (rather than serum) from diabetics
with proliferative retinopathy is reduced comparedwith cells grown in
a medium containing control plasma„
In summary, the results from these three Sections indicate
that PGI^ production by endothelial cells cultured in the presence
of sera from patients with proliferative retinopathy is significantly
reduced comparedwith cells grown in control serum. This depressor
effect appeared to be related to the quality of metabolic control of the
diabetes. The effect was not reproduced by growing the endothelial
cells in a glucose-enriched medium, nor when a group of poorly-controlled
diabetics without overt vascular complications were compared with a group
of well-controlled diabetics, also without clinically detectable vascular
disease.
PART V METABOLIC CONTROL OF DIABETES AND HAEMOSTATIC FUNCTION
METABOLIC CONTROL OF DIABETES AMD HAEMOSTATIC FUNCTION
In view of the large numbers of publications devoted to
aspects of the haemostatic function in diabetic patients, it is perhaps
surprising that so few studies have been concerned with the effect of
the metabolic disturbances of diabetes on haemostasis.
This Section describes two studies relating to this
problem. The first involves the disturbances of acute metabolic decompens¬
ation - diabetic coma and the second deals with the sequential changes in
certain components of the haemostatic system during the establishment
of glycaemic control in patients with newly-diagnosed non-insulin
dependent diabetes.
SECTION I HAEMOSTATIC CHANGES IN DIABETIC COMA
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HAEMOSTATIC CHANGES IN DIABETIC COMA
INTRODUCTION
Despite modern intensive therapy, acute metabolic decompens¬
ation remains a potentially fatal complication of diabetes mellitus.
Estimates of mortality rates due to diabetic ketoacidosis range from
0.5 to as high as 15%, depending on the centre, and rates do not seem
to have altered greatly over the past 20 years (Hockaday & Albert!, 1972;
Clements & Vourganti, 1978). In the non-ketotic hyperosmolar variety of
diabetic coma, even higher mortality rates of 15 - 20% are generally
recorded (Gordon & Kabadi, 1976).
Arterial thrombosis may now be responsible for up to one
third of deaths from diabetic ketoacidosis (Clements & Vourganti, 1978)
and is a frequent complication in non-ketotic hyperosmolar coma (Whelton
et al., I97l). In addition, Timperley et al„ (197^0 have shown that
localized deposition of fibrin may occur in the cerebral capillaries
of fatal cases of ketoacidosis. Over the past decade, a number of in¬
vestigators have described the association of disseminated intravascular
coagulation and diabetic coma (Table 20). Most of the described cases
have been ketoacidotic, but two patients probably had non-ketotic
hyperosmolar comas. The diagnosis of disseminated intravascular coagul¬
ation was based on haematological evidence in nine, but pathological
evidence of fibrin deposition was described in six cases.
Such case reports have been sporadic, and laboratory
studies were only undertaken after clinical signs had become apparent.
A prospective study was therefore designed to determine the nature of




Fifteen diabetics, admitted to the Aberdeen Teaching
Hospitals with ketoacidosis or the hyperosmolar syndrome over a period
of 12 months, were included in the study. Diabetic ketoacidosis was
arbitrarily defined as a plasma glucose greater than l4mmol/l and a
serum bicarbonate of Ilmmol/l or less in association with ketonuria.
The non-ketotic hyperosmolar syndrome was defined as a plasma glucose
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greater than 30mmol/l with a serum osmolality of more than 350m0smol/l
(Gordon & Kabadi, 1976), serum bicarbonate greater than 20mmol/l and
with no more than a trace of ketonuria0
Where possible, a second "convalescent" sample of blood
was obtained from the patients at a subsequent out-patient visit when
the diabetic state was stable, the non-fasting plasma glucose was
less than IOmmol/l and no detectable ketones were present in the urine0
Methods
Venous blood was removed from the patients as soon as
possible after arrival at hospital.(mean 2.2h, range 0.1 - 5h) for
biochemical and haematological studies. Blood for assays of the
coagulation system was immediately placed on ice for transport to the
laboratory where it was immediately centrifuged at 1,500 g and 4°C
within 30min of venepuncture.
Partial thromboplastin Time, Prothrombin time were measured on fresh
plasma, using the techniques described in Part II, Section 2.
Fibrinogen and Plasminogen were assayed in oxalated plasmas as
described in Part II, Section 2. Plasmas were stored at - 70°C until
required.
Ihctors V and VIII;G were measured on citrated samples stored at - 70°C
as described in Part II, Section 2.
Whole Blood Platelet Count was performed using the method described
in Part II, Section I.
Antithrombin III was measured using the method described in Part II,
Section
Fibrin Degradation Products were estimated using the kit supplied
by Wellcome Reagents (Beckenham, Kent).
Factor VIII-Related Antigen (VIIIR:Ag) was measured by Immunoelectro¬
phoresis using monospecific antibody to factor VIII produced by Behring-
werke AG, Marburg, W. Germany, by the method described by Laurell (1966).
Results were expressed as a percentage of the values obtained from the
normal plasma pool described in Part II, Section 2.
Haematocrit was measured using a microhaematocrit centrifuge (Hawksley
& Sons, Lancing Sussex).
Plasma Glucose was measured by the glucose oxidase method.
Serum Urea and Electrolytes were measured by autoanalyzer.
Urinary Ketones were measured by reagent strips (Ketostix, Ames Go.)
Serum Osmolarity was calculated using the formula :
serum osmolarity (mOsmol/l) = 2(Na + K) + G + U
where Na is the serum sodium, K the potassium, U the urea concentration
and G the plasma glucose concentration in mmol/l (Gordon & Kabadi, 1976)
Depth of Coma on admission was assessed clinically using a score of
I - k (i = normal; 2 = drowsy, but responding to verbal commands ;
3 = responding only to painful stimuli; k = unrousable).
Correction for Dehydration Since dehydration occurs in most cases
of diabetic coma, where possible, concentrations of haemostatic factors
were adjusted for changes in haematocrit (Bennett et al., 1967) :
HI (IOO - H2)
corrected concentration = measured concentration x
H2 (IOO - HI)
where is the haematocrit after coma and the haematocrit during coma
This formula is based on the assumption that the red cell mass remains
relatively constant during dehydration, and that changes in haematocrit
therefore reflect changes in plasma volume. Results are presented as
both measured and corrected concentrations. The coagulation tests where
an activity rather than a concentration are measured (e.g. prothrombin
time ) were left uncorrected.
Statistics
Comparison between the results before and after diabetic
coma was made using the Wilcoxon rank sign test for paired samples.
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RESULTS
Fifteen diabetics fulfilled the entry criteria and were
admitted to the study. The diagnosis of diabetes was made for the first
time in six patients on entry to hospital. Clinical details are shown in
Table 21 and the biochemical data in Table 22., Findings in the 12
patients with ketoacidosis are presented separately from the three
patients with the hyperosmolar syndrome.
Patients with Ketoacidosis
Patient No. 3 died Jh after admission following a cardiac
arrest. The results of the haemostatic tests of the surviving II diabetics
are summarized in Table 23/. The normal values for fibrinogen, plasminogen,
and antithrombin III shown in Tables 23 and 24' are those of the 3^
non-diabetic controls previously discussed in PartII, Section I,
Compared with convalescent values, platelet count, factor VIII:C
factor VIIIR:Ag and fibrinogen degradation products were significantly
increased. These differences were particularly striking in the case of
factor VIII:C and VIIIRrAg (Fig. 29). Antithrombin III concentrations
were significantly lower and there was a significant shortening of the
partial thromboplastin time during ketoacidosis compared with convalescent
values (Table 22). Factor V, fibrinogen, plasminogen and prothrombin time
were not significantly different from convalescent values.
When the results were corrected for the effect of dehydration
using the formula described above, factors VIII:C and VIIIR:Ag were still
significantly higher and antithrombin III concentrations lower, during
ketoacidosis. The differences in platelet count and fibrin degradation
products were no longer significant, though seven out of the eleven
patients had corrected concentrations of fibrin degradation products
greater than IOug/ml compared to only one out of eleven convalescent
samples. In addition, corrected mean plasminogen concentrations were
significantly lower during ketoacidosis.
The mean + SEM factor VIIIRrAg : VIII:C ratio was 1.44 1 0.27durin,
ketoacidosis , which was significantly higher than the convalescent
value of 0.73 i 0.08 (p <0.0l)„ There was no significant correlation
between the levels of the various haemostatic factors and the depth of
coma, the presence of overt infection, plasma glucose, serum bicarbonate
and the serum osmolarity. Neither the two patients with severe hypokal-
aemia (Nos. 2, II) nor the two with a serum urea greater than 30mmol/l
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had haemostatic values strikingly different from the remaining diabetic
patients.
Patients with the Hyperosmolar Syndrome
As can be seen from Table 21, the three patients with the
hyperosmolar syndrome (Nos0 13, 1^, 15) comprized the most elderly
patients in the study. Two died in the course of their admission
to hospital (Nos. 14, 15). The haemostatic results on admission are
shown in Table 2k, together with the fatal case with ketoacidosis
(No. 3). Results are necessarily presented as uncorrected values.
As can be seen from Tables 22 and 23, patients 3 and 13 showed results
similar to the surviving patients with ketoacidosis. In contrast, the
two fatal hyperosmolar cases (Nos. 1^, 15) had thrombocytopenia, low
concentrations of plasminogen and high levels of fibrin degradation
products.
Patient 14 had a past history of ischaemic heart disease
and intermittent claudication. On admission, he was found to have
impalpable pulses from the left femoral downwards. The hyperosmolar
state was rapidly corrected with fluid and insulin therapy, but per¬
fusion of the left leg did not improve, below-knee amputation being
required six days later, followed by death after a further eight days.
The severe thrombocytopenia persisted throughout his final illness.
Permission for post-mortem examination was refused.
Patient 15 was admitted in hyperosmolar coma. On examination,
she had minimal abdominal tenderness and absent bowel sounds. Death
occurred I2h after admission. At autopsy, she was found to have 80cm
of infarcted small intestine and when sections were stained with
Martius Yellow, Crystal Scarlet and Soluble Blue, there was evidence
of fibrin deposition in capillaries, arterioles and venules of
cerebral cortex (Plate 2 ) , kidney (Plate 3 ), lung and small intestine.
DISCUSSION
This study has shown that characteristic changes occur in
the haemostatic system during diabetic ketoacidosis, the most striking
being a rise in factor VIII:C and factorVIIIRjAg. Raised factor VIII
levels are not exclusive to diabetic ketoacidosis, increases having
been described in a variety of inflammatory, thromboembolic and neoplastic
conditions (Holmberg & Nilsson, 197*0 • Raised concentrations of factor
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VIIIR:Ag (Pandolfi et al., 197^; Goller et al., I978; Lufkin et al.f 1979;
Gensini et al., 1979) and factor VIII:ristocetin activity (Bensoussan et
al., 1975; Goller et al., 1978; Lufkin et al., 1979; Gensini et al., 1979)
have frequently been observed in stable diabetes. Raised levels were only found
in patients with proliferative retinopathy in certain studies (Bensoussan
et al., 1975; Goller et al., 1978), tint others have reported high
levels in patients free from vascular complications (Pandolfi et al.,
197^; Lufkin et al., 1979; Gensini et al., 1979). Apart from Goller
et al. (1978), who found no correlation between HbA^ and concentrations
of factor VIIIR:Ag,none of these studies attempted to determine whether
there was a relation between factor VIILR:Ag and diabetic control,
though Gonzalez et al. (1980) found that in insulin-treated diabetics
strictly controlled under hospital conditions, improvement in
diabetic control was parallelled in some cases by a reduction in factor VIII:
ristocetin cofactor activity. Results of measurements of factor VIII:C
have been equally contradictory, with normal (Bensoussan et al., 1975;
Fuller et al., 1979) and high levels (Pandolfi et al., 197^-; Gensini
et al., 1979) having been reported. The importance of the present
study is that these changes appear to be reversible with metabolic
control of the diabetes.
The cause of increased VIII:C activity during ketoacidosis
is not known, but could be a non-specific response to acute stress
(Brozovic, 1977). Though increased concentrations of coagulation
factors do not necessarily lead to an increased tendency to thrombosis
Davis & McNicol (1978), the finding of a significantly shortened partial
thromboplastin time during ketoacidosis suggests that there is increased
activation of the intrinsic coagulation system, which might be expected
to favour intravascular clotting. A slight, but significant, rise in
the ratio of factor VIIIR:Ag/VIII:G was also observed during keto¬
acidosis. Denson has shown that a disproportionate rise in factor VIIIR:Ag
relative to VIII:G can indicate intravascular coagulation (Denson, I977)«
However, since factor VIII:C is relatively more labile than VIIIR:Ag,
the possibility that coagulant activity was lost during blood collection
and storage cannot be discounted.
Since factor VIIIR:Ag is synthesized by vascular endothelial
cells (Jaffe et al., 1973), the high levels of this factor observed in
the present study could reflect endothelial damage caused by metabolic
factors during ketoacidosis. There is some evidence that antithrombin III
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may also be synthesized by endothelial cells (Chan & Chan, 1979), so that the
finding of reduced concentrations of antithrombin III during ketoacidosis
is of interest, A fall in the concentration of antithrombin III appears
to be an early and sensitive indicator of intravascular coagulation
(Bick et al., 1977). In "the present study, the observed fall in anti¬
thrombin III together with a modest rise in fibrin degradation products
provides evidence that even in relatively uncomplicated cases of keto¬
acidosis, a degree of fibrin deposition occurs, and could contribute to
the cerebral dysfunction often seen in this condition, as suggested
by Timperley et al. (197^+)•
No relation was found between the magnitude of the individual
haemostatic factor abnormalities and clinical and biochemical variables.
Since levels of both haemostatic and metabolic factors can change rapidly,
future studies with frequent blood sampling during recovery from keto¬
acidosis are required for a clearer understanding of the relationships
between clinical, metabolic and haemostatic parameters.
Two of the three patients admitted with hyperosmolar comas
died. Both deaths occurred in elderly patients, and illustrate the con¬
siderably higher mortality of this condition compared with ketoacidosis
(Gordon & Kabadi, 1976). Both patients had laboratory, and in one case,
pathological evidence of disseminated intravascular coagulation. The
majority of patients with disseminated intravascular coagulation have
reduced levels of fibrinogen and plasminogen, thrombocytopenia and
diminished factor VIII:C and V with high levels of fibrin degradation
products (Colman et al., 1972). These haematological findings do not
clearly distinguish disseminated intravascular coagulation from massive
thrombosis at a single site, such as was found in patient 14. Netherthe-
less, the persistant thrombocytopenia during this patient's final illness
is suggestive of platelet consumption in sites additional to the occluded
femoral artery.
As shown in the present study, coagulation factor levels
are frequently raised during uncomplicated diabetic coma, which may
obscure any changes induced by disseminated intravascular coagulation
difficult to interpret. Thus, in previous reports of disseminated
intravascular coagulation associated with diabetic coma, fibrinogen
and factors V and VIII:G were high, low or normal (Table 20), in
common with the two cases in the present series. Thrombocytopenia and
raised titres of fibrin degradation products appear to be more con¬
sistent findings. In addition, a low plasminogen may point to the diagnosis.
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The aetiology of disseminated, intravascular coagulation
during diabetic coma is likely to be multiple. Infection and shock
are recognized precipitating factors (Colman et al„, 1972). Metabolic
disturbances may play a part since disseminated intravascular coagulation
is more readily induced in alloxan-treated compared to control rats
(Antoniades et al„, 1973)° ln addition, Kwaanetal. (l972b) isolated
a platelet aggregating-enhancing factor from a diabetic with diabetic
coma who died with disseminated intravascular coagulation. The use of
sensitive radioimmunoassays such as for fibrinopeptide A, beta-thrombo-
globulin and platelet factor 4 may provide information on the relative
contributions of the coagulation system, platelets and endothelium to
the pathogenesis of intravascular coagulation in diabetic coma.
In summary, this study has shown that during diabetic
ketoacidosis, haemostatic changes are found which may reflect endothelial
damage and also suggest a degree of fibrin deposition. In two fatal
cases of the hyperosmolar syndrome, evidence of disseminated intra¬
vascular coagulation was found. In view of the high incidence of
arterial thromboembolic complications associated with diabetic keto¬
acidosis and the hyperosmolar syndrome, controlled trials of platelet-
inhibiting and/or anticoagulant drugs would seem to be justified in
the management of these two conditions.
SECTION 2 EFFECT OF DIET AND GLICLAZIDE ON THE HAEMOSTATIC SYSTEM
OF NON-INSULIN DEPENDENT DIABETICS
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EFFECT OF DIET AND GLICLAZIDE ON THE HAEMOSTATIC SYSTEM OF NON-INSULIN
DEPENDENT DIABETES
INTRODUCTION
Diabetic ketoacidosis represents a particularly severe
stress to the body, so that it is perhaps not surprising that disturb¬
ances of the haemostatic system occur. Whether similar changes may be
observed during the equilibration of hyperglycaemic, but not otherwise
ill diabetic patients, was the objective of the present study.
The sulphonylurea gliclazide has recently been introduced
into clinical practice in the United Kingdom. Apart from its hypogly-
caemic properties, it has been claimed that administration of this drug
to non-insulin dependent diabetics reduces platelet retention to glass
bead columns (Rubinjoni et al., 1978; Ponari et al0, 1979) and ADP
and adrenaline-induced platelet aggregation (Ponari et al., 1979)o
However, these studies have not distinguished between a
specific drug-induced effect on platelet function and the possible
influence of improved glycaemic control brought about by the hypoglcaemic
properties of this drug.
It was therefore decided to assess the effects of diet
and gliclazide on a panel of haemostatic tests in newly-diagnosed




Newly diagnosed non-insulin dependent diabetics were
recruited for the study from the Diabetic Clinic at Leeds General
Infirmary. There was no age limitation for the study, but patients
already receiving other drug treatment, those who were expected to
eventually require insulin therapy and grossly obese patients were
excluded. A diagnosis of diabetes mellitus was made on the basis of a
50g two hour glucose tolerance test, using the criteria proposed by
Keen et al. (1979). Patients with impaired glucose only, as defined by
Keen et al. (1979), were also excluded.
The aims and the protocol of the study were explained
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to each patient. If the patient agreed to participate in the study,
blood was removed for haemostatic tests. The patient was then interviewed
by the dietitian, who explained a conventional carbohydrate—restricted
diet compatible with the patient's obesity and energy expenditure.
In the initial phases of the study, the patient was encouraged to see
the dietitian at two-weekly intervals, and thereafter every two months.
After eight weeks dietary treatment, the patients underwent a second
glucose tolerance test. If the two hr plasma glucose level exceeded
6mmol/l, in addition to the same diet, gliclazide was introduced, the
dose being adjusted to give optimal control of the diabetes as judged
by urine tests performed by the patient and 2hr post-prandial plasma
glucose levels performed at two-monthly intervals at the diabetic
clinic. Patients were asked to avoid all aspirin-containing compounds
and were given paracetamol as a substitute.
Methods
Blood Sampling
Throughout the study, patients were reviewed at two-
monthly intervals when non-fasting blood was removed using a 19 gauge
"butterfly" from an antecubital vein using minimal stasis and a multiple
syringe technique. As far as possible, the venesection was performed
at the same time each day for each patient, and the order of syringes
for the various tests remained constant. Platelet retention was perform¬
ed immediately using fresh unanticoagulated blood. Blood for fibrinogen,
heparin neutralizing activity, antithrombin III, factor VIII:G, factor
VIIIRsAg and euglobulin lysis times was taken into a 60ml syringe
containing a solution of trisodium citrate in a volume of I : 9 volumes
of blood, giving a final citrate concentration of 0.I29M. The citrated
blood was mixed gently in the syringe and transferred to 10ml plastic tubes
and centrifuged within 10 min at 1,500 g. The plasma was stored until
required at - 70°G, except for that required for measurement of the
euglobulin clot lysis time, which was performed on fresh plasma. Blood
for estimation of p-thromboglobulin was taken into the anticoagulant
supplied with the assay kit and processed following the maker's instruct-
ions (The Radiochemical Centre, Amersham). Blood for plasma glucose
was placed in a tube containing fluoride oxalate and serum for gliclazide
levels was produced by incubating 5iml blood in a plastic tube at 37°G
for one hr.
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A plasma pool from 20 healthy male volunteers was obtained
as detailed in Part II, Section 2„
Plasma glucose was measured using the glucose oxidase method0
Platelet ,Counts were measured using aCoulter Thrombocounter (Coulter
Electronics Ltd„, Harpenden, Herts,)
Factor VIII:C was measured by the one stage clotting assay previously
described (Part II, Section 2) adapted for an automated coagulometer
(Coag-a-Pet, General Diagnostics, Thame, 0xon„).
Euglobulin Clot Lysis Time was performed as previously described (Part II,
Section 3), with the difference that clot lysis was determined visually
using a transparent-sided waterbath,
Ihctor VIIIR;Ag was estimated by Immunoelectrophoresis as previously
described (Part V, Section i).
p-Thromboglobulin was measured using the radioimmunoassay provided
by the Radiochemical Centre (Amersham).
Fibrinogen was measured as described previously (Part II,Section 2).
Heparin-neutralizing Activity was measured using the method described
by Donati et al. (1972). In a water bath at 37°C , 0.05ml of heparin
(concentrations of 0.1 -4.0 IU /ml in 0.I5M saline) was placed in a
succession of tubes containing 0.25ml test plasma preincubated at
37°C for I min. 0.1ml bovine thrombin (Roche) at a concentration of
10 NIHu/ml was added and the clotting times of duplicate samples were
recorded. When the clotting times were plotted against the concentration
of heparin, a curve was obtained. The concentration of heparin producing
a 20 s heparin clotting time was extrapolated from the curve, and the
heparin-neutralizing activity was calculated from the formula :
Heparin-neutralizing activity = a x b
c
where a = units of heparin giving a heparin clotting time of 20 s,
b = volume of heparin and c = volume of the test plasma (Donati et al,, 1972).
Antithrombin III was measured by radial immunodiffusion, as described in
Part II, Section 3« Results were expressed as per cent of a normal plasma
pool.
Per Gent Ideal Body Weight was calculated using Metropolitan Life Assurance
tables (Documenta Geigy).
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Platelet Retention was measured using a modification of the method
of Salzman (1963). Seven ml venous blood was taken into a 5ml plastic
syringe. Two ml was immediately expelled into a tube containing ECTA
powder. The syringe was then swiftly attached to a polyvinyl catheter
containing I.5g of glass beads (0.5mm diameter) supplied by Servier
Laboratories (Suresnes, Prance) and the assembly was placed on a constant
rate pump (5ml in 46 sec), also supplied by Servier Laboratories.
The 5ml of blood was forced through the glass bead column, and collected
in a tube containing EDTA. A single batch of glass bead columns was
used throughout the study. The drop in platelet count after passage
through the column was expressed as a percentage of the platelet count
before passage of the blood.
Serum Gliclazide was measured by Servier Laboratories UK (Horesdon,
Surrey) using a gas-liquid chromatographic technique (Campbell et
al., 1980), Samples were coded so that the technician who performed
the measurements was unaware of the dose of gliclazide the patient
was receiving,
STATISTICS
Comparisons were made with pre-treatment values using
Wilcoxon's test for paired samples.
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RESULTS
Fifteen patients were recruited into the study0 One patient
was withdrawn at the onset of gliclazide treatment because of dyspepsia
(superficial gastritis shown by gastroscopy) which also recurred when
another sulphonylurea, glipizide s was introduced.
Clinical details of the 14 remaining patients are shown in
Table 25. There were eight men and six women, with a mean age of 59.1 years.
Two patients presented with impaired vision and were found to have
exudative retinopathy. Two had symptoms of peripheral neuropathy and
the remainder had no clinical or electrocardiographic evidence of macro-
or microvascular disease.
At diagnosis, the mean ideal body weight for height was
II6.7 - SEM 2.5% and after two months dietary treatment fell significantly
to 110 1 2.5% (p <0.0l). However, at the end of the study, weight had in¬
creased significantly to 113 + 3compared to the mean at two months
(p CO.Ol).
Three patients responded to dietary restriction alone and
remained well-controlled throughout the study (mean postprandial plasma
glucose at 12 months 4.3mmol/l)„ After two months of diet alone the re¬
maining II diabetics were not satisfactorily controlled and gliclazide
was introduced, daily doses ranging from 80 to 320mg/day.
Table 26 summarizes the laboratory findings in the II
patients treated with diet and gliclazide. After two months of diet alone,
significant reductions were observed in plasma glucose and factor VIIIsC
levels. Following the introduction of gliclazide, there was a further
significant fall in plasma glucose. Platelet retention, factors VIII:C
and VIIIRsAg and plasma neutralizing activity were significantly reduced
compared with pretreatment levels. These values remained relatively
constant thereafter, though there was a tendency for platelet retention,
factor VIIIsC and factor VIIIRrAg to increase towards the end of the study.
Mean serum gliclazide concentrations remained constant throughout and
the remaining haemostatic tests showed no significant changes. As shown
in Fig. 30, when the per cent changes compared to pre-treatment values
were plotted, platelet retention and factor VIIIRsAg tended to parallel
postprandial plasma glucose concentrations.
Because of the small number of patients adequately controlled
on diet alone, statistical analysis of this group was not possible.
Nonetheless, reductions in mean platelet retention, factors VIII:G and
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VIIIR:Ag were observed as shown in Table 27 .
DISCUSSION
This study has shown that when gliclazide was added to
the dietary treatment of newly-diagnosed non-insulin dependent diabetics
who were not adequately controlled on diet alone, satisfactory gly-
caemic control was achieved„ Reduction in blood glucose concentrations
was associated with changes in tests of haemostatic function, namely
a reduction in platelet retention, factor VIII:C, factor VIIIRrAg
and heparin-neutralizing activity. Smaller alterations in these tests
occurred after the two months of diet alone, which with the exception of
factor VIII:C, failed to reach statistical significance. Since the
ideal weight was not achieved in all these patients, it is possible that
an extension of the dietary period could have caused further falls
in plasma glucose, with a corresponding improvement in haemostatic
tests.
Towards the end of the 12 months, there was a tendency
for the tests to return towards pretreatment values, whether the
patients were treated by diet alone or by diet plus gliclazide. In
the gliclazide treated group, mean serum drug levels remained constant,
suggesting good compliance with therapy, but there was a significant
weight gain and a slight rise in plasma glucose concentrations at
12 months which may imply a deterioration in dietary habits towards
the end of the study.
At the time that this study was started, the measurement
of glycosylated haemoglobin was not available in this laboratory. It may
be that measurement of HbA^ is a more satisfactory method of assessing
glycaemic control than postprandial plasma glucose estimations. However,
unlike the situation in insulin-dependent diabetics where wide swings
in plasma glucose may be expected, there is evidence that plasma glucose
estimations generally correspond with HbA^ estimations in non-insulin
dependent diabetics under stable conditions (Graf et al., 1978).
Previous workers have shown that treatment of non-insulin
dependent diabetics (previously inadequately controlled by diet alone,
sulphonylureas or biguanides) with gliclazide resulted in reductions in
platelet retention and platelet aggregation (Rubinjoni et al., 1978;
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Ponari et al., 1979).However, in both studies, treatment with gliclazide
(and probably also'increased surveillance by the diabetic clinic) also
produced an improvement in plasma glucose levels, and it is therefore
uncertain whether changes in platelet function were due to the drug or
to improved metabolic control. The results reported in the present study
would appear to favour the latter hypothesis, since treatment with diet
alone resulted in improvements in certain haemostatic tests, and falls
in plasma glucose were parallelled by corresponding reductions in factor
VIIIR:Ag and platelet retention.
The biological significance of such changes is uncertain.
Evidence presented elsewhere in this Thesis suggests that haemostatic
abnormalities tend to be most marked in diabetics with vascular complications.
If an abnormal haemostatic mechanism plays a part in the pathogenesis of
diabetic angiopathies, then a return of these tests towards normal might
be expected to be beneficial. However, direct evidence that states of hyper¬
coagulability or platelet hyper-reactivity cause thrombotic disease is
not available. On the other hand, such abnormalities may be purely second¬
ary to vascular damage. A hypothesis that vessel wall damage may be
irreversible (eg microangiopathic changes) or reversible (eg during keto¬
acidosis or equilibration of poorly controlled diabetes), resulting in
permanently abnormal or fluctuating levels and activities of haemostatic
factors, has been postulated (Paton et al., I98l).
The relationship between platelet adhesion, platelet retention
and factor VIII:vWf has been discussed in Part I, Section 2. A number of
investigators have reported platelet retention to be raised in diabetic
patients (odegaard et al., 1964; Hellem, 1971» Mayne et al., 1970; Heath
et al., I97l). In the majority of these studies, the increased retention
was found to be related to the presence of microvascular complications.
A relation between platelet retention and factor VIIIRrAg has not been
reported previously. Though platelet retention measures platelet-platelet
as well as platelet-surface interactions, it seems probable that the
reductions in platelet retention during treatment were at least partly
caused by reductions in factor VIIIR:Ag. It has been previously observed
that administration of glucose resulted in increased platelet adhesion
to glass (Bridges et al., 1965) in diabetics, and a high sucrose diet
was reported to result in an increased platelet retention in a proportion
of normal volunteers (Szanto & Yudkin, 1969)» which also suggests that changes
in carbohydrate metabolism may influence the adhesive properties of platelets.
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Factor VIIIRtAg is known to be synthesized by vascular
endothelial cells (jaffe et al.t 19731>). Though a number of stimuli
in vivo produce rises in this antigen (Brozovic, 1977), "to date
stimulation of endothelial cells cultured in vitro has not resulted
in increased synthesis of factor VIIIRtAg (Tuddenham et al., 1981)
so that the mechanism of control is unknown,, The site of synthesis
of factor VIII:G is not firmly established, but may be in the
reticuloendothelial system (Bloom, 1979)- Rises of this factor may
represent a non-specific response to tissue injury caused by the disorder¬
ed carbohydrate and lipid metabolism in uncontrolled diabetes.
The ability of plasma to neutralize heparin is in part due
to a factor released from platelets during the release reaction (platelet
factor 4). Plasma levels of both heparin-neutralizing activity (Chmiel-
ewski & Fhrbizewski, 1970) an(i platelet factor 4 (White & Marouf, 1981)
have been reported in diabetic patients. However, a proportion
of heparin-neutralizing activity is contributed by a-glycoproteins
(Andersen & Godal, 1977) which are also known to be increased in
diabetic subjects (jonsson & Wales, 1976)• Since p-thromboglobulin
and platelet factor 4 are released simultaneously from platelets
during the release reaction (Kaplan & Owen, I98l), the most likely
explanation for the observed fall in heparin neutralizing activity
would appear to be an alteration in a-glycoprotein components,
since p-thromboglobulin levels did not alter throughout the study.
In conclusion, this study does not support the view that
gliclazide per se exerts a beneficial effect on the hemostatic system
of non-insulin dependent diabetics„ However, control of plasma glucose
levels with diet and gliclazide did lead to an improvement in some tests
of coagulation and platelet function. Whether such changes are secondary
to improvement in the health of the vascular endothelium, or whether
such changes lead to a reduction in vascular complications must
await the results of controlled clinical trials.
PART VI GENERAL DISCUSSION
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GENERAL DISCUSSION
A brief resume of the contents of this Thesis will be
followed by a general discussion of the results in the context of
diabetic vascular disease„
In Part I was discussed the possible pathogenetic
factors of atherosclerotic and microvascular disease, and their relation
to the high prevalence of vascular complications in diabetic patients.
Evidence that the haemostatic system is involved in these two processes
was reviewed. The implications of increased glycosylation of haemoglobin
and other glycoproteins in diabetic subjects in relation to the assess¬
ment of diabetic control and possible pathogenetic mechanisms were discussed,
followed by a review of platelet physiology and the coagulation and
fibrinolytic systems, with particular emphasis on their possible roles
in thrombogenesis and of attempts which have been made to detect a
tendency to thrombosis.
In Part II, a cross-sectional study of platelet aggregation
and coagulation and fibrinolytic factors was performed on a sample of
patients attending a diabetic clinic. Compared with non-diabetic controls,
no significant differences were observed in second-phase platelet aggreg¬
ation, but significant increases in fibrinogen, factor II, V, VIII:G,
d^-macroglobulin and c^ -esterase inhibitor and reduced levels of
factor XI and antithrombin III were found. In general, such changes were
related to the presence of clinically-detectable large vessel disease,
the prevalence of microangiopathy being low in this sample.
Part III was concerned with the development of a new method
for measurement of platelet survival using an aspirin-labelling technique.
With this non-radioisotopic method, platelet survival was found to be
reduced in diabetic subjects compared with non-diabetic controls.
I-labelled fibrinogen binding to washed platelets and ADP-induced
platelet aggregation in platelet-rich plasma (using a kinetic method
of measurement) were found to be significantly increased in diabetic
patients with severe retinopathy compared with diabetics with background
and non-diabetic controls, illustrating that in vitro platelet behaviour
is abnormal in diabetics with severe microvascular complications. A
relationship between platelet aggregation and the concentration of
glycosylated haemoglobin was also observed, suggesting that the state
of metabolic control may .also influence platelet function. Evidence
that the findings of reduced platelet survival and increased fibrinogen
binding by platelets from diabetics may represent an alteration of
the platelet membrane was discussed.
In Part IV, the possible role of the thromboxane-prostacyclin
system in the modulation of platelet behaviour in diabetes was discussed.
The effect of diabetic serum on the production of prostacyclin by cultured
vascular endothelial cells was assessed. When the serum from diabetics
with proliferative retinopathy was compared with serum from non-diabetic
controls, an inhibitory effect on prostacyclin production was observed
when added to the culture medium. This effect appeared to be related to
the quality of metabolic control of the diabetes, but was not reproduced
when a) glucose was added to the culture medium or b) when serum from well and
poorly controlled diabeticswith no vascular complications were compared,
suggesting that the presence of severe microangiopathy is required before
an inhibitory factor is observed.
Part V examined two aspects of haemostatic abnormalities
in relation to the metabolic control of diabetes. In contrast to the
other work presented in this Thesis, these were prospective longitudinal
studies. The first was designed to measure haemostatic factors during
and after diabetic coma. During ketoacidosis and the hyperosmolar syndrome
uncomplicated by clinically-evident thrombotic episodes, patients showed
significant rises in factors VIIIRsAg and VIII:C; and increases in fibrin
degradation products together with a significant fall in antithrombin III
which returned towards normal levels after re-equilibration of the diabetes.
Evidence that these results represent signs of endothelial injury and
intravascular fibrin deposition were presented. In two of the three
deaths reported in this series, evidence of disseminated intravascular
coagulation was found.
The second study was devised\ to observe the sequential
changes in a panel of haemostatic tests during equilibration of newly-
diagnosed non-insulin dependent diabetics with diet and the sulphonylurea
gliclazide. Levels of factors VIIIRrAg and VIII:G, and platelet retention
and heparin-neutralizing activity were significantly reduced during
treatment, the results tending to alter in parallel with the plasma
glucose concentration.
In agreement with previously published studies, the results
presented in this Thesis show that abnormalities of platelet behaviour
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and. altered levels of coagulation and fibrinolytic factors are observed
in many diabetic subjects, and particularly in those patients with severe
vascular complications. However, there is also evidence, presented in
Parts III, IV and V of the Thesis, that the quality of glycaemic control
is also capable of influencing some of these parameters. The relationship
between metabolic control, alterations in haemostatic factors and the
development of vascular complications is one of the major unsolved
problems in diabetes.
It is possible that currently-available techniques are
inadequate to completely resolve this problem. With the exception of the
retina, assessment and quantification of micro and macrovascular disease
by non-invasive means is difficult and imprecise. Patients (or controls)
classified as being free of clinical vascular disease may have extensive
atheroma affecting cerebral or coronary vessels. Doppler angiography and
ultrasonic techniques have not yet been fully evaluated but may be of
use in future studies. In the case of microvascular disease, a clinical
search for evidence of microvascular disease cannot detect the early
changes of basement membrane thickening. Thus subjects with abnormal
haemostatic tests may be wrongly allocated to a group with "no vascular
complications". In addition, tests of haemostatic function, particularly
those related to platelet behaviour, are frequently poorly standardized
between laboratories, making comparisons of the results of different
research groups difficult. Moreover, the relation of these often highly
unphysiological tests to in vivo thrombus formation is uncertain. Finally,
diabetic patients comprise a heterogeneous group, particularly in regard
to aetiology and pattern of inheritance (Irvine et al., 1977 > Cudworth
& Ftestenstein, 1978). Though the separation of diabetics into Type I
(possessing islet cell antibodies, and typically insulin-dependent)
and Type II (absence of islet cell antibodies, typically insulin-
independent) has important implications for the aetiology of diabetes,
both Type I and Type II develop vascular complications. However, since
a proportion of diabetics escape vascular disease, even after many years
of diabetes (Oakley et al., 197^; Paz-Guavera et al., 1975). it seems probable
that genetic factors play a role in determining suceptibility to macro-
and microangiopathy. That the importance of genetic susceptibility and
control of glycaemia can be reconciled has recently been shown by Dornan
et al. (l98l) who found that the association of HLA type DR4 with poor
diabetic control increases the risk of developing retinopathy.
122
For all these reasons, interpretation of cross-sectional studies which
relate haemostatic tests to vascular complications is frequently difficult.
Prospective, long-term population studies have been advocated as an
alternative approach to determine whether abnormalities in haemostatic
tests precede or follow the development of vascular complications; at
least one such study is in progress (Fuller et al., 1979). Yet any
results which suggest that these tests predict macro or microvascular
disease should be interpreted with caution, since sub-clinical vascular
disease may be already present at the onset of the study.
The cause of the observed haemostatic abnormalities is
also uncertain. Possible mechanisms for altered platelet behaviour are
discussed in Parts III, IV and V of this Thesis. Evidence is presented
that one factor may be an alteration in the platelet membrane, resulting
in increased fibrinogen binding and shortened platelet survival. That a
membrane abnormality is not restricted to platelets is suggested by the
study of Wautier et al. (l98l) who showed that adhesion of erythrocytes
from diabetic subjects to cultured endothelial cells was increased
compared with controls. Moreover, this increased adhesiveness correlated
with the extent and severity of vascular disease, but not with the degree
of metabolic control as expressed by the concentration of HhA . It is
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also of interest that Cr-labelled erythrocyte survival has been reported
to be reduced in diabetic patients with severe microvascular disease
(Brunning et al., 1976). A hypothesis may be constructed to explain these
findings : repeated cell-vessel wall interactions, particularly in areas
where the vessel wall is irregular or denuded of endothelium produce
damage or loss of part of the cell membrane, resulting in exposure of
receptor sites (e.g. fibrinogen receptors in the case of platelets) and |
alterations of the surface properties of the cell membrane (e.g. increased
adhesion of erythrocytes to endothelial cells, ) with accelerated removal
of these cells from the circulation. Since the in vitro reactivity of
newly-formed platelets appears to be higher than that of platlelets which
have aged in the circulation (Karpatkin, 1969; Ginsburg & Aster, 197^),
this may be another factor contributing to hyper-reactivity of platlets
from diabetic subjects with vascular complications.
Metabolic influences may also influence platelet function,
as suggested by the finding of a correlation between the sensitivity of
ADP-induced platelet aggregation and HbA^ in Part III. Evidence from the
animal studies cited in Part IV suggests that the balance between platelet
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thromboxane synthesis and vessel wall production of prostacyclin is
shifted towards thrombosis in rats made experimentally diabetic, this
imbalance being corrected by treatment of the hyperglycaemia. This
view receives some support from the results presented in Part IV which
showed that both poor metabolic control of the diabetes and the presence
of vascular complications needed to be present before a depressor effect
of diabetic serum on endothelial cell prostacyclin production was observed.
An inter-relationship between hyperglycaemia, factor VIIIR:Ag
and platelet retention was demonstrated in Part V, further illustrating
the complexity of the factors affecting platelet behaviour. The results
of Part V also show that certain alterations in tests of haemostatic
function are at least partially reversible with improved diabetic
control. Such tests may act as early markers of the degree of endothelial
injury, and could provide an additional element to the assessment of
diabetic control.
Whether these changes in haemostatic factors are involved in
the pathogenesis of diabetic macro and microvascular disease is more
speculative. As discussed in Part I, while there is reasonable experiment¬
al and pathological evidence for the involvement of platelet thrombi in
the processes of atherogenesis and its thromboembolic complications,
proof of a role in microvascular disease is scanty. One approach to
assess the platelet contribution to microangiopathy could be to determine
whether experimentally-induced diabetic animal models developed micro¬
angiopathy when rendered thrombocytopenic by anti-platelet serum.
Alternatively, in a similar way to the study of the role of von Willebrand's
disease in atheroma, it should be possible to establish an international
register of diabetics with congenital bleeding disorders. As well as
providing information on the genetic aspects of diabetes, it should
be possible to discover whether these patients escape the vascular
complications of diabetes.
In view of the difficulties of establishing a direct
cause and effect relationship between haemostatic abnormalities and
the pathogenesis of vascular disease in the diabetic, an indirect approach
may be more fruitful. Certain drugs which have been shown to prolong
a shortened platelet survival in patients with rheumatic or prosthetic
heart valves such as dipyridamole (Harker & Slichter, 1970) anc^- sulphin-
pyrazone (Weily et al., 1974) also appear to be effective in reducing the
number of thromboembolic events (Sullivan et al„, I97l)« 4s platelet
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survival is lalso reduced in diabetic patients (Part III), and can be
prolonged by combined aspirin-dipyridamole therapy (Tindall et al., 1981c),
it may be justified to commence prospective trials of such drugs in
the prevention of long-term vascular complications. Several studies are
already in progress (Verstraete,I98o). Anti-platelet prophylactic therapy,
if proved successful, should not replace attempts to keep the control
of glycaemia as close to normal as possible.
As opposed to the prevention of the long term complications
of diabetes, the results presented in Part V argue strongly that in
the acute metabolic dysequilibrium during diabetic coma, endothelial
damage and fibrin deposition occur. In this situation, prospective
studies of both anticoagulants and anti-platelet agents would appear to
be justified to reduce the thromboembolic sequelae of this condition.
In conclusion, the results of this Thesis have shown that
certain changes in haemostatic tests, and in particular tests of platelet
behaviour, occur in diabetic patients. Some of these changes appear to
be secondary to established vascular disease and others may be markers
of endothelial injury, partially reversible by control of hyperglycaemia.
The contribution of these abnormalities to the pathogenesis of micro-
and macrovascular disease is still uncertain and further research in
this area is required. At present, in the absence of reliable methods
of identifying which patients will develop vascular disease, and for
obtaining perfect metabolic control in all patients, clinical trials
to assess the benefits of platelet inhibiting agents appear to be justified,
and may indirectly provide evidence of the involvement of the haemo¬
static system in the pathogenesis of diabetic vascular disease.
SUMMARY
1. In a group of 2>k diabetics, levels of fibrinogen, factors II, V, VII,
VIII:G, Or?-macroglobulin and c^-esterase inhibitor were significantly-
higher and concentrations of factor XI and antithrombin III were signif¬
icantly lower than in Jk non-diabetic controls, o^-^croglobulin levels
were significantly higher in insulin dependent compared with insulin
independent diabetics and c^-esterase inhibitor concentrations were
highest in those diabetics with vascular complications. The threshold
concentrations of ADP, adrenaline and collagen required to produce
second phase platelet aggregation was similar in diabetics and controls.
2. A non-radioisotopic method for measuring platelet survival employing
aspirin as a label was refined. Using this technique, platelet survival
times of 12 diabetics were found to be significantly shorter than those
of 12 non-diabetic controls.
125
3. I-fibrinogen binding to platelets from 8 patients with severe
retinopathy was significantly increased compared with 9 non-diabetic
controls, and 8 diabetics with background retinopathy had fibrinogen
binding values between the two groups. In the same study, using a
kinetic analysis of the data, ADP-induced first phase platelet
aggregation was significantly increased in the patients with
severe retinopathy. In the diabetic patients, sensitivity of
platelets to ADP was correlated with the concentration of haemoglobin
Aj, but not with the degree of fibrinogen binding.
^4. When the production of prostacyclin (PGI0) by thrombin-stimulated
human vascular endothelial cells was measured, cells cultured in the
presence of 20% serum from diabetics with proliferative retinopathy
generated significantly less PGI^-like activity and 6-keto-PGF^Q,
compared with cells cultured with control serum. Diminished 6-keto-PGF^
production was correlated with the concentration of haemoglobin A^..
However, the same effect was not observed when the culture medium was
supplemented with a) different concentrations of glucose and b) when
sera from well controllled diabetics were compared with serum from
poorly controlled diabetics without vascular complications.
5.A study of haemostatic factors in 15 patients admitted with diabetic
coma (il with ketoacidosis and 3 with the hyperosmolar syndrome) was
performed. Compared with values after recovery, during ketoacidosis,
significant increases in factors VIII:C and VIIIR:Ag, fibrin degradation
products and reduced concentrations of antithrombin III were observed.
Out of 3 heaths in the series, 2 had evidence of disseminated intra¬
vascular coagulation.
(5. A panel of haemostatic tests were performed in 14 newly-diagnosed
non-insulin dependent diabetics. After 2 months of treatment with diet
alone, II were given the sulphonylurea gliclazide, the three others
remaining on dietary treatment. Compared with pre-treatment values,
significant reductions in platelet retention, factors VIII;C and
VIIIRiAg and plasma heparin-neutralizing activity accompanied a fall
in plasma glucose due to diet or to diet plus gliclazide.
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The work presented in this Thesis was undertaken independently
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Coagulation and fibrinolytic assays were performed by the
technical staffs of the Departments of Aberdeen and Leeds.
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myself and partly by Dr H Lee and Mme A Thomaides, Hopital St Louis, Paris.
Cultures of vascular endothelial cells were produced by
Dr R Guillot, Department of Embryology, UER Biomedicale, rue des Saints-
Peres, Paris.
Statistics were calculated by me, though I received advice
from Dr S Gore, Department of Statistics, Aberdeen University.
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PLATELET SURVIVAL IN DIABETES MELLITUS
USING AN ASPIRIN-LABELLING TECHNIQUE
R.C. Paton
Department of Medicine, University of Aberdeen
(Received 21.1.1979; in revised form 1.5.1979.
Accepted by Editor A.L. Bloom)
ABSTRACT
Using an aspirin-1abei1ing technique, platelet survival was
measured in twelve diabetics and twelve non-diabetic controls.
Platelet survival times were significantly shorter in the diabetics
compared to the controls (p<0.01). The shortening did not appear
to correlate with the presence of diabetic vascular complications.
INTRODUCTION
Diabetes mel1itus is characterised by a susceptibility to atherosclerotic
and microvascular disease. Platelets may be important in the production of
these complications (1). When tested in vitro diabetic platelets show many
abnormalities including enhanced retention to glass surfaces (2,3), increased
sensitivity to aggregating agents such as adenosine diphosphate, adrenaline
and collagen (4-6), and increased pro-aggregatory prostaglandin production (7).
Fewer studies have examined the behaviour of diabetic platelets in vivo.
Using "^Cr-sodium chromate, Abrahamsen (8) found platelet survival to be
reduced in juvenile-onset diabetics with microvascular complications and
Ferguson et al (9), using ^Se-selenomethionine, showed juvenile-onset
diabetics without obvious complications had shorter platelet survival times
than controls.
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Wider application of this technique has been hindered by the fact
that radioisotopic labels are expensive and special equipment and
expertise is required. Direct labels (e.g. "^chromium) involve the handling
and possible damage of platelets ex-vivo, whereas in vivo labels
(e.g. ^selenium) usually undergo re-utilisation, making interpretation of
results difficult (10).
An alternative non-radioisotopic method was suggested by Stuart et al
(11) which used aspirin as the platelet label. The results appear to
correlate with those obtained using "^chromium (11,12). A modification of
this technique, evolved in the University Department of Medicine, University
of Leeds, was used to compare platelet survival in diabetic and control
subjects.
Subjects
Twelve non-diabetic controls (7 men; 5 women) and 12 diabetics (5 women;
7 men) were studied. The controls were healthy laboratory and medical
staff with a mean age of 30.8 years (range 23-it9 years). The diabetics,
with two exceptions, were fully ambulant and had a mean age of 39.^ (range
16-65). Clinical details of the diabetics are shown in table 1.








EW F AO 11 Insulin Nephrotic syndrome, neuropathy
CW F 3A 11 Insui in Retinopathy, proteinuria,
neu ropathy
MC F A5 1 Metformi n None
MF F 37 12 1nsul in None
AW M 50 8 Tolazamide Nephrotic syndrome, gangrenous
toe
AG M A7 2 Metformi n BP 17i,/9A
AMc I F 20 0.5 1nsu1 in None
JM M A1 9 1 nsulin Neu ropathy
RW M AO 16 1nsulin Neuropathy, ischaemic heart
disease
JM M 65 0.5 Insul in Neuropathic ulcer, ischaemic
heart disease
CM M A9 6 Chlorpropamide None
MD M 16 11 1nsul in None
Clinical Details of Diabetic Subjects
None of the subjects were taking any medications known to influence platelet
behaviour. None of the female subjects were menstruating at the time of
study. On the days of blood sampling, diabetics had their normal
antidiabetic therapy.
METHODS
a) Estimation of platelet MDA production
Non-fasting blood was collected into plastic tubes containin g Vl0 volume
0.77M EDTA. The tubes were centrifuged at 250g for 10 minutes to yield
platelet-rich plasma (PRP). Platelet count was measured using the method of
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Brecher & Cronkite (1950) (13). 1 ml aliquots of PRP were centrifuged at
500 gfor 12J minutes and the resulting platelet-poor plasma was poured off,
and the inside of the tube carefully dried. The platelet buttons were
re-suspended in 1 ml phosphate-saline buffer, pH l.k, using magnetic stirrers
and polythene-coated magnets. 0.1 ml of a 20 mM solution of n-ethyl
maleimide was added to the platelet suspensions and the tubes were incubated
at 37°C for 30 minutes which results in the formation of malondia 1dehyde (MDA).
The reaction was stopped and protein precipitated by the addition of 0.2 ml
20% trichloracetic acid dissolved in 0.6 M hydochloric acid. The tubes were
re-centrifuged at 1000 g for 15 minutes and 1 ml of supernatant was placed in
boiling tubes with 0.2 ml of 1% sodium thiobarbiturate. The tubes were then
boiled for 1^ minutes, cooled, and the optical density of the resulting
pink colour was measured at a wavelength of 532 nm, using a Pye Unicam SP 1800.
gResults were arbitrarily expressed as optical density per 10 platelets,
b) Estimation of platelet survival
MDA production was estimated in platelets stimulated with n-ethyl
maleimide as described, in subjects who had taken no drugs known to affect
platelet function in the preceding two weeks. Preliminary studies showed
day-to-day variation in MDA production was small (coefficient of variation
k%). The subjects were then given 600 mg soluble aspirin and MDA production
was measured at daily intervals until values exceeded 80% of pre-aspirin
levels. Results were expressed as a percentage of the pre-aspirin level
and plotted against time. For each subject a straight line was computed
using linear regression analysis and platelet survival was expressed as
time in days where the line reached 100% of the pre-aspirin level.
Platelet survival times were compared using Wilcoxon's rank sign test.
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RESULTS
Fig. 1 shows the mean values of MDA production expressed as a percentage
of the pre-aspirin level in diabetics and controls.
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Platelet Survival in Diabetics and in
Normal Control Subjects
Tie mean platelet survival time of the diabetics was 6.92 days, which was
significantly shorter (p<0.0l) than the mean of 9.05 days found in the
controls. Platelet survival did not appear to be related to the presence
of vascular complications, and was not correlated with age or sex of the
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patient or duration of diabetes.
DISCUSSION
The aspirin labelling method is a cheap and simple alternative to
radiolabel1ing techniques. The major advantage is that labelling takes
place in vivo, obviating possible platelet damage during handling. An
additional advantage is that since there is no radiation hazard, studies
may be repeated in the same individual and the technique might also be of
use during pregnancy. Unlike radioisotopic methods the technique cannot be
used when the subject is taking a drug which inhbits MDA production, e.g.
non-steroidal anti-inf1ammatory drugs, and since it actually measures
platelet renewal rather than survival, platelet production must equal
platelet destruction as reflected by a constant platelet count throughout
the period of study.
Shortened platelet survival has been found in a variety of conditions
associated with thromboembolism including rheumatic heart disease (14),
prosthetic heart valves (15-17), familial hypercholesterolaemia (12),
and coronary artery disease (18,19). In patients with prosthetic heart
valves and in rheumatic mitral valve disease, the frequency of thromboembolic
events has been related to shortened platelet survival (14,17). The
present study confirms earlier work (8,9) that platelet survival is
shortened in some diabetics. The cause of shortened survival times is
unclear. Platelets from diabetics appear to be unduly sensitive to
aggregating agents (4-6), and therefore may be more prone to participate
in thrombus formation. In addition the vascular endothelium in diabetic
patients may be abnormally thrombogenic. Atheroma is more widespread in
diabetics (20) and could enhance a tendency to thrombus formation. In
addition it has recently been shown that production of the anti-aggregatory
prostaglandin I2 by the vascular endothelium of diabetic patients is
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impaired (21).
One patient with a greatly reduced platelet survival of 4.25 days, was
newly-diagnosed and undergoing stabilisation at the time of the study.
Preston et al (22) have shown that g-thrombog1obu1in levels fall when the
blood sugar is lowered in newly diagnosed diabetes and it is possible that
poor diabetic control may be associated with shortened platelet survival.
It has been suggested that shortened platelet survival may identify
proneness to thrombosis in groups of patients, and in whom antithrombotic
therapy would be particularly indicated (23). Drugs such as dipyridamole
(16) and sulphinpyrazone (17) have been shown to prolong shortened platelet
survival in patients with prosthetic heart valves and clinical studies are
in progress to evaluate their effectiveness in coronary artery and
cerebrovascular disease. Clinical trials of such drugs to assess their
ability to prevent the vascular complications in diabetes may be indicated.
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Haemostatic Changes in Diabetic Coma
R. C. Paton
Department of Medicine, University of Aberdeen, UK
Summary. Diabetic coma is frequently associated
with thromboembolic complications. A prospective
study was undertaken of the haemostatic changes
occurring in 15 patients (12 with ketoacidosis, three
with the hyperosmolar syndrome) during diabetic
coma. When compared with the results after stabili¬
zation of the diabetes, ketoacidosis was associated
with significantly higher levels of factor VIII coagu¬
lant activity, factor VHI-related antigen and fibrin
degradation products, a shorter partial thromboplas¬
tin time and reduced concentrations of antithrom-
bin III. These results suggest that in uncomplicated
ketoacidosis, haematological changes occur which
may reflect vascular endothelial damage and intra¬
vascular fibrin deposition. Out of three deaths, two
patients (both with the hyperosmolar syndrome) had
evidence of disseminated intravascular coagulation.
To reduce further the mortality and morbidity from
diabetic coma, controlled clinical trials of anticoagu¬
lant and antiplatelet drugs may be indicated.
Key words: Diabetic coma, factor VIII, disseminated
intravascular coagulation.
Many abnormalities of haemostatic function have
been described in diabetes mellitus. These include
increased platelet retention and aggregation [1],
increased levels of coagulation factors [2] and
diminished fibrinolytic activity [3], Whether these
abnormalities are related to the metabolic disturb¬
ances of diabetes is unclear.
Whatever the relationship between metabolic
control and haemostatic dysfunction, it is increasingly
realized that thromboembolic disease is a frequent
complication of diabetic coma. Arterial thrombosis
may be responsible for up to one-third of deaths in
patients with diabetic ketoacidosis [4], and is a fre¬
quent occurrence in non-ketotic hyperosmolar coma
[5], In addition, Timperley et al. have shown that
localized deposition of fibrin may occur in fatal cases
of ketoacidosis, particularly in the cerebral capillaries
[6], Over the past decade, a number of authors have
described the association of disseminated intravascu¬
lar coagulation and diabetic coma [6—8]. However,
such case reports have been sporadic, and laboratory
studies have generally been undertaken only after
clinical signs were apparent. A prospective study was
therefore designed to determine the nature of
haemostatic changes in unselected cases of diabetic




Fifteen diabetic patients, admitted to the Aberdeen Teaching Hos¬
pitals with ketoacidosis or the hyperosmolar syndrome over a
period of 12 months, were included in the study. Diabetic
ketoacidosis was arbitrarily defined as a plasma glucose
>14mmol/l and a serum bicarbonate of llmmol/1 or less in
association with ketonuria. The non-ketotic hyperosmolar syn¬
drome was defined as a plasma glucose >30 mmol/1 with a serum
osmolarity of >350 mOsmol/1 [9], serum bicarbonate >20 mmol/1
and with no more than a trace of ketonuria.
Where possible, a second, "convalescent" sample was obtained
from the patients at a subsequent outpatient visit when the diabetic
state was stable (non-fasting plasma glucose <10 mmol/1 and ab¬
sence of ketonuria).
Methods
Venous blood was removed from the patients as soon as possible
after arrival at hospital (mean 2.2 h, range 0.1-5 h) for biochemi¬
cal and haematological studies. Blood for assays of the coagulation
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Table 1. Clinical details of patients with diabetic coma
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Patient Sex Age Duration Previous Possible Additional Depth of Outcome







1 M 18 4 insulin tonsillitis erythromycin 3 recovery
2 F 52 new none breast abcess amoxycillin, 1 recoverybendrofluazide K +
3 F 65 46 insulin unknown - 4 death
4 F 21 10 insulin unstable diabetes - 3 recovery
5 M 17 new none unknown — 4 recovery
6 F 15 6 insulin unstable diabetes — 2 recovery
7 F 13 1 insulin dental abcess — 2 recovery
8 M 33 13 insulin ischiorectal abcess - 2 recovery
9 F 16 1 insulin unstable diabetes — 2 recovery
10 M 17 new insulin stopped insulin - 3 recovery
11 F 33 new none unknown — 2 recovery
12 M 42 16 insulin unknown - 3 recovery
13 M 65 new none unknown — 3 recovery
14 M 73 new none unknown frusemide, digoxin, 3 death
inositol nicotinate
15 F 81 17 chlorpropamide stopped sulphonylurea - 3 death
Table 2. Biochemical data of patients with diabetic coma
Patient Plasma Serum Serum Serum Serum Serum Urinary
no. glucose urea sodium potassium bicarbonate osmolarity ketones
(mmol/1) (mmol/1) (mmol/1) (mmol/1) (mmol/1) (mOsmol/1)
1 32.4 9.4 128 5.4 5 309 + + +
2 21.4 8.0 151 2.4 8 336 + + +
3 54.9 14.7 132 7.2 5 348 + + +
4 14.2 5.5 153 6.5 5 339 + + +
5 78.5 38.0 146 4.4 11 417 + + +
6 39.3 6.8 136 5.5 5 329 + + +
7 25.0 4.0 133 3.7 5 302 + + +
8 34.6 8.3 134 6.6 5 324 + + +
9 17.1 8.2 142 4.6 11 318 + +
10 20.9 5.6 136 3.5 5 305 + + +
11 42.9 7.0 138 2.5 5 331 + + +
12 69.0 39.0 143 6.5 11 407 + +
13 31.1 18.2 161 4.1 24 380 —
14 56.1 35.2 145 5.7 22 393 trace
15 48.4 28.1 163 4.0 24 410 —
system was immediately placed on ice and centrifuged at 1500 X g
and 4 °C within 30 min of venepuncture. Prothrombin and partial
thromboplastin times were measured on fresh samples and the
remaining plasma stored at — 70 °C until required.
The whole blood platelet count was measured microscopically
[10]. Partial thromboplastin time was measured by the method of
Langdell et al. [11] and the prothrombin time by the method of
Quick [12], Factor V and factor VIII coagulant activity (VIII: C)
were assayed by one-stage techniques based on the correction of
the prolonged clotting times of specific factor deficient plasmas
[13, 14]. Factor VHI-related antigen (VIII R: Ag) was measured
by immuno-electrophoresis using antibody to factor VIIIR: Ag
produced by Behringwerke (Marburg, FRG) [15]. A normal pool
of plasma obtained from 20 healthy male medical students was
used as a control. Plasma antithrombin III was measured by a
radial diffusion technique, using plates and standards supplied by
Behringwerke. Plasma fibrinogen was measured by a modification
[16] of the method of Ratnoff and Menzie, and plasma plasmino¬
gen by the method of Alkjaersig et al. [17], Fibrin degradation
products were measured using the kit supplied by Wellcome Rea¬
gents (Beckenham, Kent, UK) Packed cell volume was estimated
using a microhaematocrit centrifuge (Hawksley & Sons, Lancing,
Sussex, UK). Since dehydration occurs during diabetic coma, con¬
centrations of haemostatic factors were adjusted for changes in
haematocrit [18]: Corrected concentration = measured concen¬
tration X Hj (100 -H2)
H2 (100-H,)
Where: H, = haematocrit after coma
H2 = haematocrit during coma
This formula is based on the assumption that the red cell mass
remains relatively constant during diabetic coma, and that changes
in haematocrit reflect changes in plasma volume. Results are pre-
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Table 3. Mean ± SEM values of haemostatic factors of 11 diabetics during ketoacidosis, ketoacidosis with the values corrected for






Haematocrit (%) 45.6±1.8d 40.7±1.5
Prothrombin time (ratio) 1.00±0.03 0.96±0.04
Partial thromboplastin time (ratio) 0.90±0.04c 0.99±0.03
Platelet count (x 109/1) 406±43c 331 ±31 299±17
Factor V (%) 110±10 90±9 118± 15
Factor VIII: C (%) 350±36b 278±33d 189±23
Factor VIIIR: Ag (%) 535±156b 511 ±226b 125±10
Fibrinogen (g/1) 6.35±0.63 5.63±1.02 5.19±0.32 3.92±1.35
Plasminogen (casein U/ml) 4.19±0.16 3.51±0.29d 4.09±0.17 3.56±0.07
Antithrombin III (mg/dl) 32.2±1.4b 26.4±1.0b 36.3±0.3 46.5±1.0
Fibrin degradation products (pg/ml) 17.7±4.5d 15.4±4.4 8.7±0.9 <5
a Mean ± SEM values for 34 healthy non--diabetic subjects.
b
p <0.01, c p <0.02, d p <0.05 compared with convalescent values
Table 4. Haemostatic tests of the fatal case of ketoacidosis (patient 3) and the three diabetics with the hyperosmolar syndrome (patients 13,
14, 15)
Test Patient 3 Patient 13 Patient 14 Patient 15 Normal control"
Haematocrit (%) 40 40 49 39
Prothrombin time (ratio) 1.01 1.01 1.41 0.88
Partial thromboplastin time (ratio) 1.33 0.60 0.98 0.83
Platelet count (x 109/1) 540 311 82 184
Factor V (%) 104 102 42 104
Factor VIII: C (%) 240 570 184 760
Factor VIIR: Ag (%) 248 280 352 1200
Fibrinogen (g/1) 5.20 10.15 10.32 4.25 3.92±1.35
Plasminogen (casein U/ml) 3.31 4.34 2.75 1.76 3.56±0.07
Antithrombin III (mg/dl) 27.2 27.2 26.0 27.7 46.5 ±1.0
Fibrin degradation products (pg/ml) 20 10 160 80 <5
Mean ± SEM values for 34 healthy non-diabetic subjects
sented both as measured and corrected concentrations. Plasma
glucose was measured by the glucose oxidase method and serum
urea and electrolytes by autoanalyzer. Urinary ketones were meas¬
ured by Ketostix (Ames). Serum osmolarity was calculated using
the formula of Gordon and Kabadi [9], and depth of coma on
admission was assessed clinically, using a score of 1-4 (1 = nor¬
mal, 2 = drowsy, but responding to verbal commands, 3 =
responding only to painful stimuli, 4 = unrousable).
Statistics
Comparison between results during and after diabetic coma was
made using the Wilcoxon rank sign test for paired samples.
Results
Patients
Fifteen diabetics were admitted to the study. Clinical
details are shown in Table 1 and biochemical data in
Table 2. Findings in the 12 patients with ketoacidosis
are discussed separately from the three patients with
the hyperosmolar syndrome.
Patients with Ketoacidosis
Patient 3 died 3 h after admission following a cardiac
arrest. The results of the haemostatic tests of the sur¬
viving 11 patients are summarized in Table 3. The
normal values for fibrinogen, plasminogen, anti-
thrombin III and fibrin degradation products shown
in Tables 3 and 4 were obtained from 34 healthy
non-diabetic controls (22 men, 12 women) with a
mean age of 39.1 years (range 26—65 years). Com¬
pared with convalescent values, platelet count, factor
VIII: C, VIIIR:Ag and fibrin degradation products
were significantly increased. Antithrombin III con¬
centrations were significantly lower and there was a
significant shortening of the partial thromboplastin
time during ketoacidosis.
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When the results were corrected for the effect of
dehydration, factor VIII: C and VIIIR: Ag were still
significantly higher and antithrombin III concentra¬
tions lower, during ketoacidosis. The differences in
platelet count and fibrin degradation products were
no longer significant, though seven out of the 11
patients had corrected concentrations of fibrin degra¬
dation products greater than 10 pg/ml compared with
only one out of 11 convalescent samples. In addition,
corrected mean plasminogen concentrations were
significantly lower during ketoacidosis. The mean
(± SEM) factor VIIIR: Ag/VIII: C ratio was 1.44 ±
0.27 during ketoacidosis, which was significantly
higher than the convalescent value of 0.73 ± 0.08
(p< 0.01). There was no correlation between the
levels of the various haemostatic factors and the
depth of coma, the presence of overt infection,
plasma glucose, serum bicarbonate and the serum os-
molarity. Neither the two patients with severe hypo¬
kalemia (patients 2 and 11) nor the two with a blood
urea greater than 30mmol/l (patients 5 and 12) had
haemostatic values strikingly different from the
remaining ketoacidotic patients.
Patients with the Hyperosmolar Syndrome
Out of the three diabetics with the hyperosmolar syn¬
drome, two died (patients 14 and 15). The haemo¬
static results on admission are shown in Table 4,
together with the fatal case with ketoacidosis (pa¬
tient 3). Results are reported as uncorrected values.
Patients 3 and 13 showed results similar to the sur¬
viving patients with ketoacidosis shown in Table 3. In
contrast, the two fatal hyperosmolar cases (patients
14 and 15) had thrombocytopenia, low concentra¬
tions of plasminogen and raised levels of fibrin degra¬
dation products.
Patient 14 had a past history of ischaemic heart
disease and intermittent claudication. On admission,
he was found to have impalpable pulses from the left
femoral downwards. The hyperosmolar state was
rapidly corrected with fluid and insulin therapy, but
perfusion of the left leg did not improve, below-knee
amputation being required six days later, followed by
death after a further eight days. The severe throm¬
bocytopenia present on admission persisted through¬
out his final illness. Post-mortem was not performed.
Patient 15 was admitted in hyperosmolar coma.
On examination she had minimal abdominal tender¬
ness and absent bowel sounds. Death occurred 12 h
after admission. At autopsy she was found to have
80 cm of infarcted small intestine and when sections
were stained with Martius yellow, Crystal scarlet and
soluble blue, fibrin was observed in capillaries, ven¬
ules and arterioles of lungs, mesentry, renal glom¬
eruli and cerebral cortex.
Discussion
This study shows that characteristic changes occur in
the haemostatic system during diabetic ketoacidosis,
the most striking abnormality being a rise in factor
VIII: C and VIIIR: Ag. Increased levels of the factor
VIII complex are found in a variety of inflammatory,
thromboembolic and neoplastic conditions [19]. On
the other hand, high factor VIII: C and particularly
VIIIR: Ag concentrations have frequently been ob¬
served in stable diabetics [20, 21]. Recent evidence
suggests that factor VIII Ristocetin cofactor activity
(which tends to parallel the VIIIR: Ag level) can be
reduced by strict metabolic control of the diabetes
[22]. The present study lends additional support to
the view that poor diabetic control produces raised
factor VIII levels. Since factor VIIIR: Ag is syn-
thetized by vascular endothelial cells [23], the high
concentrations of this antigen found in diabetics with
ketoacidosis may indicate the degree of insult sus¬
tained by the endothelium. Exposure of the vascular
subendothelium is the first stage in the initiation of
thrombus formation [24], so that endothelial cell
damage with resulting de-endothelialization could be
a major contributing factor to the high incidence of
arterial thrombosis in fatal cases of diabetic ketoaci¬
dosis [4].
The cause of raised factor VIII: C activity during
ketoacidosis is not known, but could be a non¬
specific response to acute stress [19]. Though raised
levels of individual coagulation factors do not neces¬
sarily lead to an increased tendency to thrombosis
[25], the finding of a significantly shortened partial
thromboplastin time during ketoacidosis suggests
that there is an increased activity of the intrinsic co¬
agulation system, which might be expected to favour
intravascular clotting. A slight, but significant, rise in
the ratio of factor VIIIR: Ag/VIII: C was observed
during ketoacidosis. Denson has shown that a pro¬
portionate decrease in factor VIII: C in relation to
VIIIR: Ag can indicate intravascular coagulation
[26]. However, since factor VIII: C activity is rela¬
tively labile, the possibility that coagulant activity
was lost during blood collection or storage of the
plasma cannot be excluded.
A fall in the concentration of antithrombin III
appears to be an early and sensitive indicator of
intravascular coagulation [27]. In the present study, a
significant fall in antithrombin III together with a
modest rise in fibrin degradation products provides
evidence that even in relatively uncomplicated cases
of ketoacidosis, a degree of fibrin generation occurs,
and could contribute to the cerebral dysfunction
often seen in this condition [6]. No correlation was
found between the magnitude of the individual
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haemostatic factor abnormalities and clinical and
biochemical variables such as presence of overt infec¬
tion, depth of coma, extent of hyperglycaemia, osmo-
larity or uraemia. Since levels of both haemostatic
and metabolic factors can change rapidly, future
studies with more frequent blood sampling during
recovery from ketoacidosis are required for clearer
understanding of the relationships between clinical,
metabolic and haemostatic parameters.
Two of the three patients with the hyperosmolar
syndrome died during their admission to hospital.
Both deaths occurred in elderly patients and illus¬
trated the considerably higher mortality rate due to
the hyperosmolar syndrome compared with that from
ketoacidosis [9]. Both patients had laboratory, and in
one case, pathological evidence of disseminated
intravascular coagulation. The majority of patients
with disseminated intravascular coagulation have
reduced levels of fibrinogen and plasminogen,
thrombocytopenia and diminished factor V and
VIII: C with high levels of fibrin degradation pro¬
ducts [27, 28]. These haematological findings do not
clearly distinguish disseminated intravascular coagu¬
lation from massive thrombosis at a single site, as was
found in patient 14. Nevertheless, the persistent
thrombocytopenia found in this patient is suggestive
of platelet consumption in sites additional to the
occluded femoral artery.
As shown in the present study, coagulation factor
levels are frequently raised during uncomplicated
diabetic coma, making any changes induced by dis¬
seminated intravascular coagulation difficult to inter¬
pret. Thus in previous reports of disseminated
intravascular coagulation associated with diabetic
coma, fibrinogen and factors V and VIII: C were
high, low or normal [6-8], in agreement with the two
cases in the present series. Thrombocytopaenia and
raised fibrin degradation products appear to be more
consistent findings. In addition, a low plasma plas¬
minogen concentration may point to the diagnosis.
The aetiology of disseminated intravascular co¬
agulation during diabetic coma is likely to be multi¬
ple. Infection [27, 28] and hypovolaemia [28] are
known precipitating factors. Metabolic abnormalities
may also play a part since disseminated intravascular
coagulation is more readily induced in alloxan-
treated compared with control rats [29], The use of
sensitive radioimmunoassays such as those for fi-
brinopeptide A, beta-thromboglobulin and platelet
factor 4 may provide information on the relative con¬
tributions of the coagulation system, platelets and
endothelium to the pathogenesis of intravascular
coagulation during diabetic coma.
In summary, this study shows that during diabetic
ketoacidosis, haemostatic changes are found which
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may reflect endothelial damage and also suggest
intravascular fibrin deposition. In two fatal cases of
the hyperosmolar syndrome, evidence of dissemi¬
nated intravascular coagulation was found. In view of
the high incidence of thromboembolic complications
associated with diabetic ketoacidosis and the hy¬
perosmolar syndrome, and the disturbances of the
haemostatic system reported in this paper, controlled
clinical trials of anticoagulant and antiplatelet drugs
would appear to be justified in the management of
these two conditions.
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Effects of diet and gliclazide on the haemostatic system of
non-insulin-dependent diabetics
R C PATON, P B A KERNOFF, J K WALES, G P McNICOL
Abstract
The effect of the sulphonylurea gliclazide on tests of
haemostatic function was studied in 14 newly diagnosed
non-insulin-dependent diabetics. After two months'
treatment with diet alone 11 of the 14 were given glic¬
lazide; the three others remained on dietary treatment.
Compared with pretreatment values, significant re¬
ductions in platelet retention, factor VHI-related antigen,
factor VIII coagulant activity, and plasma heparin
neutralising activity accompanied a fall in the plasma
glucose concentration due to either diet alone or diet
and gliclazide.
The beneficial effects of gliclazide on platelet abnor¬
malities seem likely to be due to its hypoglycaemic
action rather than to any direct effect on haemostatic
function.
Introduction
Abnormalities of platelet function and of the coagulation and
fibrinolytic systems occur in association with diabetes mellitus.12
The effect of the degree of metabolic control of diabetes on
these tests of haemostasis has received little attention, though
adrenaline-induced platelet aggregation3 and factor VIII
function and the possible influence of improved glycaemic
control brought about by this sulphonylurea. We therefore
assessed for one year the effects of diet and gliclazide on a
panel of haemostatic tests in patients with non-insulin-dependent
diabetes.
Patients and methods
Fourteen newly diagnosed non-insulin-dependent diabetics com¬
pleted the study. Table I gives their clinical details. Their mean
age was 591 (range 42-70) years. Two patients had exudative retino¬
pathy and two had symptoms of peripheral neuropathy at the time
of diagnosis, the remainder having no symptoms or signs of vascular
disease. Diabetes mellitus was diagnosed on the basis of a 50 g
two-hour glucose tolerance test using the criteria proposed by
Keen el aW
All patients were seen at regular intervals by a dietitian and were
educated to follow a conventional carbohydrate-restricted diet.
After eight weeks they underwent a second glucose tolerance test. If
the two-hour blood glucose concentration exceeded 6 mmol/1 (108 mg/
100ml) gliclazide was prescribed in addition to the diet, the dose being
adjusted to give optimal control of blood glucose concentrations. No
other drugs were prescribed during the study. The patients were
asked not to take aspirin-containing compounds and were given
paracetamol as a substitute.
After informed consent had been obtained patients were reviewed
table i—Clinical details of diabetics studied
Case Age Sex Complications
No (years)
°0 ideal body weight*' at: Dose of
gliclazide
Onset 2 months 12 months (mg/day)
Treated by diet and gliclazide
1 55 F 141 132 126 80
2 62 F 112 103 103 80
3 70 M 107 101 101 160
4 61 M Peripheral neuropathy 114 111 120 240
5 61 F 156 141 147 160
6 42 F 100 99 103 240
7 55 M Peripheral neuropathy 123 110 110 80
8 64 M Exudative retinopathy 106 105 109 240
9 68 F 111 106 107 320
10 66 F 128 122 126 120
11 65 M Exudative retinopathy 101 103 107 160
Treated by diet alone
12 56 M 103 102 105
13 55 M 120 107 105
14 47 M 110 111 118
•Calculated using Metropolitan Life Assurance Co tables.
ristocetin cofactor activity1 have been reported to be reduced
when diabetics were intensively treated with diet and insulin.
Recently, the sulphonylurea gliclazide was introduced to clinical
practice in the United Kingdom. This drug has been claimed
to reduce platelet retention and aggregation when given to
patients with maturity-onset diabetes,5 6 but studies have not
distinguished between a specific drug-induced effect on platelet
University Department of Medicine, General Infirmary, Leeds
LSI 3EX
R C PATON, mrcp, lecturer
P B A KERNOFF, md, mrcp, lecturer (now consultant haematologist,
Royal Free Hospital, London)
J K WALES, md, frcp, senior lecturer
G P McNICOL, md, phd, professor
at two-monthly intervals throughout the study, when non-fasting
venous blood was removed using a 19-gauge butterfly cannula.
Blood was obtained at the same time at each visit (one to two hours
after breakfast).
Blood glucose concentration was measured by a glucose oxidase
method, platelet count with a Coulter Thrombocounter, platelet
retention to glass beads by a modification6 of Salzman's method,
factor VIII coagulant activity by a one-stage clotting assay,8 and
factor Vlll-related antigen by immunoelectrophoresis.9 Euglobulin
clot lysis time was measured by the method of Blix10 (results expressed
as arbitrary units11), fibrinogen concentration by the method ofRatnoff
and Menzie,12 antithrombin III concentration by immunodiffusion,13
heparin neutralising activity of platelet-poor plasma by a heparin-
thrombin clotting time assay,14 and [3-thromboglobulin concentration
using a radioimmunoassay provided by the Radiochemical Centre
(Amersham, England). Results for factor VIII and antithrombin III
were expressed as the percentage of the results obtained in a normal
plasma pool from 20 healthy male controls. Serum gliclazide con-
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ations were measured by gas-liquid chromatography.15 Platelet
tion and euglobulin lysis times were measured immediately
blood sampling; the remaining tests were performed on samples
n and stored at -70 C.
suits were compared with pretreatment values using the Wilcoxon
sign test for paired samples.
ults
le mean percentage ideal body weight for height at diagnosis
116-7±SEM 2-5",, and after two months' dietary treatment
"alien significantly to 110; 2-5",, (p<0 01). By the end of the
however, it had increased significantly to 113 : 3-4",, compared
the mean at two months (p<0-01).
iree patients responded to dietary restriction alone and remained
controlled at the end of the study (mean postprandial plasma
se concentration 4-3 mmoll (77 mg/100 ml)). After two months
emaining 11 diabetics were not satisfactorily controlled by diet
and gliclazide was introduced, daily doses ranging from 80 to
ng/day. One patient withdrew from the study at the onset of
zide treatment because of dyspepsia (superficial gastritis shown
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Months of treatment
Percentage changes in mean blood glucose concentration, platelet
retention, and factor Vlll-related antigen (FVIIIR:Ag) com¬
pared with pretreatment values in 11 diabetics treated with diet
for 12 months and gliclazide from the second to the twelfth
month.
TABLE II—Laboratory results in the 11 diabetics treated w
Values are means (~S£M)
<ith diet for 12 months and with gliclazide fr>om two to 12 months.
Months of treatment
0 2 4 6 8 10 12
Blood glucose (mmol 1) 14-7 9-3+ 6 6* 7-5f 6*7+ 7-o; 7-3:
(1-5) (0-8) (0-7) (0-6) (0-5) (0-7) (0-7)
Serum gliclazide (mg 1) 5 3 5 0 5 7 4-8 5-3
(0-7) (10) (11) (10) (10)
Platelet retention 35 5 31-3 24-7* 26 7* 25 0* 22-3+ 29-2
(31) (2-5) (2 1) (3 3) (2-7) (20) (41)
Factor Vlll-related antigen ("„) 165 161 143* 149 156 151 165
(16) (19) (22) (24) (23) (29) (34)
Factor VIII coagulant activity ("„) 172 129* 130* 112t 131* 176 151
(20) (14) (8) (10) (10) (27) (28)
Heparin neutralising activity (U. ml} 0-21 0 16 014' 011* 014* 0 12* 013*
(0 04) (003) (0 02) (001) (0 03) (0-02) (0 01)
Euglobulin lysis time (U) 13-2 12 1 12 6 12-7 12 9 12-7 12-4
(0-4) (0 6) (0 3) (0-3) (0-3) (0-5) (0-4)
H-thromboglobulin (;a.g. 1) 56 2 68 9 43 4 77-9 64 2 63 2 44 1
.12-4) (115) (6 8) (18-1) (17-3 (10 1) (60)
Fibrogen (g 1, 3 00 2 72 2 94 2-81 2-70 2 95 2-77
(0 18) (0 17) (0 16) (0-21) (0-24) (018) (019)
Antithrombin III ("„) 107-8 1114 1120 105-0 98 9 99 9 100-5
(4-6) (4-5) (58) (4-6) (4-7) (5 6) (3 9)
*p- 0 05, tp-^0 01 compared with pretreatment values.
;p 0 01 compared with values after two months' diet alone.
Conversion: SI to traditional units—Glucose: 1 mmol li 18 mg/100 ml.
table III—Laboratory results in the three patients treated with diet alone
Months of treatment with diet alone
Case
No 0 2 4 6 8 10 12
f 12 14-4 5-6 6 1 51 7-7 5-2 2 6
^ 13 101 50 45 4 0 3 5 3-2 40
(, 14 22-0 40 5 2 4-8 3-6 4-5 7-7
[ 12 480 160 17-0 20-0 8-0 260 24 0
< 13 170 27-9 25-0 24-0 17-0 80 200
114 17 0 200 9 0 8-0 17 0 140 140
1 12 147 105 88 116 104 98 126
-4 13 123 136 127 91 150 162 156
il4 202 100 112 103 109 171 175
( 12 175 195 140 86 102 113 98
1 13 108 98 121 121 93 120 123
114 219 126 135 155 140 128 163
f 12 0 172 0112 0136 0-102 0-105 0110 0-136
13 0194 0120 0 218 0-204 0-092 0128 0-124
114 0 304 0-118 0-290 0-550 0-222 0 180 0125
Blood glucose (mmol 1)
Platelet retention (°y)
Factor Vlll-related antigen ("0)
Factor VIII coagulant activity ("„)
Heparin neutralising activity (U/ml)
Comersion: SI to traditional units—Glucose: 1 mmol/1 £ 18 mg 100 ml.
;ide, was given. Two patients had symptoms of hypoglycaemia,
t were abolished when the dose of gliclazide was reduced,
ble II summarises the laboratory findings in the 11 patients
id with diet and gliclazide. After two months of diet alone
icant reductions were observed in plasma glucose concentration
actor VIII coagulant activity. After the introduction of gliclazide
was a further significant fall in plasma glucose concentration.
Platelet retention, factor VIII coagulant activity, factor Vlll-related
antigen, and plasma heparin neutralising activity were reduced
significantly compared with pretreatment values. Mean serum
gliclazide concentrations remained constant throughout the treatment
period, and the remaining haemostatic tests showed no significant
changes. When percentage changes compared with pretreatment
values were plotted (figure) the changes in platelet retention and
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factor VUI-related antigen followed the same pattern as changes in
postprandial plasma glucose concentrations.
Because of the small number of patients who were adequately
controlled by diet alone, statistical analysis of this group was not
possible. Nevertheless, reductions in mean platelet retention, factor
VIII coagulant activity, factor VHI-related antigen, and heparin
neutralising activity were observed (table III), while results of the
remaining tests did not change.
Discussion
In this study satisfactory glycaemic control was achieved when
gliclazide was added to the dietary treatment of newly diag¬
nosed non-insulin dependent diabetics who were not adequately
controlled with diet alone. Reduction of blood glucose con¬
centrations was associated with changes in tests of haemostatic
function—namely, a reduction in platelet retention, factor VIII
coagulant activity, factor VHI-related antigen, and heparin
neutralising activity. Smaller changes in these tests occurred
after the two months of diet alone, which, with the exception
of the change in factor VIII coagulant activity, failed to reach
significance. Since the "ideal" weight was not achieved in all
these patients, extending the dietary period might possibly have
caused further falls in plasma glucose concentration with a
corresponding improvement in these haemostatic tests.
Towards the end of the 12 months the results of the tests
tended to return towards pretreatment values, whether the
patients were treated by diet alone or by diet plus gliclazide. In
the gliclazide-treated group mean drug concentrations re¬
mained constant, suggesting good compliance with treatment,
but there was a significant increase in body weight and a slight
rise in blood glucose concentrations at 12 months, which may
imply that dietary habits deteriorated towards the end of the
study.
Previous workers showed that treatment of maturity-onset
diabetes with gliclazide resulted in reduction of platelet re¬
tention to glass beads and of adenosine-diphosphate-induced
platelet aggregation.56 In those studies, however, such treat¬
ment also produced an improvement in plasma glucose con¬
centrations, and it is therefore uncertain whether the changes
in platelet function were due to the drug or to improved
metabolic control. The present study appears to favour the
latter hypothesis. Treatment by diet alone resulted in improve¬
ments in certain haemostatic tests, and falls in plasma glucose
concentration were paralleled by a corresponding reduction in
factor Vlll-related antigen and platelet retention.
The biological implications of such changes are uncertain.
Previous studies have shown that haemostatic abnormalities
tend to be most pronounced in patients with diabetic vascular
complications.1 2 If an abnormal haemostatic mechanism plays
a part in the pathogenesis of diabetic angiopathies then a
return of these tests towards normal might be expected to be
beneficial. On the other hand, such abnormalities may be purely
secondary to vascular damage. For example, in adequately
controlled diabetes the highest concentrations of factor VIII-
related antigen are generally found in diabetics with micro¬
vascular disease, but concentrations rise sharply during diabetic
ketoacidosis and return towards normal after correction of the
metabolic disturbance.16 Factor Vlll-related antigen is pro¬
duced by vascular endothelial cells,17 so it is possible that
raised concentrations of this antigen during periods of poor
diabetic control indicate vascular endothelial damage. Factor
VIII coagulant activity, considered to be an acute-phase
reactant,18 is not synthesised by endothelial cells. Raised
factor VIII coagulant activity may therefore represent tissue
injury also caused by the disordered carbohydrate and lipid
metabolism in uncontrolled diabetes.
The ability of plasma to neutralise heparin is partly due to a
factor released from platelets (platelet factor 4). Plasma values
of both heparin neutralising activity19 and platelet factor 420
have been reported to be increased in diabetes. A proportion
of heparin neutralising activity, however, is contributed by
x-glycoproteins,21 which are also raised in diabetes.22 As plasma
J3-thromboglobulin and platelet factor 4 are released simul¬
taneously from platelets23 the most likely explanation from the
present study for a change in heparin neutralising activity
during treatment would appear to be a change in x-glycoprotein
components.
In conclusion, the results of this study do not support the
view that gliclazide per se exerts a beneficial effect on the
haemostatic function of non-insulin-dependent diabetes. Never¬
theless, control of plasma glucose concentrations by diet and
gliclazide led to an improvement in some tests of coagulation
and platelet function. Whether such changes lead to a reduction
in diabetic vascular complications must await the results of
controlled prospective clinical trials.
We thank Miss C Jackson and Mrs A Spencer for expert technical
help and Servier Laboratories (UK) for providing the gliclazide
tablets and for performing the serum gliclazide measurements.
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